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The ability of bacterial pathogens to evolve and adapt to our antimicrobial agents has precipitated a
global health crisis where treatment options for bacterial infections are running low. Recently, studies
have shown that the ability to acquire resistance is linked to the SOS response, which is a widely
conserved network of genes involved in both high fidelity and error-prone DNA damage repair. The SOS
response is regulated by the DNA-binding protein, RecA, and a repressor-protease, LexA. When the cell
experiences stress, which can be caused by antibiotics, RecA polymerizes along single-stranded DNA and
thereby stimulates LexA to undergo a conformational change and self-cleavage reaction
(autoproteolysis). LexA self-cleavage de-represses downstream SOS genes, which are involved in both
stress tolerance and mutagenesis. Various studies have shown that inactivating LexA autoproteolysis can
both reduce the viability of bacteria under antibiotic stress and impede their ability to acquire resistance.
These results therefore suggest that targeting LexA therapeutically could offer a novel way to combat the
rise of resistance in pathogens, although to date no LexA inhibitors have been found. To facilitate the
development of such therapeutics, we focused our efforts on examining LexA from 1) biochemical, 2)
microbiological, and 3) drug discovery perspectives. On the biochemical front, we elucidated the
substrate preference of LexA’s serine protease active site to form a better understanding of the target
enzyme’s active site architecture. Performing saturation mutagenesis on the LexA’s internal cleavage
loop, we showed that LexA possesses a unique active site, revealing residues involved in specific
molecular recognition and conformational change. On the microbiological front, we examined how
different LexA activities can impact bacterial drug susceptibility and stress-induced mutagenesis.
Employing engineered E. coli strains with a spectrum of SOS activities, we showed that modulating LexA
activity can increase bacterial susceptibility to antibiotics, while also tuning stress-induced mutagenesis.
Finally, on the drug discovery front, we designed a high-throughput screen that enabled us to discover
small molecule inhibitors of the LexA/RecA axis in collaboration with GlaxoSmithKline. Together, this
work provides a multi-pronged foray into developing therapeutics that target the SOS pathway and
combat the rise of antibiotic resistance.
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ABSTRACT
MAKE ANTIBIOTICS GREAT AGAIN: COMBATING DRUG RESISTANCE BY TARGETING
LEXA, A REGULATOR OF BACTERIAL EVOLUTION
Charlie Y. Mo
Rahul M. Kohli
The ability of bacterial pathogens to evolve and adapt to our antimicrobial agents has
precipitated a global health crisis where treatment options for bacterial infections are running low.
Recently, studies have shown that the ability to acquire resistance is linked to the SOS response,
which is a widely conserved network of genes involved in both high fidelity and error-prone DNA
damage repair. The SOS response is regulated by the DNA-binding protein, RecA, and a
repressor-protease, LexA. When the cell experiences stress, which can be caused by antibiotics,
RecA polymerizes along single-stranded DNA and thereby stimulates LexA to undergo a
conformational change and self-cleavage reaction (autoproteolysis). LexA self-cleavage derepresses downstream SOS genes, which are involved in both stress tolerance and mutagenesis.
Various studies have shown that inactivating LexA autoproteolysis can both reduce the viability of
bacteria under antibiotic stress and impede their ability to acquire resistance. These results
therefore suggest that targeting LexA therapeutically could offer a novel way to combat the rise of
resistance in pathogens, although to date no LexA inhibitors have been found. To facilitate the
development of such therapeutics, we focused our efforts on examining LexA from 1)
biochemical, 2) microbiological, and 3) drug discovery perspectives. On the biochemical front, we
elucidated the substrate preference of LexA’s serine protease active site to form a better
understanding of the target enzyme’s active site architecture. Performing saturation mutagenesis
on the LexA’s internal cleavage loop, we showed that LexA possesses a unique active site,
revealing residues involved in specific molecular recognition and conformational change. On the
microbiological front, we examined how different LexA activities can impact bacterial drug
susceptibility and stress-induced mutagenesis. Employing engineered E. coli strains with a
spectrum of SOS activities, we showed that modulating LexA activity can increase bacterial
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susceptibility to antibiotics, while also tuning stress-induced mutagenesis. Finally, on the drug
discovery front, we designed a high-throughput screen that enabled us to discover small molecule
inhibitors of the LexA/RecA axis in collaboration with GlaxoSmithKline. Together, this work
provides a multi-pronged foray into developing therapeutics that target the SOS pathway and
combat the rise of antibiotic resistance.
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CHAPTER 1: Introduction
The contents of the chapter have been adapted from the following publication:
Culyba MJ,* Mo CY,* Kohli RM (2015) Targets for Combating the Evolution of Acquired Drug
Resistance. Biochemistry 54, 3573-3582.
* These authors contributed equally to this review
1.1 The problem of antibiotic resistance
“We are continually faced with a series of great opportunities brilliantly disguised as insoluble
problems.” - John W. Gardner
The use of penicillin and sulfonamides in the 1940s marked the start of a new era in the
management of human health and disease and, with it, the problem of antibiotic resistance
(Kardos and Demain, 2011). Widespread success of these drugs led to the enthusiastic discovery
of several new classes of antibiotics peaking during the 1950s−1970s, a time now often termed
the “golden era” of antibiotic discovery. Unfortunately, for each new antibiotic class discovered,
reports of microbes resistant to those drugs emerged within only a few years of clinical use of the
drugs (Neu, 1992; Palumbi, 2001). The rising tide of multi-drug-resistant organisms (MDROs) is
increasingly diminishing the efficacy of our antibiotic arsenal (Centers for Disease Control and
Prevention, 2013). This trend is in part due to the selection of resistant bacteria via widespread
use of antibiotics and the dissemination of resistance genes in bacterial populations across the
globe (Centers for Disease Control and Prevention, 2014; Sievert et al., 2013; World Health
Organization, 2014). Additionally, the unique pharmacological challenges of targeting bacteria,
coupled with economic disincentives to developing antibiotics, have conspired to slow the rate of
discovery (Livermore and British Society for Antimicrobial Chemotherapy Working Party on The
Urgent Need: Regenerating Antibacterial Drug Discovery and Development, 2011; Payne et al.,
2007). Despite infection control efforts, resistance continues to outpace drug discovery, raising
the specter of a “post-antibiotic era”, a time in the future when high mortality caused by MDROs
cannot be easily prevented (Appelbaum, 2012).
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While innovative new approaches are underway to discover antimicrobials with different
mechanisms of action (Clatworthy et al., 2007; Ling et al., 2015; Thaker et al., 2013), the most
conventional approach to overcoming resistance has involved the chemical modification of
existing antibiotic scaffolds (Fischbach and Walsh, 2009). Our antibiotic arsenal has undergone a
stepwise tailoring of core structures, akin to evolution, to both increase their spectrum of activity
and overcome resistance mechanisms. For example, antibiotics that maintain the β-lactam core
started with penicillins, moved forward through “generations” of cephalosporins, and onward to
carbapenems. While these “next-generation” antibiotics could overcome some existing
resistance mechanisms, many bacteria, in turn, have rapidly adapted to counteract these drugs
(Figure 1). These cycles of antibiotic discovery and resistance illustrate the importance of
understanding how drug resistance evolves. Although seemingly an intractable problem, the
evolution of antibiotic resistance may represent a great opportunity. Indeed, efforts to understand
the evolution of drug resistance could serve a dual purpose: providing a window into how bacteria
adapt to harsh environments while simultaneously elucidating novel targets to potentiate our
current antibiotic arsenal.
TEM β-lactamase
e.g. Escherichia coli

AmpC cephalosporinase
e.g. Pseudomonas aeruginosa

1TEM
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Figure 1. Cycles of drug discovery and antimicrobial resistance
An illustrative schematic is shown presenting several generations of β-lactam antibiotics
chronologically coupled to the β-lactamases that have emerged in clinical pathogens to
counteract these “next-generation” antibiotics.
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1.2 Acquired antibiotic resistance
Antibiotic resistance can be classified as either intrinsic or acquired, and by whether the
mechanism involves a genetic change. Intrinsic resistance refers to a generalizable trait that does
not change regardless of antibiotic selective pressure. For example, resistance to vancomycin in
Gram-negative bacteria is due to differences in their cell wall architecture, relative to Grampositive bacteria, and not a specific resistance mechanism. By contrast, acquired resistance
develops when a new trait is expressed, often because of a genetic change that has been
selected for in the setting of antibiotic exposure (Smith and Romesberg, 2007). Bacteria can also
mediate tolerance to antibiotics independent of genetic change, such as with persister states or
biofilm formation (Maisonneuve and Gerdes, 2014).
Genetic changes can confer resistance to antibiotics through a diverse set of
mechanisms. Though other mechanisms are known, common and prominent examples include
altering the target site of the drug, enzymatically inactivating the drug, and preventing the drug
from accessing the target. Many of these resistance mechanisms result either from a small
number of specific genomic mutations or, alternatively, from horizontal gene transfer (HGT)
(Figure 2). Point mutations can alter the interactions between a drug and its target, as evidenced
by mutations in RNA polymerase that mediate resistance to rifampin. Point mutations can also
affect non-target genes, as illustrated by promoter mutations resulting in the overexpression of
drug efflux pumps. Unlike point mutations, HGT can result in the acquisition of genes with entirely
novel functions for the cell. For example, some acquired genes can inactivate drugs, such as
plasmid-encoded β-lactamases. Others can even alter cellular metabolic or structural products,
as in the case with vancomycin-resistant enterococci, where a cassette of genes mediates
changes to a peptidoglycan motif that dramatically weakens vancomycin binding (Courvalin,
2006). While the genetic elements that directly confer resistance have been well reviewed (Blair
et al., 2015; Walsh, 2000), the biochemical mechanisms by which these genetic changes arise
within bacteria have been less scrutinized.
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A mutagenesis

Antibiotics

Patient A

B gene transfer

C

Patient B

Figure 2. Acquisition and spread of antimicrobial resistance
Stress, including treatment with antibiotics, promotes acquired resistance in an initially sensitive
strain by driving (A) mutagenesis or (B) horizontal gene transfer. Strains with preexisting
resistance can (C) then spread by transmission between people.
1.3 Fixed and transient hypermutation
Mutation is a major contributor to the evolution of drug resistance. Some important
pathogens, such as Mycobacterium tuberculosis (Mtb), rely almost exclusively on mutagenesis,
rather than gene transfer, to evolve resistance (Almeida Da Silva and Palomino, 2011). Similarly,
for certain classes of antibiotics, such as fluoroquinolones, point mutations are the primary
mechanism of acquired resistance (Redgrave et al., 2014). Furthermore, although mobile
resistance genes largely account for the high prevalence of MDROs, the evolution of these genes
against “next-generation” antibiotics also occurs at the level of mutation.
Bacteria can acquire mutations spontaneously and at a relatively constant rate because
of the inherent mutational frequency associated with genomic replication. However, under various
conditions, mutation rates can increase, in some cases as high as 100-fold above the basal rates
(Blazquez, 2003; Galhardo et al., 2007; Tippin et al., 2004). Two basic mechanisms are known to
accelerate mutation in bacterial strains: a loss of DNA repair or proofreading systems and the
induction of pro-mutagenic pathways.
The best-studied disruption in DNA repair involves loss of mismatch repair (MMR). MMR
deficiency can result in a fixed hypermutator phenotype where the organism’s mutation rate is
rendered constitutively high (Tippin et al., 2004). The clinical implications of this phenotype are
evident in cystic fibrosis patients, where hypermutator Pseudomonas aeruginosa strains with
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MMR deficiency are frequently isolated (Oliver et al., 2000).
Interestingly, although MMR deficiency is typically the result of a fixed loss of function,
bacterial strains that exhibit transient inactivation via excision and reintegration of a cryptic
prophage at a gene locus critical for MMR function have also been isolated (Scott et al., 2008).
While fixed hypermutators are important to acquired resistance, the induction of transient promutagenic pathways is another important driving force for acquired antibiotic resistance.
Transient hypermutation has been linked to conserved stress responses within bacteria (Al
Mamun et al., 2012; Gibson et al., 2010). These stress responses are mediated by tightly
regulated genetic pathways that poise bacteria to respond to a wide range of stressful
environments, from host immune systems to ultraviolet radiation to toxic biomolecules, including
antibiotics (Erill et al., 2007). Different stress responses have been shown to contribute to
accelerated mutagenesis, including the starvation response and envelope stress response (Al
Mamun et al., 2012; Gibson et al., 2010); however, the majority of studies on induced
mutagenesis have focused on the bacterial SOS pathway, where the biochemistry of the key
players in the pathway has been well-delineated (Radman, 1975; Schlacher and Goodman,
2007). To this end, we next turn our attention to the biochemistry of the SOS response and
opportunities for slowing acquired drug resistance by targeting the sensor, regulator, or effector
enzymes in the pathway.

1.4 Targeting the SOS response to delay the acquisition of resistance
The SOS pathway is a widely conserved DNA damage response pathway that, upon
detection of DNA damage, responds by expressing genes involved in DNA repair and damage
tolerance (Figure 3) (Radman, 1975; Schlacher and Goodman, 2007). SOS genes lie under the
control of the transcriptional repressor LexA. In the basal, unstressed state, LexA binds to specific
operator DNA (SOS box) sequences in SOS gene promoters (Lewis et al., 1994). In the setting of
DNA damage, single-stranded DNA (ssDNA) accumulates at stalled replication forks and serves
to activate the DNA damage sensor of the system, RecA. Activated RecA stimulates LexA to
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undergo a self-cleavage reaction, which promotes LexA dissociation and de-repression of SOS
genes. The induced genes follow an interesting chronology that implies a transition from high- to
low-fidelity repair, based on damage severity. Initially, repair genes, including those for nucleotide
excision repair, are expressed; however, later in the SOS response, error-prone translesion DNA
polymerases are induced (Courcelle et al., 2001).
Sensor

Regulator

RecA
SOS box

SOS genes

Effector
- High-fidelity repair
- Recombination
- Translesion DNA
synthesis

DNA
damage

X

Induction
of SOS genes
RecA*

SOS mutagenesis

Figure 3. SOS response is the key regulator of transient hypermutation in bacteria
Activation of the stress sensor, RecA (red ovals), promotes self-cleavage of the SOS regulator,
LexA (blue ovals). LexA cleavage results in induction of the SOS effectors, which include errorprone DNA polymerases (green circles) that can bypass DNA lesions leading to mutations during
error-prone repair.
Notably, LexA is self-regulated, and re-accumulation of full-length LexA upon rescue from
damage can halt the SOS response. As a result, DNA damage can cause a transient
hypermutator phenotype, known as SOS mutagenesis, which occurs for the duration of the
genotoxic stress. Genetic experiments have validated the SOS pathway as an important target for
combating the evolution of antibiotic resistance. Experimentally inactivating the SOS regulators,
either by deletion of recA or by engineering a noncleavable LexA into the bacteria, renders the
bacteria unable to initiate the SOS response. These mutant bacteria are hypersensitive to
genotoxic antimicrobials and exhibit decreased mutation rates (Cirz et al., 2005; Kohanski et al.,
2007; Thi et al., 2011). In a particularly revealing experiment, the Romesberg group infected mice
with either wild type Escherichia coli or E. coli harboring a noncleavable mutant of LexA. Upon
treatment with either rifampin or ciprofloxacin, the wild type infection showed an initial response to
therapy but then rebounded with drug-resistant bacteria. By contrast, infection with the strain
containing noncleavable LexA continued on a trajectory toward eradication with no evidence of
detectable resistance (Cirz et al., 2005). In a different experiment by the Collins group, infecting

	
   6	
  
	
  

drug-resistant E. coli with a phage overexpressing a noncleavable LexA exerted a dominantnegative effect that prevented SOS activation and resensitized the E. coli to antibiotics (Lu and
Collins, 2009).
With regard to SOS effectors, deletion of the SOS-induced translesion polymerases
decreases bacterial fitness, lowers their mutation rate, and slows acquisition of drug resistance
(Boshoff et al., 2003; Galhardo et al., 2009). Some of the most compelling evidence comes from
studies in Mtb. While the Mtb SOS operon contains fewer genes than other pathogens, the key
effector in the pathway is DnaE2, a translesion DNA polymerase (Rand et al., 2003). Deletion of
dnaE2 is associated with decreased Mtb virulence in infection models and suppresses the
emergence of resistance to rifampin, a key first-line anti-tuberculosis agent (Boshoff et al., 2003).
Together, these genetic studies suggest the potential therapeutic benefits of perturbing the
regulators or effectors of the SOS pathway.

1.4.1 RecA, the damage sensor of the SOS response
RecA is a highly conserved ∼38 kDa protein that plays a critical role in homologous
recombination and also acts to stimulate LexA self-cleavage (Schlacher et al., 2006). Structurally,
monomeric RecA consists of three domains with a central core RecA fold that is flanked by
smaller regulatory domains (Story et al., 1992). These monomers can form large nucleoprotein
filaments on ssDNA (Figure 4A), which can extend across thousands of base pairs via
cooperative oligomerization mediated by the core RecA fold (Joo et al., 2006). Filamentous RecA
has a deep helical groove that envelops, stretches, and unwinds the bound DNA, preparing it for
homology searching and subsequent DNA strand exchange. The core RecA fold binds ATP at the
monomer−monomer interface (Figure 4A) (Story et al., 1992). While only binding of ATP is
required for filament formation and simple DNA strand exchange reactions, RecA also catalyzes
ATP hydrolysis, which is important for filament depolymerization as well as some specific types of
recombination activities. Filamentous RecA acts as a co-protease to stimulate self-cleavage of
LexA (discussed below), as well as other related members of the LexA/signal peptidase
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superfamily, such as phage λ repressor and UmuD in E. coli. In the case of phage repressor,
cleavage stimulates the prophage to enter the lytic cycle (Jiang et al., 2009).
A. RecA filament

B.

LexA dimer

C.

Dpo4

CTD
ssDNA
NTD

3JSO

3CMW

Glu 96

1JX4

LexA serine protease active site

RecA ATPase

Ser 119

Thr 73

Polymerase catalytic sites
1JX4

1T7P

Lys 156

Ser 69

1JHC & 1JHE

1XMS

Figure 4. Targets of the SOS pathway
(A) Structure of the SOS sensor, RecA, shown as a filament (PDB entry 3CMV), with alternating
monomers colored dark or light blue. The ssDNA is shown as red spheres. The panel below is a
close-up of the ATP binding pocket (PDB entry 1XMS), a site that could be targeted. (B) Shown is
dimeric LexA, bound to SOS box DNA (PDB entry 3JSO), with individual monomers colored
green and yellow. The C-terminal protease domain (CTD) is connected to the N-terminal DNA
binding domain (NTD) by a structurally unresolved linker (dashed line). In the self-cleavage
mechanism, LexA undergoes a large conformational change in its C-terminal domain between
inactive (red sticks, PDB entry 1JHC) and active states (purple sticks, PDB entry 1JHE) that
positions the cleavage loop within the active site, adjacent to the Ser/Lys dyad. The overlaid
active and inactive conformations are shown in the bottom panel. (C) Shown is a representative
Y-family polymerase, Dpo4, an error-prone polymerase, bound to DNA (PDB entry 1JX4). Unlike
high-fidelity T7 polymerase, shown for comparison (PDB entry 1T7P), Dpo4 possesses a more
open, exposed catalytic site, which reduces the selectivity for the incoming nucleotide, colored
green.
Interestingly, RecA serves two roles in association with UmuD: it stimulates self-cleavage
of UmuD to UmuD′ and it also is, itself, an essential component of the associated Pol V
mutasome (Jiang et al., 2009). The LexA binding site on the RecA filament has not been fully
elucidated, but current models suggest that LexA may span adjacent RecA monomers across the
deep helical groove (Adikesavan et al., 2011). ATP binding, but not hydrolysis, is required for the
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co-protease activity. As ΔrecA strains are hypersensitive to antibiotics and less prone to acquired
resistance (Kohanski et al., 2007; Thi et al., 2011), RecA has been proposed as a novel target for
slowing the evolution of antibiotic resistance. The feasibility of targeting RecA is further supported
by the existence of biological protein modulators of RecA, including RecX and DinI, which both
can antagonize SOS induction (Cox, 2007).
In an effort to discover small molecule RecA inhibitors, Singleton and colleagues have
designed several high-throughput screens largely focused on E. coli RecA ATPase activity and
identified potential inhibitors (Lee et al., 2007; Sexton et al., 2010; Wigle et al., 2009). While
antimicrobial activity against E. coli has not yet been described, one lead RecA probe, suramin,
was characterized against Mtb, where the inhibitor was suggested to potentiate the activity of the
fluoroquinolone ciprofloxacin (Nautiyal et al., 2014). More recently, Alam et al. reported the
discovery of inhibitors that target RecA/DNA binding and showed that these compounds have the
ability to reduce SOS induction in stress-stimulated bacteria (Alam et al., 2016). Although studies
aimed at inhibiting RecA are promising, specificity is one important consideration that needs to be
explored. In mammals, RecA has up to seven important homologues (Rad51 family) (Kawabata
et al., 2005). In this context, rational approaches using nucleotide analogues to target RecA’s
ATP binding site have been examined to a limited extent (Wigle et al., 2006) and offer a potential
starting point for applying strategies that have yielded analogous protein kinase inhibitors that are
ATP competitive and selective (Knight and Shokat, 2005).

1.4.2 LexA, the regulator of the SOS response
The ∼25 kDa LexA molecule consists of two domains separated by a short flexible linker
and exists as a homodimer in solution. The N-terminal domain (NTD) contains specific DNA
binding activity, and the C-terminal domain (CTD) contains protease activity (Figure 4B) (Luo et
al., 2001; Zhang et al., 2010). Dimeric LexA binds to SOS box DNA through a winged helix−turn−
helix motif in the NTD with dimerization mediated by the CTDs (Zhang et al., 2010). The CTD
contains a protease active site, with a serine-lysine catalytic dyad. Self-cleavage occurs at a
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protein loop in the same monomer, located near the linker between the two domains (Luo et al.,
2001). Crystal structures of well-characterized LexA mutants show that this cleavage loop can
exist in two distinct states. In the “non-cleavable” state, the loop is far removed from the active
site. In the “cleavable” state, it undergoes a large ∼20 Å conformational change, positioning the
scissile peptide bond adjacent to the active site serine (Luo et al., 2001). Interestingly, in the
“cleavable” state, LexA binds its peptide substrate in a sharp β-turn, rather than the extended βsheet peptide conformation common to canonical proteases (Luo et al., 2001; Tyndall et al.,
2005).
Given the promising genetic studies on bacteria with noncleavable LexA discussed
above, small molecule inhibition of LexA’s protease domain has been proposed (Cirz et al., 2005;
Smith and Romesberg, 2007). To this end, while LexA’s distinct active site architecture offers
potential advantages, it also poses two major challenges. First, as the substrate is tethered in cis,
any competitive inhibitor will have to overcome the high local substrate concentration of the
internal cleavage loop. Indeed, LexA shows inhibition only under large excesses of nonspecific
protease inhibitors, such as diisopropyl fluorophosphates (Roland and Little, 1990). Second,
given self-cleavage, classical high-throughput protease assays, such as using fluorophore
quencher-containing peptides in trans, cannot be readily translated to LexA. Despite these
challenges, rational or screening-based approaches to the discovery of LexA inhibitors are well
justified.

1.4.3 Error-Prone Polymerases, effectors of the SOS response
Foremost among the effectors in SOS mutagenesis are DNA polymerases (Pol II, IV, and
V in E. coli) (Courcelle et al., 2001). These polymerases catalyze translesion synthesis (TLS) by
replacing the replicative Pol III, which stalls when encountering a damaged DNA template base
(Sale et al., 2012). The ability of these polymerases to catalyze TLS, however, is associated with
an increased frequency of mutation because of the lack of 3′−5′ exonuclease proofreading
activity, weak processivity, and low fidelity (Boudsocq et al., 2002; Jarosz et al., 2007).
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Several of the critical enzymes involved in TLS, including Pol IV and Pol V in E. coli, are
dissimilar enough from replicative polymerases that their identity as DNA polymerases was
revealed only after the discovery of their role in mutagenesis (Radman, 1999; Tippin et al., 2004).
Crystal structures of several of these “Y-family” DNA polymerases have yielded insight into their
function and fidelity (Figure 4C). Despite a low level of sequence identity, the error-prone
polymerases share the palm, finger, and thumb domains characteristic of their high-fidelity
relatives (Figure 4C) (Ling et al., 2001; Silvian et al., 2001; Zhou et al., 2001); however, a detailed
comparison shows structural differences that likely account for their lower fidelity (Pata, 2010;
Tippin et al., 2004; Yang, 2014). The finger and thumb domains of the error-prone polymerases
are in general shorter and appended with an additional domain known as the little finger domain,
which has specialized function in Y-family polymerases. Further, O-helices, which typically play a
role in proper Watson−Crick base pairing, are absent from the finger domains. Overall, these
modifications result in a more flexible and open active site that may facilitate TLS over DNA
damage due to bulky adducts or strand cross-links. Notably, elegant studies using FRET or timeresolved crystallography have demonstrated that, despite the appearance of a more static open
active site, enzyme dynamics are critical to lesion bypass and catalysis (Maxwell et al., 2014;
Nakamura et al., 2012). Since these error-prone polymerases are crucial in generating mutation,
targeting their regulation and expression could prove to be important for combating the rise of
resistance. These approaches, however, are not discussed in this thesis.

1.4.4 Other SOS effectors
Apart from the expression of error-prone polymerases, the SOS response has been
associated with a host of other phenotypes linked with resistance and drug susceptibility. Most
notably, functional SOS boxes have been found within integrons and shown to regulate activation
of the gene transfer by controlling expression of the integrase gene (Guerin et al., 2009).
Likewise, in pathogens such as Vibrio cholerae, a large integrative and conjugative element
encoding resistance to multiple antibiotics is under the control of a LexA homologue, SetR, which
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also requires SOS activation for mobilization (Beaber et al., 2004). Thus, SOS activation can be
associated with horizontal gene transfer and the spread of resistance genes. Preventing SOS
activation has also been reported to antagonize other mechanisms that mediate survival in
response to antibiotic stress, biofilm formation, activation of qnr resistance genes, and bacterial
persistence (Da Re et al., 2009; Dorr et al., 2009; Gotoh et al., 2010). Thus, targeting the SOS
response can not only reduce resistance, but also reduce the ability of bacteria to tolerate and
survive antimicrobial treatment.

1.5 Thesis objectives
Numerous lines of evidence suggests that the SOS response plays an important role in
driving acquired resistance and antibiotic tolerance in bacteria. Therefore, in this body of work we
focused on the central regulator of the SOS response, LexA. With an eye towards developing
therapeutics, we examined how genetic and chemical modulation of LexA’s self-cleavage
reaction could affect the SOS response and broader downstream phenotypes. We engaged in a
three-pronged approach to investigate the LexA regulator and the SOS response. In Chapter 2
we examine the active site architecture of the LexA protease domain; in Chapter 3 we investigate
how different LexA cleavage rates and SOS induction levels affect antibiotic susceptibility and
stress-induced mutagenesis; and in Chapter 4 we describe our efforts to discover small molecule
inhibitors of LexA and RecA. Together, the insights gained from these basic science studies
assist in the development of therapeutics against LexA and the SOS response in an effort to
combat the evolution of drug resistance, while also providing a deeper understanding of the
unique functions of this protein.
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CHAPTER 2: Specificity determinants for autoproteolysis of LexA, a key regulator
of bacterial SOS mutagenesis
The contents of the chapter have been published:
Mo CY, Birdwell LD, Kohli RM (2014). Specificity Determinants for Autoproteolysis of LexA, a Key
Regulator of Bacterial SOS Mutagenesis. Biochemistry 53, 3158-3168.
Contributions: CYM and RMK conceived of the study; CYM performed the experiments; LDB
assisted with the molecular cloning of LexA variants; CYM and RMK wrote the paper, with input
from LDB.
2.1 Abstract
Bacteria utilize the tightly regulated stress response (SOS) pathway to respond to a
variety of genotoxic agents, including antimicrobials. Activation of the SOS response is regulated
by a key repressor-protease, LexA, which undergoes autoproteolysis in the setting of stress,
resulting in de-repression of SOS genes. Remarkably, genetic inactivation of LexA’s selfcleavage activity significantly decreases acquired antibiotic resistance in infection models and
renders bacteria hypersensitive to traditional antibiotics, suggesting that a mechanistic study of
LexA could help inform its viability as a novel target for combating acquired drug resistance.
Despite structural insights into LexA, a detailed knowledge of the enzyme’s protease specificity is
lacking. Here, we employ saturation and positional scanning mutagenesis on LexA’s internal
cleavage region to analyze >140 mutants and generate a comprehensive specificity profile of
LexA from the human pathogen Pseudomonas aeruginosa (LexAPa). We find that the LexAPa
active site possesses a unique mode of substrate recognition. Positions P1−P3 prefer small
hydrophobic residues that suggest specific contacts with the active site, while positions P5 and
P1′ show a preference for flexible glycine residues that may facilitate the conformational change
that permits autoproteolysis. We further show that stabilizing the β-turn within the cleavage region
enhances LexA autoproteolytic activity. Finally, we identify permissive positions flanking the
scissile bond (P4 and P2′) that are tolerant to extensive mutagenesis. Our studies shed light on
the active site architecture of the LexA autoprotease and provide insights that may inform the
design of probes of the SOS pathway.
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2.2 Introduction
In an era of rising drug resistance and a diminishing pipeline for new antibiotics,
understanding the mechanisms that drive acquired drug resistance in bacteria has become
critical. Bacterial adaptation and evolution are closely tied to the stress response (SOS) pathway,
a widely conserved, inducible network of genes involved in DNA repair and recombination that
allows bacteria to respond to DNA damage. The SOS response is governed by a bifunctional
repressor-protease, LexA. In its basal state, LexA represses the transcription of 15−40 genes
involved in the SOS response (Figure 5). Interactions with RecA, a sensor of DNA damage,
cause LexA to self-cleave (autoproteolyze), resulting in the de-repression of the downstream
SOS genes (Courcelle et al., 2001; Michel, 2005; Schlacher and Goodman, 2007; Sutton et al.,
2000). These induced SOS genes include Y-family DNA polymerases, which catalyze error-prone
translesional replication over damaged DNA and can promote acquired drug resistance (Boshoff
et al., 2003; Galhardo et al., 2009). Further, LexA autoproteolysis increases the level of
expression of integrons involved in the transfer of mobile genetic elements and has been
associated with the formation of biofilms (Gotoh et al., 2010; Guerin et al., 2009). Thus, LexA and
the SOS pathway regulate several of the major mechanisms by which pathogens can tolerate
antimicrobials and acquire drug resistance.
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Figure 5. LexA repressor-protease regulates the bacterial stress response (SOS pathway)
(A) Autoproteolysis of the LexA repressor-protease activates the mutagenic SOS response in
bacteria. In the absence of stress, LexA binds to SOS-controlled promoters, limiting their action.
When DNA is damaged, RecA filaments form at the site of damage and stimulate LexA selfcleavage. Autoproteolysis prompts dissociation of LexA from DNA, permitting expression of
downstream SOS genes. Activation of the SOS response and its associated DNA damage
tolerance pathways increases bacterial survival and mutation rates. (B) Structure of LexA from E.
coli. LexA binds to DNA as a dimer. The C-terminal domain (CTD) contains the major
dimerization interface and a serine protease active site. The N-terminal domain displays a winged
helix−turn−helix motif and binds to the palindromic DNA of the SOS box. The CTD and NTD are
connected by a flexible linker peptide (dashed line), which was not resolved in the crystal
structure (PDB entry 3JSO). The close-up of the LexA CTD active site shows an overlay of the
cleavage-competent and cleavage-incompetent forms of LexA (PDB entries 1JHE and 1JHC,
respectively). The internal cleavage loop of LexA undergoes a large conformational change
between the cleavage-incompetent state (red) and the cleavage-competent state (purple), placing
a scissile bond in the proximity of the active site serine-lysine catalytic dyad (red and blue
surfaces, respectively). The active site is boxed for the sake of clarity. (C) The LexA cleavage
regions across species from different families of pathogenic bacteria (Gram-negative, Grampositive, and mycobacteria) are shown. The scissile Ala-Gly bond is noted (green arrow), and
numbering is shown relative to Pseudomonas aeruginosa LexA (LexAPa). The percent identity is
represented by the degree of shading with red and plotted below the alignment.
The LexA repressor was the notable first of a family of enzymes shown to undergo selfcleavage as part of their physiological function (Burckhardt et al., 1988; Cezairliyan and Sauer,
2009; Little, 1984; Luo et al., 2001; McDonald et al., 1999; Slilaty et al., 1986; Slilaty and Little,
1987). Members of this family possess a conserved serine-lysine catalytic dyad that cleaves
between an Ala-Gly or Cys-Gly sequence within the protease domain (Luo et al., 2001). In its
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repressor role, LexA functions as a dimer, with each monomer containing an N-terminal DNA
binding domain (NTD) that is connected by a flexible linker to the C-terminal serine protease
domain (CTD) (Figure 5B)(Zhang et al., 2010). Structural studies of Escherichia coli LexA have
shown that the CTD can exist in two distinct conformations, and that self-cleavage is associated
with a shift from a basal cleavage-incompetent conformation of the CTD to a cleavage-proficient
conformation (Luo et al., 2001; Zhang et al., 2010). Self-cleavage is initiated when LexA is
exposed to either activated RecA (RecA*) in vivo and in vitro or high pH in vitro, features shared
by several other members of the LexA superfamily (Burckhardt et al., 1988; Kim and Little, 1993;
McDonald et al., 1999; Nohmi et al., 1988; Slilaty et al., 1986).
The cleavage-proficient conformation of LexA has several unique features. The protein
loop containing the scissile Ala-Gly bond appears to form specific contacts near the active site,
suggesting that like classical serine proteases, there is a binding pocket involved in cleavage
sequence recognition (Luo et al., 2001). Indeed, genetic mutagenesis and selection studies of
LexA and the related λ CI repressor have indicated that point mutations at several of the residues
surrounding the cleavage loop can interfere with self-cleavage (Gimble and Sauer, 1985; Lin and
Little, 1988; Shepley and Little, 1996). However, in conventional serine proteases, the scissile
bond of the substrate peptide is almost uniformly bound in the middle of an extended β-sheet. In
LexA, by contrast, the bond is positioned at the end of a β-turn (Hedstrom, 2002; Luo et al., 2001;
Perona and Craik, 1995; Tyndall et al., 2005). Furthermore, because LexA acts upon a tethered
substrate (the cleavage region within the same molecule), the effective local concentration of the
substrate is high. This feature may explain why common serine protease inhibitors, such as
diisopropyl fluorophosphate, inhibit LexA only at extremely high concentrations, and why wild type
LexA only weakly cleaves peptides or other proteins in trans (Kim and Little, 1993; Roland and
Little, 1990). This distinctive binding mode and requirement for a conformational change for
catalysis make LexA a potentially distinctive therapeutic target among proteases.
Genetic and synthetic biology studies have shown that preventing LexA autoproteolysis
decreases the rate of development of resistance and can sensitize bacteria to antibiotics. Most
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notably, when an E. coli strain harboring a noncleavable mutant of LexA was evaluated in a
murine infection model, the development of antibiotic resistance was abrogated by the loss of
normal LexA function (Cirz et al., 2005). Specifically, while the wild type bacteria thrived and
became entirely resistant to rifampin after drug exposure in the mouse model, the mutant strain
failed to acquire any rifampin resistance. In an alternative study, phage-mediated transduction of
E. coli with an inactivated LexA protease was shown to greatly hypersensitize the bacteria to
traditional antibiotics (Lu and Collins, 2009). In addition to participating in the transfer of mobile
genetic elements, LexA has been suggested to mediate persister formation and play a role in
stress-induced mutagenesis (Al Mamun et al., 2012; Dorr et al., 2009; Guerin et al., 2009).
Targeting LexA pharmacologically, therefore, has been suggested as a means to delay the
acquisition of resistance, increase the efficacy of known antimicrobials, and offer insight into
bacterial adaptation and evolution (Cirz et al., 2005; Cirz and Romesberg, 2007; Smith and
Romesberg, 2007).
Despite the availability of crystal structures of the LexA, a detailed structure−function
relationship of the LexA active site and the cleavage sequence has yet to be established. Here,
we study the LexA protein from Pseudomonas aeruginosa (LexAPa), a Gram-negative pathogen
that is an archetype for the problem of acquired drug resistance and a major cause of mortality in
cystic fibrosis patients (Folkesson et al., 2012; Lyczak et al., 2002). We developed a methodology
for high-efficiency mutagenesis and enzymatic characterization to profile the substrate
preferences of LexA autoproteolysis comprehensively for the first time. Combined with available
structural data, this study provides insight into the mechanism of LexA substrate recognition and
lays the groundwork for efforts to develop inhibitors and probes of LexA, the SOS pathway, and
bacterial evolution.

2.3 Experimental procedures
2.3.1 LexAPa cloning and expression
All oligonucleotide sequences used in LexAPa amplification, cloning, and cassette
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mutagenesis were purchased from Integrated DNA Technologies (IDT) and are available upon
request. The lexA gene was amplified via polymerase chain reaction with LexAPa genomic
primers from the P. aeruginosa PA01 strain and cloned into the pET41 expression vector
engineered with an N-terminal His tag and C-terminal Streptavidin tag (Jacobs et al., 2003). The
S125A active site mutant was generated by QuikChange site-directed mutagenesis. The enzyme
was heterologously expressed in E. coli, followed by one-step purification using the N-terminal
tag. The purified product was predominantly full-length (~26 kDa), with trace amounts of selfcleavage that occurs during the course of purification.

2.3.2 Saturation mutagenesis
For the efficient generation of saturation and positional scanning mutagenesis variants,
mutations introducing the unique restriction sites AgeI and Eagl were engineered at nucleotide
positions 255 and 282, respectively, in the lexA coding sequence using QuikChange site-directed
mutagenesis. An additional mutation (BamHI) at nucleotide 267 and a TAG stop were included
within the cassette region, as mechanisms for selection against wild type sequences from the
parent vector. This construct served as the parent cloning vector for cassette-based mutagenesis.
Briefly, the LexAPa cloning vector was digested with AgeI, BamHI, and EagI for 2 h at 37 °C and
treated with calf intestinal phosphatase. Individual oligonucleotides containing a degenerate
codon (NNS) at each position from position 85 to 94 were ordered from IDT and annealed to their
complement with a standard annealing protocol. Annealed oligonucleotides containing sticky
ends complementary to AgeI and EagI cleavage sites were phosphorylated with T4
polynucleotide kinase for 1 h at 37 °C. The oligonucleotide cassettes were ligated into the
digested cloning vector using T4 DNA ligase. The ligation product was then transformed into New
England Biolabs (NEB) 10-β competent cells using standard transformation procedures. Onetenth of the transformation mixture was plated to estimate the library size, and the remaining
portion was grown overnight in Luria-Bertani broth. The isolated plasmids from this culture
constituted the saturation mutagenesis library at each position (I85X, G86X, etc.). Successful
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incorporation of the degenerate NNS codon was verified by Sanger sequencing of the library.

2.3.3 Point mutations of selected residues in the LexAPa cleavage loop
The same cassette-based mutagenesis strategy was adopted to generate the individual
point mutations in residues spanning positions P5 to P2′ of the LexAPa cleavage region (residues
86−92). For each of the seven positions, 20 forward and reverse oligonucleotides encoding each
amino acid mutation were constructed and ordered from IDT. Oligoncleotides containing two
mutant codons were used for the LexAPa A89C/I94C double mutant. Oligonucleotide pairs were
annealed, phosphorylated, and ligated into the digested parent vector, as described above. After
transformation, individual colonies were selected and mutant plasmids were sequenced to
confirm the proper insertion of the mutation cassettes.

2.3.4 Expression and purification of LexAPa, saturation mutant cohorts, or individual
positional scanning mutants
Expression plasmids were transformed into BL21-(DE3)-pLysS E. coli cells for
heterologous expression. For the saturation mutant library, the liquid culture after transformation
was used as the starter overnight culture. For point mutants, the transformation was plated and
an individual colony selected for the starter overnight culture. The following day, 35 mL LuriaBertani broth cultures were inoculated with 1 mL of overnight culture and grown at 37 °C until the
OD600 reached ~0.6. The cultures were subsequently induced with 1 mM isopropyl β-D-1thiogalactopyranoside, shifted to 30 °C, and grown for 4 h. The culture was centrifuged at 4000
rpm for 20 min at 4 °C and the pellet stored at −80 °C until it was purified. Thawed cell pellets
were lysed per protocol with Bugbuster Mastermix (Novagen). The soluble supernatant was
incubated with 100 µL of reconstituted HisPur resin (Pierce) for batch binding at 4 °C for 1 h in 10
mL polyprep columns (Bio-Rad). The flowthrough was discarded and the resin subsequently
washed three times with 10 resin volumes of wash buffer [25 mM sodium phosphate (pH 7.0),
150 mM NaCl, and 30 mM imidazole]. Following the wash, bound protein was eluted from the
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resin with 3 resin volumes of elution buffer [25 mM sodium phosphate (pH 7.0), 150 mM NaCl,
and 200 mM imidazole]. The eluted proteins were then dialyzed into 25 mM Tris-HCl (pH 7.0),
150 mM NaCl, and 10% glycerol. The same protocol was used for the wild type enzyme,
saturation mutant libraries, and individual positional scanning mutants. For the 140 positional
scanning mutants (20 amino acids x 7 positions), the cohorts of 20 mutants at each position were
processed in parallel to provide an internal (wild type) control.

2.3.5 Alkali-mediated qualitative cleavage assays of LexAPa
To qualitatively screen the cleavage ability of LexAPa variants, purified protein was mixed
in a 1:1 ratio with 2x cleavage buffer (100 mM Tris-Glycine-CAPS and 300 mM NaCl) at pH 7.2 or
10.6. Reaction mixtures were incubated at room temperature for 16 h. Cleavage was quenched
by adding 2x Laemmli sample buffer to the reaction mixture and by denaturation at 95 °C for 10
min. The extent of LexAPa cleavage was visualized by running reaction samples on 15% sodium
dodecyl sulfate−polyacrylamide gel electrophoresis (SDS−PAGE) gels and Coomassie staining.
Mutants that displayed cleavage were selected for further quantitative analysis. Coomassiestained gels were imaged on a Typhoon Imager using red laser excitation at 633 nm and no
filters. The fraction of cleaved protein was calculated by dividing the density of the LexAPa
cleavage products by the sum of the density of all LexAPa full-length and cleaved components,
using Quantity One (Bio-Rad). Linear detection of Coomassie-stained products was verified by
analysis of standards.

2.3.6 RecA*-mediated cleavage of LexAPa proteins
RecA of E. coli was purchased from NEB. Purified LexAPa was incubated with an excess
of activated RecA*, generated by premixing ~100 µg/mL RecA, 900 µM ATPγS, and 10 µM
ssDNA (Tracy and Kowalczykowski, 1996). Reactions without RecA were run parallel as a
negative control. Reaction mixtures were incubated at room temperature for 16 h. The cleavage
products were analyzed and quantified as described for alkali-mediated cleavage.
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2.3.7 Alkali-mediated quantitative assays of LexAPa
For quantitative kinetic analysis, 25 µL of purified protein was mixed with 25 µL of 2x
cleavage buffer (pH 10.6) and the mixture incubated at 37 °C for 2 h. At the given time points, 5
µL of the reaction mixture was removed and the reaction rapidly quenched in 2x Laemmli sample
buffer. The extent of cleavage over time was visualized on Coomassie-stained 15% SDS−PAGE
gels. For restrictive positions, time points were collected in triplicate, while reactions were run in
duplicate for the permissive positions. Coomassie-stained gels were imaged and quantified as
detailed above.

2.3.8 Calculation of LexAPa cleavage rates and generation of the LexAPa cleavage profile
The density of the protein bands was quantified using Quantity One (Bio-Rad). For each
time point, the fraction of uncleaved LexAPa was calculated as described above and plotted
versus time. Rate plots were then fit to the first-order exponential decay equation A = A0e

−kt

using

Prism to obtain k, the observed rate of cleavage. To calculate the specificity profile, we used the
enoLOGOS web tool to generate a normalized sequence LOGO of the P5−P2′ sequence
preferences (Workman et al., 2005). The cleavage rate constants, k, at each position were used
as the relative scaling factors, with an unknown weight type and the frequency method for
calculating the height of the symbol stacks.

2.3.9 Structural modeling of LexAPa
To assist with the analysis of our biochemical data, we generated a structural model of
the LexAPa CTD. We entered the amino acid sequence of the LexAPa CTD (residues 81−204) into
Modeler 2.0 (Sali and Blundell, 1993), with the crystal structure of activated LexA from E. coli as
the homology template (PDB entry 1JHE) (Luo et al., 2001).
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2.3.10 Liquid chromatography and tandem mass spectrometry (LC−MS/MS)
LC−MS/MS was performed at the Proteomics & Systems Biology Core Facility at the
University of Pennsylvania Perelman School of Medicine. Purified LexAPa A89C/I94C samples
were either reduced or not reduced with 1 M dithiothreitol and treated with 300 mM
iodoacetamide (molecular mass of 57 Da). Samples were subsequently digested with trypsin and
subjected to LC−MS/MS. Peptide fragments were identified and analyzed with PEAKS (Ma et al.,
2003).

2.4 Results
2.4.1 Sequence identity between LexAPa and LexA of E. coli
The LexA protein is strongly conserved across all families of bacteria and shares a high
level of sequence similarity (Burckhardt et al., 1988; Cezairliyan and Sauer, 2009; Little, 1984;
Luo et al., 2001; McDonald et al., 1999; Slilaty et al., 1986; Slilaty and Little, 1987). Given the
importance of drug resistance in the opportunistic pathogen P. aeruginosa, we focused our efforts
on studying the LexA of P. aeruginosa (LexAPa). A sequence alignment of LexAPa with LexA of E.
coli (LexAEc) reveals a 64% sequence identity, with notable features such as the serine-lysine
catalytic dyad and the internal cleavage loop conserved (Figure S1A in the Appendix). This strong
sequence identity provided the basis for structural modeling of the LexAPa CTD to help interpret
our biochemical assays (Figure S2 in the Appendix). We modeled LexAPa based on the structure
of the CTD of LexAEc in the active conformation (PDB entry 1JHE), with the high degree of
sequence homology resulting in a root-mean-square deviation of 1.2 Å between the known and
modeled structures.

2.4.2 Saturation mutagenesis of LexAPa‘s cleavage region
We next cloned, expressed, and purified LexA from reference strain PA01. In accordance
with prior biochemical assays on LexA from other species, we demonstrated that our tagged
LexAPa is proficient in both alkali- and RecA*-mediated autoproteolysis (Figure S3 in the
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Appendix). Recombinant LexAPa displayed cleavage kinetics similar to that of tagged or untagged
LexA from other species (see below) (Cohn et al., 2011; Kim and Little, 1993; Miller et al., 1996;
Movahedzadeh et al., 1997).
Prior biochemical studies have revealed that the LexA protease has poor cleavage
activity in trans (Hedstrom, 2002; Kim and Little, 1993). In its wild type catalytic form, both the fulllength LexA protein and the isolated LexA protease domain are unable to efficiently cleave the
target substrate of a second LexA enzyme (Kim and Little, 1993). Extensive mutagenesis of the
enzyme’s active site and the target sequence can allow for trace detectable activity in trans;
however, it is clear that the native substrate of LexA is itself (Kim and Little, 1993). We explored
the possibility that full-length LexA or the CTD alone may cleave short peptides that mimic the
internal cleavage loop; however, we did not observe cleavage in fluorescence- or LC−MS-based
cleavage assays (data not shown). For these reasons, conventional peptide array-, genetic
library-, and mass spectrometry-based methods for assessing protease specificity could not be
readily translated to characterizing LexAPa specificity (Harris et al., 2000; O'Donoghue et al.,
2012; Salisbury et al., 2002; Schilling and Overall, 2008; Van Damme et al., 2008). We therefore
decided to directly assess LexA’s specificity by exhaustive mutagenesis of the cleavage loop
within the enzyme and assessing (in cis) autoproteolysis activity. Given that this approach would
require extensive mutagenesis, we implemented an efficient cassette mutagenesis strategy for
introducing variations into the internal substrate of LexA (Figure S4 in the Appendix) (Bowie et al.,
1990; Davidson et al., 1995; Reidhaar-Olson and Sauer, 1988). The specificity determinants of
LexAPa could be delineated broadly at first by saturation mutagenesis (the introduction of a
degenerate codon) and then in detail by positional scanning mutagenesis (the generation of
individual point mutants to each of the 20 amino acids).
For saturation mutagenesis, 10 duplexed oligonucleotide cassettes that contain a
degenerate NNS codon at each position from Ile85 to Ile94 (e.g., I85X) were produced. The
degenerate NNS codon encodes all 20 potential amino acid variants and one potential stop
codon (TAG). The calculated depth of the library at each position was >1000-fold, and the
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presence of a degenerate NNS codon at each position was verified by sequencing. Although this
library is not proportionally represented for the various amino acid substitutions, we reasoned that
the general patterns of restrictive and permissive positions could be gleaned from analysis of a
positionally diversified cohort of variants. For each position, we expressed and purified the mutant
protein library in cohort, which showed expression characteristics and solubility similar to those of
wild type LexAPa. Each cohort was then incubated overnight at pH 7.2 or 10.6, and the fraction of
cleavage was assessed under these conditions (Figure 6). The positions clustered into two
general groups based upon comparison to wild type LexAPa: positions P5 (G86), P3 (V88), P2
(A89), P1 (A90), and P1′ (G91) appear to be restrictive to mutation, displaying small changes in
the fraction of cleaved protein (<30%), while the remaining positions were more permissive to the
introduction of a degenerate codon, exhibiting changes in cleavage levels closer to that of the
wild type enzyme despite being highly diversified (Figure 6).
P6 (I85) P5 (G86) P4 (R87) P3 (V88) P2 (A89)
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L
H
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H
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Figure 6. Saturation mutagenesis of the LexAPa cleavage region
For each position from I85 to I94, the wild type codon was substituted with a degenerate NNS
codon. To determine the tolerance for mutation at each position qualitatively, the saturation
mutant library at each position was purified as a cohort and subjected to overnight self-cleavage
at pH 7.2 (L) or pH 10.6 (H). Self-cleavage of the full-length (FL) enzyme results in the generation
of the isolated C-terminal and N-terminal domains (CTD and NTD, respectively). The multiple
banding in the lower-molecular weight fragments is caused by the migration patterns of mutants
with an altered charge state. The fraction of cleavage product detected under each condition is
shown (pH 7.2, gray columns; pH 10.6, black columns). Error bars represent the standard error of
duplicate trials.
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We repeated the analysis in the presence or absence of RecA* and found the same overall
patterns of tolerant and restrictive positions with this alternative stimulus for autoproteolysis
(Figure S5 in the Appendix). Notably, as RecA*-mediated cleavage analysis was used as a purely
qualitative measure, we used RecA from E. coli in our assays (74% identical and 87% similar to
that of P. aeruginosa) because of its availability and the observation that LexAPa cleaves as
efficiently as LexAEc under RecA* stimulation.

2.4.3 Positional scanning mutagenesis and cleavage screen of the residues P5−P2′ of
LexAPa
The qualitative overview from saturation mutagenesis set the stage for detailed
quantitative analysis. Here, we focused on the residues of positions P5−P2′, spanning the most
restrictive sites we identified by saturation mutagenesis. Furthermore, the LexAPa homology
model suggests that these residues form the most extensive interactions with the surrounding
active site pocket (Figure S2 in the Appendix). In our positional scanning mutagenesis approach,
for each position of interest, we individually mutated the residues to each of the 20 potential
amino acids (G86A, G86S, G86T, etc.) using cassette mutagenesis. For each position, all 20
variants were expressed, purified in parallel and subjected to both alkali and RecA*-mediated
cleavage overnight to identify specific variants that permitted autoproteolysis (Figure S6 in the
Appendix). Together, the individual point mutants in this assay validated the patterns observed
with saturation mutagenesis. The full cleavage profiles for each position are provided in Figure S6
in the Appendix, with select examples of a restrictive and tolerant position shown in Figure 7.
Restrictive positions, such as P1 (A90), tolerate only a few mutations, while permissive positions,
such as P4 (R87), tolerated all amino acids, although to varying degrees (Figure 7).
Both alkali- and RecA*-mediated cleavage screens yielded similar cleavage results, with
the exception of position P5, where RecA*-mediated cleavage was more restrictive than alkalimediated cleavage (Figure S6A in the Appendix). Overall, the cleavage behavior of select
restrictive mutations in LexAPa (G86V, G86D, V88M, V88E, A89V, A90D, and A90T) agrees
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qualitatively with the results of a prior study of LexA from E. coli that identified slow- cleaving
variants via limited mutagenesis and genetic screening (Lin and Little, 1989). One notable
exception is the aspartate mutation at the P1′ glycine, which completely abrogates alkalimediated and RecA*-mediated cleavage in LexAPa (Figure S6F in the Appendix) but allows
limited levels of cleavage in LexA from E. coli (Lin and Little, 1989).
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Figure 7. Positional scanning mutagenesis and kinetic analysis of the LexAPa cleavage
region
Each residue from G85 to A92 was mutated to each of the 20 amino acids. Each point mutant
was expressed and purified separately. Shown are the results from overnight cleavage at pH 7.2
(L) or pH 10.6 (H) for each mutant of (A) A90 (position P1), a relatively restrictive position, or (B)
R87 (position P4), a relatively tolerant position. The wild type enzyme is denoted by WT.
Cleavable mutants of (C) A90 (position P1) or (D) R87 (position P4) from the initial cleavage
screen were then evaluated for their alkali-stimulated cleavage kinetics. The data represent three
replicates for restrictive (P1) positions and two replicates for tolerant (P4) positions. For the sake
of clarity, the kinetic data for five of the 20 R87 variants representing varying cleavage rates are
shown. The points are fit as a first-order exponential decay, and the standard error is shown.
Mutants are grouped by the properties of their side chains at physiological pH (orange for
hydrophobic, purple for aromatic, yellow for hydrophilic, green for positive charge, and blue for
negative charge). The wild type (WT) residue is indicated with a thicker dotted line.
Corresponding results for all positions from P5 to P2′ are displayed in Figures S6 and S7 in the
Appendix, with quantitative results for rates listed in Table 1.
2.4.4 Kinetic evaluation of cleavable mutants
Individual mutants deemed cleavage proficient under overnight cleavage conditions were
next subjected to detailed kinetic analysis. We performed the cleavage reaction under alkaliinduced conditions to allow for direct comparison of the various mutants. Alkali-mediated
cleavage, while nonphysiological, has the distinctive advantage of being a unimolecular first-order
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reaction, allowing us to probe the intrinsic substrate preferences of LexAPa without confounders
such as potential alterations in RecA* interactions (Table 1).
Table 1. First-order rate constants for alkali-induced self-cleavage of LexAPa mutants
-5

-1

Rate, k (10 s )
Amino
acid
mutation

P5

P4

P3

P2

P1

P1’

P2’

G86

R87

V88

A89

A90

G91

A92

G

76 ± 13

23 ± 2

3.2 ± 0.2

113 ± 8

38 ± 2

144 ± 3

26 ± 2

A

25 ± 2

143 ± 10

10.5 ± 0.8

98 ± 3

157 ± 10

-

95 ± 13

S

11 ± 1

85 ± 10

0.5 ± 0.1

121 ± 8

2.0 ± 0.3

2.8 ± 0.3

50 ± 3

C

3.8 ± 0.3

63 ± 10

5.5 ± 0.5

4.0 ± 0.5

2.3 ± 0.2

-

105 ± 10

T

2.8 ± 0.3

130 ± 17

8.7 ± 0.5

3.0 ± 0.5

1.0 ± 0.2

-

53 ± 7

D

7.8 ± 0.2

63 ± 7

-

2.2 ± 0.3

-

-

27 ± 2

P

-

103 ± 12

-

3.2 ± 0.5

-

-

433 ± 150

N

15.8 ± 0.3

45 ± 8

-

6.5 ± 0.5

-

-

137 ± 12

V

0.5 ± 0.2

113 ± 20

76 ± 7

1.0 ± 0.1

-

-

62 ± 5

E

3.8 ± 0.1

183 ± 33

-

2.2 ± 0.3

-

-

85 ± 8

Q

2.5 ± 0.2

100 ± 17

-

5.5 ± 0.8

-

-

167 ± 20

H

7.3 ± 0.2

25 ± 5

-

5.2 ± 1.2

-

-

85 ± 7

L

0.5 ± 0.2

45 ± 7

0.16 ± 0.01

4.8 ± 0.3

-

-

73 ± 5

I

7.8 ± 0.2

50 ± 8

15.2 ± 0.7

2.2 ± 0.2

-

-

125 ± 12

M

11 ± 2

60 ± 7

0.3 ± 0.1

2.2 ± 1.2

-

-

65 ± 5

K

6.0 ± 0.2

78 ± 10

-

1.3 ± 0.3

-

-

103 ± 10

F

5.8 ± 0.3

68 ± 10

-

6.8 ± 1.0

-

-

75 ± 12

Y

6.5 ± 0.3

210 ± 45

-

9.0 ± 1.3

-

-

65 ± 5

R

3.2± 0.2

53 ± 3

-

4.7 ± 0.2

-

-

77 ± 13

W

5.5 ± 0.2

216 ± 12

-

25 ± 3

-

-

113 ± 15

Employing our method, we determined the rate of autoproteolysis of all cleavable mutants.
Representative data from one highly restrictive (P1) position and one tolerant position (P4) are
presented in panels C and D of Figure 7, with kinetic plots for all cleavable variants shown in
Figure S7 in the Appendix. Notably, the rate of cleavage of the wild type enzyme at each position
differed slightly (range of 53−144 x 10

−5

−1

s ) as a result of batch-to-batch variability in expression

and purification. Given that each cohort of 20 mutants at a position was prepared in parallel, the
rate of each mutant was scaled to that of the wild type to obtain the relative amino acid
preferences, with the comprehensive analysis summarized (Figure 8A).
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Figure 8. Substrate preference for alkali-mediated self-cleavage of LexAPa
(A) Heat map representing the cleavage rates of the LexAPa point mutants. The wild type residues
from position P5 to P2′ are listed along the top. The rows represent each point mutation, listed in
order of the increasing size of the amino acid. Crosses denote analogues that show no cleavage
in the overnight self-cleavage assay at pH 10.6. For each cleavable analogue, the first-order rate
constant for self-cleavage was determined at pH 10.6 [two or three replicates per condition (Table
1)]. The rate for each mutant was scaled relative to the wild type residue and shown in the heat
map as shades from white to blue. Residues that cleave at rates greater than that of the wild type
are colored deep blue. (B) Normalized sequence LOGO diagram summarizing the autoproteolysis
profile of LexAPa. The diagram was generated using the enoLOGOS program with the rates of
cleavage at each position as the relative scaling factors. The color scheme groups amino acids
as in Figure 7.
The positions upstream of the cleavage site show an alternating pattern of being
restrictive or permissive to variation, with restrictive positions favoring the wild type residue over
all other amino acids. At position P5 (G86), we see a modest tolerance for amino acids with either
a small or flexible side chain, such as A or S, while larger side chains reduce the level of LexAPa
self-cleavage (Figure 8B). Position P4 (R87), which appears solvent-exposed in the LexAPa
model, shows tolerance to all variants, despite being conserved as a basic residue across
species (Figure 8C). Indeed, certain acidic or large hydrophobic variants such as R87E and
R87W appear to cleave at rates higher than that of the wild type enzyme. Position P3 (V88) is
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restrictive, with the wild type residue preferred 5-fold over the next best variant, V88I. Three of the
four best variants are the β-branched amino acids, suggesting the possibility of active site
engagement with the branched side chains. Other tolerated variants are hydrophobic and
predominantly small amino acids. Position P2 (A89), exposed in the active conformation of
LexAPa, tolerates all amino acids, although to different extents. Variants with the smallest side
chains (A89G, wild type with A89, and A89S) are most readily cleaved, while the level of
cleavage generally decreases as a function of increasing size.
The positions immediately flanking the cleavage site show highly restrictive patterns,
while preferences are again relaxed in the downstream positions. At position P1 (A90), only the
five smallest amino acids are tolerated: the wild type A90 is preferred over the next best variant
A90G by 4-fold, while cleavage is detectable with A90C, A90S, and A90T, suggesting significant
active site constraints at this position. Position P1′ (G91) is situated at the β-turn of the LexA
cleavage region in its active conformation. It is the most restrictive position among those
examined, with only a serine mutation retaining any detectable self-cleavage activity (∼50-fold
slower than the WT). Position P2′ (A92) is a solvent-exposed residue and situated at the end of
the β-turn. The tolerance of this position to mutation is in line with its poor conservation across
species isoforms of LexA (Figure 5C).
The kinetic data determined at each position allow for the construction of the overall
sequence preference heat map for LexAPa (Figure 8A). The calculated cleavage rates were used
to build the position-specific scoring matrix, which was then graphically converted into a
sequence LOGO depiction that encapsulates the substrate specificity profile for LexAPa (Figure
8B). As evidenced in the sequence LOGO, positions tolerant to mutation have high entropy or
variability, while restrictive positions show low variability.

2.4.5 Kinetic analysis reveals LexAPa mutants that cleave faster than the wild type enzyme
In our kinetic assays of the LexAPa mutants, we observed that certain mutants
interestingly exhibited a cleavage rate higher than that of the wild type enzyme (“hyperactive”
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mutants). While some hyperactive mutants of LexA have previously been discovered through
genetic screens (Roland et al., 1992; Smith et al., 1991), the molecular basis for hyperactive selfcleavage has not been well-investigated. In our mutagenesis, A92P shows a notable cleavage
rate ~ 4-fold higher than that of the wild type enzyme and undergoes autoproteolysis even under
nonstimulatory conditions (neutral pH, no RecA*) (Table 1 and Figure S6G in the Appendix). The
transition between the cleavage-incompetent and cleavage-competent forms of LexA is
associated with a β-turn at the cleavage site (A90-G91) (Luo et al., 2001). Because position A92
is located at the end of the β-turn in the LexA cleavage loop, we hypothesized that a mutation to
proline stabilizes the β-turn and could thereby promote the active conformation of the protein (Fu
et al., 2009; Trevino et al., 2007).
To test this hypothesis, we introduced cysteine mutations at positions A89 and I94, two
residues that are within disulfide bonding distance in the active conformation (Figure S2 in the
Appendix). We then confirmed by mass spectrometry that the variant formed an intramolecular
disulfide bond across the β-turn (Figure S8 in the Appendix). While the individual point mutants
have rates of cleavage slower than (A89C) or comparable to (I94C) that of the wild type, the
A89C/I94C double mutant is enhanced, in line with the A92P cleavage rate (Figure 9). While the
mechanism cannot be definitively assessed, the A92P and A89C/I94C LexA variants point to the
importance of secondary structure formation in the cleavage region, with potential implications for
inhibitor design.
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Figure 9. Stabilizing the β-turn around the LexAPa scissile bond enhances autoproteolysis
(A) Time-dependent cleavage profiles of LexAPa wild type (WT), A92P, and A89C/I94C. Proteins
were incubated at pH 10.6, quenched at the given time points, and visualized using SDS−PAGE.
(B) Cleavage kinetics of hyperactive variants and controls with individual mutants to cysteine. In
triplicate, the fraction of uncleaved protein was determined using densitometry and fit as a
function of time according to first-order decay kinetics.
2.5 Discussion
The emergence of drug resistance in bacterial pathogens is one of the most pressing
issues in infectious diseases today, particularly given the limited pipeline of new antimicrobials to
combat this threat (Clatworthy et al., 2007; Fischbach and Walsh, 2009). Given the need for a
better mechanistic understanding of bacterial adaptation and novel approaches to combating
drug resistance, the idea of targeting the pathways that allow bacterial pathogens to adapt and
evolve resistance to antibiotics has been proposed (Cirz et al., 2005; Smith and Romesberg,
2007). In support of this approach, stimulating genetic and synthetic biologic studies have
suggested that targeting LexA autoproteolysis can prevent activation of the SOS pathway and
thereby hypersensitize bacteria to traditional antibiotics, slow acquired drug resistance, and offer
insights into the mechanisms driving bacterial evolution. To inform our understanding of LexA, we
performed exhaustive mutagenesis studies on >140 variants of LexA that help to delineate the
key determinants of proteolysis. These studies have led us to conclude that the LexA repressorprotease possesses a unique substrate preference, with both side-chain and conformational
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requirements that govern autoproteolysis. Dissecting each of these stringent, intermediate, and
tolerant determinants for self-cleavage offers insights into LexA’ s mechanism (Figure 10) and
can fuel future efforts to probe the SOS pathway.
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Figure 10. Postulated structure−function relationship of the key residues in the LexAPa
cleavage region
(A) Structural model demonstrating intermediate, stringent, and tolerant positions in the active
LexAPa cleavage region. This active site model is taken from the full homology model of the
LexAPa CTD described in Figure S2 in the Appendix. Positions evaluated in this study are shown
as sticks and color-coded according to their selectivity (red, stringent; orange, intermediate;
green, tolerant). Other residues in the LexA cleavage region are shown as pink lines. The LexAPa
catalytic serine S125 and basic lysine K162 are shaded red and blue, respectively, highlighting
the active site. (B) Interactions between the LexAPa cleavage loop and LexAPa active site pocket.
For each position from position P5 to P2′, the active site residues (S5−S2′) within van der Waals
contact range of the side chain are noted in the box. Positions P3 (V88) and P1 (A90) form
specific hydrophobic contacts with the surrounding active site, which are conserved in both
LexAPa and LexAEc. Position P2 (A89) interacts with position P4′ (I94) on the opposite side of the
loop turn. At each of these positions, the wild type residues and smaller side chains are more
conducive to proteolysis. The two flanking glycines, G86 and G91 (P5 and P1′, respectively),
show a preference for the wild type glycine, which may confer rotational flexibility on the LexA
cleavage region, allowing the internal loop to undergo the transition from the inactive form to the
active form. Positions P4 (R87) and P2′ (A92), which are notably solvent exposed, are tolerant to
all amino acid substitutions, including several that can enhance cleavage.
2.5.1 Stringent determinants: Positions P3, P1, and P1′
We have identified three positions in the LexA cleavage region that are restrictive to
extensive mutation. Interestingly, although exhaustive mutagenesis was not performed, point
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mutations at these positions were also identified to be important for the self-cleavage of the
related λ CI repressor, and the positions are well conserved in LexA isoforms across species
(Figure 5C) (Gimble and Sauer, 1985). For LexAPa, positions P3 and P1 favor the wild type
residues and show tolerance toward β-branched or small amino acids, respectively. For both
positions, analysis of the crystal structure shows extensive van der Waals contacts between the
side chains and hydrophobic pockets in the LexA active site (Figure 10B). Because increasing or
decreasing the size of the amino acid at these positions reduces cleavage efficiency (Table 1),
we conclude that positions P3 and P1 determine specificity through active site contacts. Position
P1′ is the most restrictive position, tolerating only the wild type glycine and a serine mutation.
Position P1′ is located at the end of the β-hairpin turn and undergoes a dramatic bond rotation
during the transition between active and inactive conformations (Luo et al., 2001). Only glycine
can readily adopt and interconvert between these unusual Ramachandran angles, thus explaining
the strong preference for the wild type residue at that position. Larger amino acids likely cause
steric clash with the surrounding protein or are hindered in making the necessary bond rotations.
Interestingly, trace cleavage was also detectable in the G91S mutant (Figure S6F in the
Appendix). We speculate that mutation to a serine likely allows for the formation of hydrogen
bonds between the side-chain hydroxyl group and peptide backbone that can stabilize the turn,
compensating for the decreased level of rotational freedom.

2.5.2 Intermediate determinants: Positions P5 and P2
Unlike the stringent determinants, positions P5 and P2 tolerate a wide range of mutations
yet display a preference for a particular subset of amino acids. At position P5, the wild type
residue, glycine, is preferred over a larger amino acid, such as alanine or serine. Similar to
position P1′, in the determined structures of LexA, the glycine at position P5 undergoes a
significant rotation during the transition from the inactive state to the active state, thus explaining
the presence of a flexible residue that can serve as a molecular hinge (Luo et al., 2001). Position
P2 displays an intermediate phenotype, as well: although all variants are tolerated, amino acids

	
   33	
  
	
  

that exceed the size of serine decrease the rate of self-cleavage. Structurally, the side chain of
position P2 forms contacts with the side chain of position P4′ (I94) located on the opposite side of
the loop (Figure S2 in the Appendix). Increasing the size of the amino acid likely reduces the rate
of cleavage due to steric clash.

2.5.3 Permissive positions and enhanced autoproteolysis: Positions P4 and P2′
In addition to deciphering specificity determinants, our study has also identified two highly
permissive positions that flank the LexA scissile bond. Positions P4 and P2′ can be mutated to
the whole amino acid spectrum without abrogating LexA cleavage, although changes in the rate
of cleavage are observed. The LexAPa model structure shows both positions to be relatively
solvent-exposed, forming few specific contacts with the surrounding active site. Interestingly, both
positions also harbor mutations that enhance the level of self-cleavage compared to that of the
wild type enzyme. At position P4 (R87), mutations removing a basic residue appear to enhance
self-cleavage (Table 1), despite the conservation of the basic residue in LexA across species
(Figure 5C). We speculate that these rate-enhancing mutations may result from the removal of a
potential repulsive interaction with an adjacent (and well-conserved) positively charged residue
(R120) in the active conformation. Position P2′, in contrast to position P4, is highly variable
across species (Figure 5C), which correlates well with its tolerance to mutagenesis in our
biochemical study. At position P2′, introduction of a proline mutation enhances self-cleavage,
likely by stabilizing the β-turn around the scissile bond and thereby promoting the cleavagecompetent state of LexA. This model is supported by our analysis of the disulfide cross-linked
A89C/I94C mutant, which shows cleavage kinetics similar to those of the A92P mutant (Figure
9B). Our results expand the list of previously identified mutations that enhance LexA cleavage
(Smith et al., 1991). In a prior study, mutations located at positions P5′ and P8′ in E. coli LexA,
distant from the catalytic site, were shown to stabilize the active conformation of the entire LexA
cleavage loop (Luo et al., 2001; Smith et al., 1991). Our results for A92P and A89C/I94C mutants
suggest that stabilizing the β-turn around the scissile bond with rigid cyclic structures similarly

	
   34	
  
	
  

enhances cleavage and could offer novel avenues for inhibitor design.

2.5.4 Conformational constraints and side-chain recognition in LexA
The nature of our experimental design, which focused on mutations in the cleavage loop
and kinetic analysis of autoproteolysis, requires that the enzyme and its substrate change
simultaneously. Additionally, given that we evaluated single-point mutants, the impact of
combinatorial modifications in the substrate could not be readily assessed from our approach.
Despite these limitations, the relative independence of the cleavage loop and the active site
residues make it possible to integrate across our biochemical analysis and structural modeling to
provide a detailed picture of LexA’s specificity. From our analysis, we postulate that the nature of
the specificity determinants of LexA can be classified under two broad categories: those
permissive for substrate recognition and those permissive for the conformational change in selfcleavage (Figure 10B). Much like conventional proteases, LexA has substrate recognition pockets
that determine its selectivity, most evident at positions P3 (V88) and P1 (A90) (Figure 6B). As a
key difference from conventional proteases, however, the LexA cleavage region must internally
rearrange to adopt a proper cleavage-competent conformation for proteolysis to occur. Positions
P5 (G85) and P1′ (G91) are highly dynamic positions, implying that conformational flexibility at
either end of the cleavage region appears to be important for autoproteolysis. In support of the
importance of dynamic rearrangements in LexA, stabilizing the β-turn across the scissile bond
promotes self-cleavage at a level above that of the wild type. We postulate that these
requirements for both proper sequence and conformation serve as a mechanism of selfrecognition and limit off -target proteolytic activity. Our findings help rationalize the low cleavage
activity of the LexA protease in trans and offer insights into rational probe design (Kim and Little,
1993).

2.5.5 Comparison of LexAPa to similar proteases
Our biochemical results are particularly informative when we compare LexAPa to
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members of the larger LexA/signal peptidase superfamily, many of which mediate bacterial stress
responses (Figure S1B in the Appendix). This superfamily includes LexA homologues such as
Bacillus subtilis DinR and Vibrio cholerae SetR, the phage λ CI repressor, and UmuD and MucA,
self-cleaving enzymes that function in the SOS-linked translesion DNA synthesis (Beaber et al.,
2004; Burckhardt et al., 1988; Cezairliyan and Sauer, 2009; Gimble and Sauer, 1985; Kim and
Little, 1993; Miller et al., 1996; Nohmi et al., 1988; Shiba et al., 1990). In these enzymes, position
P1′ is universally conserved as a glycine (Figure S1 in the Appendix), suggesting that the
flexibility of position P1′ is likely critical to the mechanism. The stringent residues involved in sidechain contacts are also strongly conserved, with a β-branched residue at position P3 and a small
residue at position P1 conserved across comparators (Figure S1B in the Appendix). Notably, the
position S3 and S1 recognition pockets are entirely conserved between LexAPa and LexAEc
(Figure S1A in the Appendix), suggesting a common mechanism of side-chain recognition in
forms of LexA from different species. For the intermediate determinants, the position P5 glycine
offers the most revealing comparison to other self-cleaving enzymes. We speculate that this
residue is a critical “hinge” for the conformational change that allows self-cleavage within a LexA
monomer. Interestingly, position P5 is not conserved in UmuD where cleavage of one monomer
can occur in the other monomer’s active site (McDonald et al., 1999). Overall, comparing the
superfamily to other common serine proteases, we note that LexA favors small amino acids in the
positions flanking the scissile bond, most similar to the elastase family of serine proteases
(Hedstrom, 2002; Perona and Craik, 1995). However, the unique self-cleaving mechanism and its
conformational requirements are distinguishing features that appear to be well conserved across
the LexA/signal peptidase superfamily.

2.5.6 Implications for the design of inhibitors and molecular probes of LexA
In addition to revealing insights into the mechanism of self-cleavage, several aspects of
our substrate specificity studies can potentially help direct future efforts to develop small molecule
probes of the SOS pathway. First, while LexA does not have proficient activity with peptides in
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trans, it does have detectable activity. Peptides or peptidomimetics that incorporate preferred
features, such as the side chains of positions P3 and P1 or β-turn-stabilizing structures, may be
exploited to enhance binding. Even weak binding peptides or peptidomimetics could be converted
into more potent probes by the incorporation of mechanism-based covalent inhibitor warheads
into such molecules. Second, our discovery of tolerance at positions P4 and P2′ could be
exploited in inhibitor discovery. The introduction of fluorescent reporters at these positions could
aid in screening for inhibitors of self-cleavage or, given the highly dynamic nature of position P2′,
potential allosteric modulators of the conformational change. Finally, our discovery of a range of
hypocleavable LexA variants can potentially help further validate LexA’s viability as a therapeutic
target. Given that LexA inhibitors would be unlikely to fully recapitulate the LexA catalytic mutant,
these variants can be used to reveal the amount of inhibition that will be necessary to synergize
with current antibiotics or to slow acquired antibiotic resistance.

2.5.7 Implications for bacterial mutation and evolution
We hypothesize that the identification of rate-enhancing mutations by prior genetic
studies and our biochemical studies has wider implications for bacterial mutagenesis and
evolution (Roland et al., 1992; Smith et al., 1991). The fact that mutations can enhance cleavage
suggests the possibility that the rate of LexA autoproteolysis may be finely tuned to be fast
enough to facilitate robust SOS responses but slow enough to prevent aberrant SOS pathway
activation. This characteristic has been thought to be functionally important in different members
of the LexA superfamily. As an example, temperate phage repressors such as the phage λ CI
repressor self-cleave more slowly than LexA during SOS-inducing treatments, thereby inducing
prophage formation only with extensive DNA damage (Kim and Little, 1993). Similarly,
mutagenesis proteins, such as UmuD, self-cleave at rates slower than that of LexA, which could
promote translesion DNA synthesis later in the SOS response, only after higher-fidelity repair
mechanisms have failed (Nohmi et al., 1988). Given that self-cleavage can be either slowed or
enhanced by mutations, we hypothesize that the LexA cleavage rate has been selected for to
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allow for proper activation of the SOS pathway and that LexA may serve as a rheostat for
evolution under stress. Our study offers the possibility of modulating the cleavage rates of LexA
across a large range to assess the impact on bacterial mutation and survival directly under
varying degrees of stress. Chapter 3 explores these ideas at a greater detail.
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CHAPTER 3: Systematically altering bacterial SOS activity under stress reveals
therapeutic strategies for potentiating antibiotics
The contents of the chapter have been published:
Mo et al. (2016) Systematically Altering Bacterial SOS Activity under Stress Reveals Therapuetic
Strategies for Potentiating Antibiotics. mSphere 1, 4, 10.1128/mSphere.00163-16. eCollection
2016 Jul-Aug.
Contributions: CYM, MG, and RMK conceived of this study; CYM, SAM, MNS, and MR generated
the bacterial strains; MJC designed the radioactive LexA cleavage assay; PDS provided guidance
with the bacterial fluctuation analysis; CYM performed the experiments; CYM and RMK wrote the
paper, with input from all the authors.
3.1 Abstract
The bacterial SOS response is a DNA damage repair network that is strongly implicated
in both survival and acquired drug resistance under antimicrobial stress. The two SOS regulators
– LexA and RecA – have therefore emerged as potential targets for adjuvant therapies aimed at
combating resistance, although many open questions remain. For example, it is not well
understood whether SOS hyperactivation is a viable therapeutic approach or whether LexA or
RecA is a better target. Furthermore, it is important to determine which antimicrobials could serve
as the best treatment partners with SOS-targeting adjuvants. Here we derived Escherichia coli
strains that have mutations in either lexA or recA genes in order to cover the full spectrum of
possible SOS activity levels. We then systematically analyzed a wide range of antimicrobials by
comparing the mean inhibitory concentrations (MICs) and induced mutation rates for each drugstrain combination. We first show that significant changes in MICs are largely confined to DNA
damaging antibiotics, with strains containing a constitutively repressed SOS response impacted
to a greater extent than hyperactivated strains. Second, antibiotic-induced mutation rates were
suppressed when SOS activity was reduced and this trend was observed across a wider
spectrum of antibiotics. Finally, perturbing either LexA or RecA proved to be equally viable
strategies for targeting the SOS response. Our work provides support for multiple adjuvant
strategies, while also suggesting that the combination of an SOS inhibitor with a DNA damaging
antibiotic could offer the best potential for lowering MICs and decreasing acquired drug
resistance.
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3.2 Introduction
The rapid rise of antibiotic resistance in bacterial pathogens is a major global health
crisis. In the United States alone, resistant bacteria are associated with approximately 2 million
infections and 23,000 deaths per year, with an economic burden upwards of $55 billion (Centers
for Disease Control and Prevention, 2013). In the past decade, the frequency of multi-drug
resistant strains has rapidly risen and even sensitive organisms are requiring higher minimal
inhibitory concentrations for effective therapy (Prabaker and Weinstein, 2011; Centers for
Disease Control and Prevention, 2014). Efforts to address the problem of resistance have
traditionally focused on modifying the scaffolds of existing antibiotics in order to circumvent the
molecular mechanisms conferring resistance (Fischbach and Walsh, 2009). While such efforts
can offer a respite, resistance often rapidly follows, as existing resistance determinants adapt to
the new agents (Walsh, 2000). As a result, alternative strategies are being pursued, such as
mining for previously inaccessible natural products, potentiating the host immune response, and
targeting bacterial virulence pathways (Clatworthy et al., 2007; Czaplewski et al., 2016; Donia et
al., 2014; Hancock et al., 2012; Thaker et al., 2013).
One of the new strategies proposed to combat resistance is to target the bacterial DNA
damage stress response pathway, also known as the SOS response (Blazquez et al., 2012; Cirz
et al., 2005; Culyba et al., 2015; Smith and Romesberg, 2007). The SOS response is a widely
conserved DNA damage repair network that enables bacteria to survive genotoxic damage, but is
also strongly associated with elevated mutagenesis and acquired resistance (Foster, 2007;
Michel, 2005; Sutton et al., 2000). The SOS pathway consists of a set of genes (SOS genes),
which are defined to be under the control of the RecA and LexA proteins (Erill et al., 2007;
Fernandez De Henestrosa et al., 2000). LexA is a dual-functional repressor-protease that blocks
the transcription of the SOS genes in the absence of stress. When bacteria experience genotoxic
stress, RecA, acting as a sensor molecule, polymerizes along exposed single-stranded DNA
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(ssDNA), forming activated nucleoprotein filaments (RecA*). RecA*, in turn, stimulates LexA to
undergo autoproteolysis (self-cleavage), leading to the de-repression of SOS effector genes.
The induced SOS effector genes can play roles in adaptation to antibiotic stress,
acquired resistance, or pathogenicity. One such effector, sulA, encodes an inhibitor of cell
division, which has been proposed to serve as a DNA damage checkpoint during the response
(Huisman and D'Ari, 1981). Other SOS effectors facilitate high-fidelity DNA damage repair, such
as uvrA, which is involved in nucleotide excision repair (Kenyon and Walker, 1981), and recA
itself, which participates in homologous recombination (Chen et al., 2008). However, under higher
levels of damage, lower fidelity processes emerge and can predominate in the response. Chief
among these error-prone SOS effectors are umuDC and dinB, which encode translesion DNA
polymerases that are able to replicate over genomic lesions, but do so at the expense of
increased mutagenesis (Sutton et al., 2000; Tippin et al., 2004). In addition, SOS activation has
also been shown to trigger the expression of integrases that mediate transfer of resistance genes.
On a phenotypic level, the response is also implicated in biofilm formation, induction of persister
states, and expression of virulence factors (Dorr et al., 2010; Gotoh et al., 2010; Guerin et al.,
2009; Ubeda et al., 2005). Thus, SOS activation serves to promote DNA damage tolerance and
survival under genotoxic stress, while also increasing the likelihood of acquiring antibiotic
resistance.
Many antibiotics trigger the SOS response, either directly through DNA damage (e.g.
fluoroquinolones) or indirectly through alternative activation pathways (e.g. β-lactams) (Kohanski
et al., 2007; Maiques et al., 2006; Miller et al., 2004). Given its role in adaptation and acquired
resistance, the SOS response has therefore been proposed as an attractive therapeutic target
that might potentiate our current antibiotic arsenal. Various lines of genetic evidence support this
possibility. Extensive historical studies have shown that mutations in recA and lexA can increase
bacterial sensitivity to DNA damaging agents such as UV radiation (Mount et al., 1972; Schlacher
and Goodman, 2007; Witkin, 1976), and these findings also extend to medically relevant
antibiotics. For example, in a murine thigh infection model, Cirz et al. demonstrated that
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inactivating LexA autoproteolysis reduces both the viability and acquired resistance of E. coli
treated with either ciprofloxacin or rifampicin (Cirz et al., 2005); likewise, Thi et al. showed that E.
coli strains with recA deleted exhibit increased antibiotic sensitivity and reduced mutagenesis
under a wide range of drug treatments (Thi et al., 2011).
The ramifications of hyperactivating the SOS response are less well understood, but
could also offer potential therapeutic avenues. Early work on E. coli with a mutant lexA gene that
resulted in a constitutive SOS activation showed heightened resistance to UV radiation and
elevated mutation levels (Mount, 1977; Pacelli et al., 1979). However, the effects of constitutive
SOS activation on antibiotic susceptibility remain, to our knowledge, less well defined. Since the
SOS response is part of a complex network of genes (Al Mamun et al., 2012; Courcelle et al.,
2001), an overactive response could disrupt coordination of DNA damage repair and increase
sensitivity to antimicrobials. Further, increased expression of some SOS effectors could enhance
the effect of some antibiotics. For example, in E. coli and other bacterial species, deletion of the
lexA gene is lethal to the cell, because constitutive expression of sulA permanently arrests cell
division (Huisman and D'Ari, 1981; Huisman et al., 1984). Additionally, a higher mutagenic
burden associated with expression of error-prone SOS effectors could compromise fitness,
analogous to lethal mutagenesis strategies utilized to combat some viruses (Loeb et al., 1999).
Despite the strong genetic data implicating the SOS response as critical for survival and
adaption of bacteria under stress, significant questions remain regarding targeting of the SOS
response. What is the best strategy for perturbing the SOS regulatory network and which
antibiotics would serve as the best partners for SOS-targeting adjuvants? What is the relative
viability of targeting RecA versus LexA? What are the implications of hyperactivating versus
inhibiting the SOS pathway? To address these questions, we generated E. coli mutants that
exhibit a spectrum of SOS activities, ranging from constitutively repressed to constitutively active
(Figure 11). These strains provided us with the tools to systematically measure bacterial
susceptibility and induced mutation rates to different classes of antibiotics. Our comprehensive
analysis offers guidance for strategies to combat drug resistance by targeting the SOS response.
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Figure 11. Engineered lexA and recA variants in E. coli displaying a range of SOS activities
The LexA protein is represented by blue ovals and the various LexA cleavage mutants are
labeled in blue. RecA is shown as red ovals and variants are labeled in red. Five LexA variants
and two RecA variants allow for examination of the spectrum of SOS activation. Activated RecA
filaments lead to cleavage of LexA and inducible expression of SOS genes in the WT strain.
Inactivating LexA self-cleavage (S119A) or deleting recA (ΔrecA) inactivates the response.
Mutations in the LexA protein can either decrease (G80A) or increase (E86P) the rate of selfcleavage relative to the WT strain and thus affect the level of SOS induction. Deleting lexA (Delta)
or hyperactivating RecA (recA730) leads to constitutive expression of SOS genes.
3.3 Experimental procedures
3.3.1 Congenic strain generation

ΔrecA::(FRT-kan-FRT) and ΔsulA::(FRT-kan-FRT) E. coli strains (JW3470 and JW0941,
respectively) were obtained from the KEIO collection (Baba et al., 2006). The recA and sulA
genes were deleted from MG1655 using T4GT7 bacteriophage transduction (Plakidou et al.,
1984), or P1vir transduction (Miller, 1992), respectively, followed by Flp-mediated removal of the
kan cassette using plasmid pCP-20 (Datsenko and Wanner, 2000). The resulting ΔrecA strain
(MG1655 ΔrecA::FRT) was subsequently used in experiments, while the ΔsulA strain (SAMP02,
MG1655 ΔsulA::FRT) served as the parent for further genetic engineering at the lexA locus.
In the ΔsulA background of SAMP02, a ΔlexA::[Cm-I-SceI] cassette was introduced into
the native lexA locus by recombineering, resulting in the strain SAMP04 (MG1655 ΔlexA::[Cm-ISceI] ΔsulA::FRT), which we refer to as Delta. In brief, the chloramphenicol cassette and I-SceI
restriction site were generated by PCR using the plasmid pWRG100 as template. PCR primers
have a 5' region of homology to lexA, allowing for double recombination of the cassette. The
Delta strain was used for recombineering-based scarless mutagenesis (Blank et al., 2011).
Overlap extension was used to generate cassettes containing 1-kb regions upstream and
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downstream of the lexA gene, along with the desired lexA variant (S119A, G80A, WT, and E86P)
(Heckman and Pease, 2007). These cassettes were transformed into the Delta strain, and
counterselection yielded the desired transformants as previously described (Blank et al., 2011).
These strains, which are all derivatives of the Delta strain containing the sulA deletion, will be
referred to as S119A, G80A, WT and E86P. The recA730 allele was introduced into the S119A
and WT strains by P1vir transduction using SS4247 as a donor strain followed by selection with
tetracycline.
For experiments examining the effect of sulA deletion in our strains, we re-engineered the
sulA gene into the S119A, G80A, and E86P strains by transduction using a P1vir lysate derived
from MMR102, which contains ΔtorT::(FRT-kan-FRT) at a locus neighboring sulA (Miller, 1992).
The kan cassette was subsequently removed by Flp-mediated recombination using plasmid
+

+

pCP20 (Datsenko and Wanner, 2000) to yield strains S119A (sulA ), G80A (sulA ), and E86P
+

+

(sulA ). For comparison to these sulA strains, we used MG1655 as a reference with native lexA.
All strains were confirmed by PCR and sequenced at relevant loci. Strain names and
relevant genotypes are summarized in Table 2. Primer sequences or strains are available upon
request.
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Table 2. List of E. coli strains used in this study
Strain name

Relevant Genotype

Description

Reference or Source

MG1655

lexA , sulA

Used as the WT LexA and sulA+
control in the MIC and fluctuation
analyses

Yale E. coli Genetic
Stock Center CGSC
#7740

JW0941

ΔsulA::(FRT-kan-FRT)

Strain source of ΔsulA

Baba et al., 2006; (KEIO
collection)

SAMP02

MG1655 ΔsulA::FRT

Parent strain for ΔlexA strain

This study

JW3470

ΔrecA::(FRT-kan-FRT)

Strain source of ΔrecA

Baba et al., 2006; (KEIO
collection)

ΔrecA

MG1655 ΔrecA::FRT

Used as the recA knockout strain

This study

Delta
(SAMP04)

MG1655 ΔlexA::[Cm-I-SceI],
ΔsulA::FRT

Parent strain for recombineering; lexA
knockout

This study

WT

MG1655 lexA+, ΔsulA::FRT

Strain with wild type LexA cleavage

This study

S119A

MG1655 lexAS119A,
ΔsulA::FRT

Strain with catalytically inactive LexA

This study

G80A

MG1655 lexAG80A, ΔsulA::FRT

Strain with slow-cleaving LexA

This study

E86P

MG1655 lexAE86P, ΔsulA::FRT

Strain with fast-cleaving LexA

This study

SS4247

TetR recA730 srlC300::Tn10

Strain source of recA730

Steven J. Sandler,
unpublished

recA730

MG1655 lexA+, ΔsulA, recA730,
TetR srlC300::Tn10

Strain with wild type LexA cleavage
and constitutive RecA activity

This study

recA730/S119A

MG1655 lexAS119A, ΔsulA,
recA730, TetR srlC300::Tn10

Strain with catalytically inactive LexA
and constitutive RecA activity

This study

MMR102

MG1655 sulA ΔtorT::(FRT-kanFRT)

Strain source of sulA

Goulian lab stock

MG1655 lexAS119A,
+
sulA ΔtorT::FRT

Strain with inactive LexA and sulA

This study

MG1655 lexAG80A,
+
sulA ΔtorT::FRT

Strain with slow-cleaving LexA and
sulA

This study

MG1655 lexAE86P,
+
sulA ΔtorT::FRT

Strain with fast-cleaving LexA and
sulA

This study

+

+

+

+

S119A (sulA )

+

G80A (sulA )

+

E86P (sulA )
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3.3.2 Measuring the Minimal Inhibitory Concentration (MIC) of strains
MICs were determined using a resazurin-based assay (Sarker et al., 2007) using serial 2fold dilutions of the drug and following previously published guidelines (Clinical and Laboratory
Standards Institute, 2006). The reported MICs represent the average of four independent
measurements performed on separate days.

3.3.3 Measuring strain growth rates
6

Overnight cultures of the strains were diluted 10 -fold into fresh LB. 100 mL of diluted
culture were distributed into a 96-well, round-bottom, transparent plate. 100 mL of LB with
sublethal doses of antibiotic agent were then added to the cultures and the plates were sealed
with transparent tape. The cultures were incubated at 37 °C with cycled agitation (3 mm orbital
shaking, 450 rpm) for 16 hours on a Tecan plate reader. OD595 measurements were obtained
every 30 min. We noted that these plate-based growth conditions result in an approximately 5%
increase in doubling times compared to culture conditions with larger volumes in aerated 15 mL
culture tubes (unpublished data). However, these conditions permit continuous measurement and
the results obtained parallel those from competition experiments (detailed below), which were
performed under conditions with more significant aeration.

3.3.4 Competition experiments
For the competition experiments, a constitutively active GFP expression plasmid pMS
pRev-GFP (See Supplemental material for Chapter 3 in the Appendix) was transformed into the
WT strain using standard chemical transformation techniques. The same vector with constitutively
repressed GFP expression (pMS pAra-GFP) was transformed into the four other variant strains.
Competition assay procedures were adapted from established protocols (Lenski et al., 1991). In
brief, overnight cultures in LB containing kanamycin for plasmid maintenance were grown. The
next morning, co-cultures were started by inoculating 3 mL of LB containing kanamycin with equal
6

amounts (10 -dilutions) of WT and a mutant strain either in the absence or presence of an
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additional antibiotic stressor. The co-culture was then incubated at 37 °C with aeration for 24
hours. To determine the starting and final colony forming units (CFU) of the strains, culture
samples were taken before and after the 24-hour growth period, plated onto LB agar (with
kanamycin selection), and incubated overnight at 37 °C. The next day, WT colonies on the plate
were distinguished from the variant colonies by visualizing GFP fluorescence on a BioRad
GelDoc XR+ imager with UV illumination through an XcitaBlue Conversion Screen (BioRad).
Quantifying population numbers (N), we estimated the relative fitness (W) of the variant strain
relative to the WT strain by calculating the change in the relative abundances between the initial
(i) and final (f) samples (Lenski et al., 1991):
𝑊 =    𝑙𝑛[
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When no rifampin resistant colonies could be detected, we calculated the lower limit of detection
by assuming one resistant colony was present and determining the mutation rate based on the
CFU detected under those conditions. We used a two-sided paired t-test to assess for statistical
significance between the fitness of each variant strain compared to the WT strain and interpreted
a p-value of < 0.05 as a significant difference.

3.3.5 Fluctuation analysis of bacterial mutation rates
Fluctuation analysis was performed using an adapted version of established protocols
(Gerrish, 2008). Briefly, six replicate 30 mL cultures in LB (containing either no antibiotic or a sub8

lethal level of antibiotic) were inoculated with a 3.3 x 10 dilution of overnight LB broth culture.
The concentration of antibiotic used in each case was a fixed level below the MIC (as provided in
Table S2 in the Appendix). The concentration of stressor antibiotic selected was the highest
concentration that permitted sufficient viable CFUs to allow for fluctuation analysis to be
performed, typically 1.5- to 8-fold below the MIC. Cultures were grown to saturation at 37 °C for
48 hours. After 48 hours, to determine the total CFU, appropriate dilutions were plated onto nonselective LB agar plates. To determine the number of mutant colonies, 300 µL of culture were
separately spun down, washed with 100 µL of 5% NaCl solution, and plated onto 100 µg/mL of
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rifampin. The rifampin plates were incubated at 37 °C for a total of 48 hours; resistant colonies
were counted once after 24 hours and a second time after 48 hours. The number of total cells
and resistant colonies were then entered into the MutRateCalc software to perform maximum
likelihood analysis, which yields the mutation rate and associated confidence intervals (Gerrish,
2008).

3.4 Results
3.4.1 Generation of recA and lexA mutant strains in E. coli
While isolated studies using strains with inactivated lexA or deleted recA have validated
the SOS pathway as a therapeutic target, a systematic comparison across the entire spectrum of
SOS activity could help guide therapeutic strategies. Towards this goal, we derived a series of
MG1655 E. coli strains that enabled us to systematically examine the consequences of altered
SOS activity. We aimed to engineer strains with lexA variations that would span from a
constitutively inactive to a constitutively active SOS response, and also mimic the extreme
phenotypes with alterations to recA (Figure 11).
+

As deletion of lexA is lethal in sulA E. coli strains, we generated congenic strains in the

ΔsulA background that only differ in the proficiency of the LexA protein to undergo self-cleavage.
To access one extreme, the constitutively active SOS pathway, we first constructed a ΔlexA strain
in the SulA-null background (defined as the Delta strain). This Delta strain was subsequently
used as the parent for genetic recombineering at the lexA locus to yield four previously described
LexA cleavage-rate variants from Chapter 2: a “hyperactive” E86P (P2’) mutant, the reconstituted
wild type (WT) enzyme, a “hypoactive” G80A (P5) mutant, and finally the SOS-inactive S119A
mutant, which is completely incompetent in self-cleavage (Lin and Little, 1988; Mo et al., 2014).
The relative in vitro self-cleavage activities of these LexA variants were confirmed in biochemical
assays, with G80A ~5-fold reduced and E86P ~10-fold enhanced relative to WT LexA and with
S119A unable to self-cleave under both base- and RecA-mediated conditions (Figure S9 in the
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Appendix). Together these five congenic strains provide the full spectrum of SOS activities,
spanning from constitutively repressed (S119A) to constitutively active (Delta).
We also sought to simultaneously compare the effect of perturbing lexA with alterations
to recA. For comparison to Delta, we generated a congenic strain containing the recA730 allele,
which encodes for a DNA recombination and co-protease proficient RecA variant, E38K, that
forms nucleoprotein filaments in the absence of DNA damage and constitutively activates the
SOS response through constant LexA cleavage (Lin and Little, 1988; Witkin et al., 1982). For
comparison to S119A, we used a strain containing a recA deletion. Together, these recA mutants,
along with the lexA mutants described above, are the main focus in our subsequent MIC, fitness,
and mutagenesis experiments. However, we recognized that the sulA deletion in the Delta strain
could in principle impact bacterial susceptibility and mutagenesis. We therefore also restored sulA
in the S119A, G80A, and E86P variants to allow for comparison to the reference MG1655 strain
(summarized in Table 2).

3.4.2 Minimal Inhibitory Concentration (MIC) of the mutant strains under varying antibiotic
stress
With our spectrum of SOS-variant strains established, we first aimed to survey their
sensitivity to a broad range of different antimicrobials and DNA damaging agents. We selected 12
drugs spanning different mechanistic classes and compared the resulting MIC for each drugstrain combination to that of the WT strain (Figure 12, Table S1 in the Appendix). For mitomycin
C, a DNA alkylator that is known to induce the SOS response through formation of intra-strand
DNA crosslinks, we observed a 16- and 4-fold reduction of the MIC for the ΔrecA and S119A
strains, respectively. We also observed reductions in the E86P, Delta, and recA730 strains to a
lesser extent, indicating that SOS hyperactivation can also increase susceptibility to DNA
damage. A similar trend in the MICs was observed with several antibiotics known to damage DNA
and activate the SOS response. For the fluoroquinolones, which target DNA gyrase and induce
double-stranded DNA breaks, treatment of the SOS-inactivating lexA and recA mutant strains
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with either ciprofloxacin or levofloxacin resulted in a ≥ 4-fold reduction in MIC, while the two SOSconstitutive mutants exhibited more modest decreases (between 2- and 4-fold). Finally, we
observed similar susceptibility patterns with nitrofurantoin, which is associated with oxidative DNA
damage (McOsker and Fitzpatrick, 1994). In comparing alterations to lexA versus recA, the
sensitivities of recA730 and Delta were generally similar to one another, while ΔrecA had slightly
enhanced sensitivity relative to S119A. In particular, ΔrecA exhibits a 32-fold reduction in MIC
with nitrofurantoin, the greatest change in sensitivity across strains and antibiotics evaluated.
1
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Figure 12. Heat map of relative MICs of different SOS variants with various antibiotics
The MIC values of the WT strain, shown in white numbers, are listed in µg/mL. MIC values
represent the average from at least four independent determinations performed on separate
days. “ND” represents a condition and strain where the MIC was not determined. The raw MIC
values of all the strains are shown in Table S1 in the Appendix.
For the remaining antibiotics tested, we saw more modest changes in susceptibility in the
strains. With novobiocin, an agent that inhibits DNA gyrase without inducing dsDNA breaks
(Gellert et al., 1976; Sugino et al., 1978), sensitivity was generally unchanged, with the exception
of a 2-fold reduction in MIC of the ΔrecA strain. The novobiocin results suggest that the
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generation of dsDNA breaks by fluoroquinolines, and not gyrase inhibition alone, is needed for
synergy with SOS perturbation. Although dihydrofolate reductase inhibitors, aminoglycosides and
β-lactams have been proposed to induce the SOS response, we observed ≤ 2-fold changes in
MICs across strains. Similarly, with non-SOS inducing antibiotics, the macrolide erythromycin or
aminoglycosides, we observed ≤ 2-fold changes in sensitivity at SOS extremes.
To determine whether the sulA deletion impacts the MIC differences, we examined
+

antibiotic sensitivity with our corresponding sulA strains (which by necessity exclude Delta and
+

recA730). For some antibiotics, such as levofloxacin and nitrofurantoin, the MIC of the WT(sulA )
strain was reduced when compared to the WT(ΔsulA) strain. However, the trend in MIC reduction
+

between the different sulA strains remained consistent with the trend in ΔsulA SOS-variants
(Figure S10 and Table S1 in the Appendix). Thus, we conclude that sulA status may alter
susceptibility for a given antibiotic, but this does not change the relative impact of perturbing SOS
regulation.

3.4.3 Impact of hypo- and hyperactive SOS variants on bacterial fitness
In our MIC analysis, we noticed that only minor differences were evident between G80A,
WT and E86P strains. We next wanted to ascertain if these intermediate SOS-variants display
any detectable changes in fitness to antibiotic-induced stress. We first confirmed that altering
LexA cleavage activities perturbed levels of SOS induction in the predicted manner. To do this,
we employed a GFP reporter plasmid where gfp is placed under the control of the SOS-inducible
recA promoter (Zaslaver et al., 2006). We measured GFP fluorescence in each lexA variant strain
in the presence of sublethal doses of mitomycin C, ciprofloxacin, or nitrofurantoin. The GFP
fluorescence profiles of the strains correlated with the rate of self-cleavage for each LexA
cleavage-rate variant, thus confirming differences in extent of SOS activation across strains
(Figure S11 in the Appendix).
Although we did not detect large changes in MICs between the intermediate SOS-variant
strains, we considered whether these strains might have relative growth deficits when compared
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to one another. To this end, we measured exponential growth in the presence or absence of
sublethal antibiotic stress across all five strains (Figure 13, Figure S12 in the Appendix). In the
absence of any antibiotic stress, all strains displayed similar growth rates. However, when the
strains were treated with ciprofloxacin at sublethal levels, growth was significantly perturbed for
the S119A and Delta strains, as expected. As ciprofloxacin approached the MIC, E86P had a
reduction in growth rate, while G80A remained similar to WT (Figure 13A). For mitomycin C and
nitrofurantoin, S119A and Delta were again compromised, G80A showed minor growth reductions
and E86P remained similar to WT (Figure S12 in the Appendix).
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Figure 13. Impact of lexA variants on cell growth under sublethal doses of stress
(A) Growth curves of the strains exposed to increasing, yet sublethal, levels of ciprofloxacin
stress. The data is represented as the mean of 3 independent measurements and the error bars
reflect the standard error of the 3 replicates. Growth curves under mitomycin C and nitrofurantoin
stress are shown in Figure S12 in the Appendix. (B) Estimated fitness of the variant strains
relative to the WT strain under different types of antibiotic stress. The mean fitness of each strain
relative to the WT strain was calculated from 3 independent competition experiments. Error bars
represent the standard error of the three trials. For strains where no colonies were detected for
the variant strain, the top of the error bar represents the limit of detection. Significant p-values (* <
0.05, ** < 0.005) are noted.
To directly compare the strains, we next performed pairwise fitness competitions between the WT
and SOS-variant strains (Figure 13B). In the absence of antibiotics, there were no fitness defects
observed in any competition experiments. In the presence of DNA-damaging antibiotics, the two
extreme lexA variants, S119A and Delta, had significantly reduced fitness as expected given the
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MIC results. Specifically, in the presence of mitomycin C and ciprofloxacin, the wild type strain
entirely outcompeted both S119A and Delta, with no colonies detected after growth. In the
presence of nitrofurantoin, at the end of competition, there were no detectable colonies with
S119A, while Delta showed a significant reduction in fitness. In contrast to the large fitness
alterations observed with S119A and Delta, we detected only small fitness defects for the
intermediate strains relative to the WT strain, and the defect depended on the antimicrobial agent.
With mitomycin C, we observed a statistically significant decrease in relative fitness for both
G80A and E86P. With ciprofloxacin, we observed a trend in favor of the WT over the variant
strains that did not achieve statistical significance, while the fitness of G80A and E86P were
similar to WT in the presence of nitrofurantoin. Thus, we conclude that although MICs are
generally unchanged for the intermediate SOS-variant strains, partial reduction or enhancement
of the SOS response could manifest as small changes in bacterial growth and fitness during
antimicrobial stress.

3.4.4 Mutagenesis under antibiotic stress
Aside from altering antibiotic sensitivity, perturbing the SOS response has been shown to
alter the likelihood of acquired antibiotic resistance. To address the impact of SOS inhibition or
activation on mutagenesis, we next applied a fluctuation analysis protocol, which utilizes rifampin
selection to examine the impact of antibiotic-induced stress on the mutation rates of the strains.
Unlike mutation frequencies, which can be biased by growth rates and the overall size of a
population, measuring the mutation rate by fluctuation analysis allows for an unbiased
assessment of the number of mutations per generation. After bacterial growth in the presence of
the stressor antibiotic, the number of mutants the acquire resistance to rifampin are counted and
compared to the total CFU. The use of an orthogonal antibiotic for selection of mutants enables
the estimation of the overall mutation rate of the strain under the growth conditions.
In the absence of antimicrobial stress, all strains displayed similar mutation rates, aside
from the two constitutive SOS mutants, Delta and recA730, which displayed approximately 7- and
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Figure 14. Impact of the SOS activities on E. coli mutation rates
(A) Mutation rates of strains grown under no stress or after exposure to sublethal doses of
ciprofloxacin. Circles and squares represent the maximum likelihood mutation rate calculated
from 6 replicate cultures and the error bars represent the 95% confidence intervals. (B) Heat map
of relative mutation rates across strains and antibiotic stressors. The heat map captures the
reduction or increase in the mutation rate, relative to the WT strain under that antibiotic. Values
-9
listed for the WT are the mutation rate (x10 ) per generation under each condition. Black boxes
represent conditions where no resistant colonies could be detected. (C) Mutation rates of strains
across a wide panel of antimicrobial agents. Data are the same as in (B) with values shown to
offer a complementary perspective for comparison between antibiotics. The squares represent
individual mutation rates and the black bars represent the mean of mutation rates under the
conditions tested; error bars were removed for clarity and included in Figure S13, with raw values
listed in Table S2. Strains that did not show resistant colonies under a particular antibiotic stress
are marked with a star (*) in the color of that antibiotic. The attributed value of the (*) denotes
mutation rate detection limit under those conditions.
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20-fold more mutations per generation, respectively (Figure 14A, Table S2 in the Appendix).
When

we

introduced

the

non-cleavable

lexA(S119A)

allele

into

the

recA730

strain

(recA730/S119A), the mutation rate was reduced back to WT levels, validating that recA730
largely mediates mutagenesis in a LexA-dependent manner (Figure S13 in the Appendix).
Next, we subjected the SOS-variant strains to sublethal doses of ciprofloxacin. In the
absence of antibiotic stress, the WT strain displays a mutation rate of 3*10

-9

per replicative

generation. However, in the presence of ciprofloxacin the mutation rate increases 7-fold. Across
the other strains, we observed a pattern of changes to mutation rates that correlated with the
LexA cleavage rates (Figure 14A). Mutagenesis was not induced in S119A and the mutation rate
increased only 1.3-fold for the hypoactive G80A relative to the unstressed condition. Compared to
the 7-fold induction of mutagenesis in the WT strain, we observed an approximately 13-fold
increase with the hyperactive E86P. Notably, even in the Delta strain, we found a 3-fold
enhancement of mutation rate with ciprofloxacin, suggesting that mutagenesis is enhanced by the
combination of antibiotic stress with a constitutively active SOS pathway. The ciprofloxacininduced mutation rates were similar whether lexA or recA are perturbed on the two extremes: the

ΔrecA and S119A strains showed mutation rates of 5*10-9 and 4*10-9, respectively, and the
-8

-8

recA730 and Delta strains displayed rates of 6*10 and 7*10 , respectively.
We then examined a broader range of antibiotic stressors and found that LexA cleavage
rates impact mutation rates across many different antibiotic classes. For each variant strain, we
plotted the mutation rate relative to the WT (Figure 14B). For clarity, the individual mutation rate
plots are also shown in Figure S13 and the raw values are summarized in Table S2 in the
supplemental material. Across most antibiotics examined, we generally observed that SOS
attenuated strains have reduced mutations rates relative to the WT, while SOS hyperactive
strains have higher mutation rates. The gradation of induced mutagenesis extended to mitomycin
C, nitrofurantoin, β-lactams and trimethoprim, but was less apparent with the ribosomal inhibitor
streptomycin, which can potentially impact the translation of SOS effectors, and with novobiocin,
which has been reported to potentially antagonize the SOS response (Schroder et al., 2013).
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Integrating across the series of antibiotics with different mechanisms of action, the average rate
of induced-mutagenesis is correlated with increased levels of SOS activation (Figure 14C). This
trend contrasts with the MIC data, where MICs tended to peak with the WT strain and were
reduced when the SOS pathway was either inactive or hyperactive.
Notably, the S119A and ΔrecA strains showed reductions in induced-mutagenesis across
multiple different agents beyond ciprofloxacin. With these strains, we were unable to select for
rifampin resistant mutants with mitomycin stress, observed 15-fold or greater reductions with
nitrofurantoin and smaller reductions with ampicillin. This result indicates that inhibition of the
SOS response could plausibly slow acquired drug resistance to multiple antimicrobial agents.
To account for the effects of the sulA deletion, we performed the same set of fluctuation
+

analyses on the four sulA strains and compared mutation rates across strains (Figure S13 and
Table S2 in the Appendix). In the absence of antibiotic stress, the four strains displayed mutation
rates comparable to that of the ΔsulA strains. While minor differences were observed in the extent
of induced mutagenesis across strains, the trend of increasing mutation rate with increasing LexA
+

cleavage rate was preserved within both the sulA or the ΔsulA background.

3.5 Discussion
Given the role of the SOS pathway in adaptation and acquired resistance to antibiotics,
targeting its two major regulators – LexA and RecA – has been proposed as a viable strategy to
increase bacterial sensitivity to antibiotics and combat the rise of resistance. Prior studies
examining antibiotic efficacy have largely focused on the loss of normal recA or lexA function in
isolation (Baharoglu and Mazel, 2011; Cirz et al., 2005; Cirz and Romesberg, 2006; Cirz et al.,
2007; Thi et al., 2011). These studies validated the SOS response as an interesting target and
motivated our effort to explore the consequences of the various different approaches that could
be taken to target LexA or RecA proteins. To this end, our study attempted to profile the full
spectrum of SOS activation, including parallel comparisons of partial or complete SOS activation
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or repression, to help provide a roadmap for several key issues relevant to future inhibitor
discovery efforts.

3.5.1 Bacterial susceptibility to antibiotics
Our study provides evidence that either inhibition or activation of the SOS pathway can
synergize with specific antimicrobial agents to reduce MICs to varying extents. With constitutive
SOS inactivation, the MIC data of the S119A and DrecA mutants are in agreement with previous
studies: relative to the WT, both strains show enhanced sensitivity to some DNA-damaging
agents, such as mitomycin C, fluoroquinolones, and nitrofurantoin (Butala et al., 2011; Da Re et
al., 2009; Thi et al., 2011). However, this increased sensitivity is largely abolished when the level
of SOS induction is merely attenuated by a slow-cleaving LexA variant, G80A, which shows
similar MIC and only minor defects in fitness competition relative to the WT. With antimicrobials
with other mechanisms of action, we see only minor changes in sensitivity relative to the WT
strain, even in the SOS inactive S119A or ΔrecA strains. Thus, we conclude that potent inhibition
of the SOS pathway in concert with particular DNA damaging agents, including fluoroquinolones
and nitrofurantoin, offers the best options for potential synergy.
Proposals to target the SOS response have largely focused on inhibiting the pathway,
and, to our knowledge, little data exists on how SOS over-activation affects bacterial sensitivity to
antibiotics. In our study, we observed that, as with SOS inhibited strains, strains with a
constitutively active SOS response have decreased fitness relative to the wild type strain. The
reduced MICs of the Delta and recA730 stains suggest that an overactive SOS pathway can also
increase antimicrobial susceptibility, albeit to a lesser extent than observed with constitutive
inhibition. DNA-damaging agents that were effectively enhanced by SOS inhibition appear to
achieve the highest levels of synergy in SOS overactive strains as well, while other drugs show
lesser effects. One important caveat to our result is that we were unable to experimentally
examine the effects of sulA-mediated lethality during constitutive SOS expression, given that

ΔlexA and recA730 strains require sulA deletion. Small molecules that disrupt LexA binding to
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SOS genes or activate RecA could potentially show greater synergy than we observed in the
presence of sulA. Furthermore, even if resistance were to arise to SOS hyperactivating agents
-

through the deletion of sulA, our results with sulA strains suggest that synergy would still be
anticipated to some degree.
Together our data indicate that the native function of the SOS pathway is important for
bacterial adaptation to antibiotics. Both an inactivated and constitutively active SOS response can
reduce bacterial viability in concert with antimicrobials that cause DNA damage. While our work
does not address the mechanisms involved in altered antibiotic sensitivity, several plausible
hypotheses can be considered. Because the SOS response functions primarily in DNA damage
repair, perturbing the network likely prohibits bacteria from repairing the genotoxic damage
caused by these agents: in the case of SOS inhibition, the DNA repair mechanisms are silenced,
while with disinhibition, the processes might be uncoordinated, energetically costly, and/or
promote genetic instability.

3.5.2 Bacterial mutagenesis during antibiotic treatment
Our study also informs efforts to slow mutagenesis and acquired resistance by targeting
the SOS pathway. While the most significant reductions in MICs were noted at both extremes of
SOS activity, the mutation rates across strains displayed a trend of continual increase, with the
constitutively inactive and active SOS variants showing the lowest and highest antibiotic-induced
mutation rates, respectively. Our results with are constitutively inactive and active variants are
consistent with more limited comparisons carried out in previous reports (Cirz et al., 2005; Cirz
and Romesberg, 2006; Cirz et al., 2007; Fijalkowska et al., 1997; Kohanski et al., 2010). Further,
we show that partial SOS pathway attenuation (G80A) or hyperactivation (E86P) result in
changes to the mutation rate. Our data are also consistent with a recent report that used a
mutation accumulation whole genome sequencing approach to show that the mutation rate is
strongly correlated with the dose of fluoroquinolone stress, which presumably results in different
levels of SOS induction (Long et al., 2016). We speculate that the tunable behavior for

	
   58	
  
	
  

mutagenesis could be due to the regulation of the error-prone DNA polymerases, whose basal
levels and stress-induced levels are likely altered by changes to LexA and RecA protein levels.
Importantly, from a therapeutic angle, our data suggest that reducing LexA’s cleavage rate has
the potential to attenuate mutagenesis under a range of different types of antibiotic stressors, not
simply DNA damaging antibiotics. While our study focuses on inducible mutagenesis controlled
by the SOS pathway, the results also hold implications for constitutive hypermutators, which may
make important clinical contributions to acquired antibiotic resistance (Oliver et al., 2000).
Activation of the SOS pathway may provide a mechanism for acquiring mutations that “fix”
hypermutation, such as inactivating mutations in mismatch repair enzymes (Mao et al., 1997).

3.5.3 Targeting LexA vs. RecA
Both RecA and LexA have been proposed as therapeutic targets to perturb SOS
induction. While small molecules that target LexA have not yet been reported to our knowledge,
several agents that target RecA both in vitro and in bacteria have been reported (Alam et al.,
2016; Nautiyal et al., 2014; Sexton et al., 2010; Wigle et al., 2006; Wigle et al., 2009). Our results
suggest that the effects of the SOS-inactive mutant strains (ΔrecA and S119A) largely mimic one
another in both synergy and acquired resistance, though a slightly greater degree of sensitivity is
seen with the DrecA strain, particularly with nitrofurantoin. Constitutive activation of the SOS
pathway has similar effects in the Delta and recA730 strains, with a slight degree of higher
sensitivity seen with Delta. Overall, we conclude that agents that target LexA, RecA or their
interface would all be similarly viable strategies to pursue.
Although our data suggest targeting either RecA or LexA might be of interest, it is worth
noting that each likely presents its own distinctive challenges. RecA, unlike LexA, has important
human homologues (Rad51 family), making specificity a particularly important requirement for
targeting RecA; indeed, some high-throughput screening efforts have yielded compounds that
readily target both RecA and Rad51 (Huang et al., 2011). Although protein interfaces can be
challenging to target, the RecA oligomerization interface may be a valuable molecular target,
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particularly since RecA’s ATPase activity is thought to be non-essential for SOS activities
(Gruenig et al., 2008). For LexA, the self-cleavage reaction of the protein’s catalytic domain
makes it a difficult target for competitive inhibition, given the high local concentration of the
cleavage loop “substrate” around the LexA active site. We therefore speculate that allosteric
inhibitors of LexA or compounds that disrupt the LexA/RecA interface will likely offer more
promise. Finally, the selection pressures for acquired resistance might also be very different for
these two targets. It is reassuring that deletion of the lexA gene is also associated with altered
sensitivity to some antibiotics, as this result implies that resistance to anti-LexA agents are less
likely to arise from simple inactivating mutations.

3.5.4 Strategies for targeting the SOS response
In aggregate, our results provide a framework for developing strategies to target the SOS
pathway. Regarding the question whether to inhibit or hyperactivate the SOS response, in line
with known aspects of SOS function, we suggest that inhibiting the pathway is the more feasible
strategy, since it can reduce bacterial viability while also tempering stress-induced mutagenesis.
Although forcing constitutive SOS induction does reduce fitness, it comes at a cost of increased
mutagenesis, thus increasing the likelihood of acquired resistance. As noted, one limitation to our
conclusion is that we were unable to explore the effects of SOS disinhibition in the presence of
sulA; however, we speculate that sulA-dependent toxicity would like lead to rapid inactivation of
sulA, as its deletion does not appear to cause a strong fitness burden. With regards to the
mechanism of action, our data suggest that reducing mutagenesis may offer more therapeutic
opportunities with different classes of existing antibiotics. We found that numerous antibiotics can
increase the mutation rate, and that induced mutagenesis is decreased with loss of SOS
induction. Even attenuation of the SOS pathway with the G80A strain is associated with reduced
mutagenesis. While the effects on the mutation rate are modest relative to hypermutator strains of
bacteria that lack mismatch repair, such strains with “intermediate” mutation rates may in fact be
more likely to evolve multidrug resistance (Denamur et al., 2005). It is also important to note that
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we limited our analysis to the effect on MIC and acquired resistance; however, it is possible that
targeting the SOS pathway could have other benefits. In diverse species including Clostridium
difficile, Vibrio cholerae, and Staphylococcus aureus, the SOS pathway has been linked to
pathogenic processes including persistence, horizontal gene transfer and expression of toxins or
virulence factors (Baharoglu and Mazel, 2011; Dorr et al., 2009; Dorr et al., 2010; Modi et al.,
2013; Ubeda et al., 2005; Walter et al., 2015). Our data taken as a whole suggest that, although
many alternative strategies may be viable, the addition of an SOS inhibitor targeting RecA or
LexA with a DNA damaging antibiotic such as a fluoroquinolone could be an optimal approach to
both increase susceptibility as well as decrease acquired resistance in important bacterial
pathogens. In Chapter 4, we discuss our efforts to target the LexA/RecA axis with small molecule
inhibitors.
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CHAPTER 4: Discovery of small molecule inhibitors of the LexA/RecA axis in
collaboration with GlaxoSmithKline
The contents of this chapter are currently being prepared as a manuscript for publication.
Contributions: CYM, MJC, and RMK conceived of the study and designed the primary HTS and
secondary assays. Members of the GSK’s DPAc team (Katherine Widdowson, Tony Jurewicz,
Jessica Schneck, Amy Quinn, and Paul Keller) optimized and performed the HTS screen at
GSK’s screening facilities in Upper Providence, PA, with input from CYM, MJC, and RMK. AQ,
CYM and MJC performed the secondary assays. CYM and RMK wrote the manuscript with input
from all authors.

	
  
4.1 Abstract
The decline of treatments against drug-resistant infections underscores a need to explore
less conventional targets and alternative models for discovery. The SOS pathway is a wellconserved bacterial DNA damage response, strongly linked with antibiotic tolerance and acquired
resistance. The response is initiated when RecA, the damage sensor, induces LexA, the SOS
repressor, to undergo autoproteolysis. The RecA/LexA axis has been validated as a promising
target whose inhibition could potentiate our current antibiotic arsenal. The target, however, is
unconventional, given the nature of the initiating reaction and the pursuit of an agent that would
function in partnership with current antimicrobials. One model for addressing the challenges of
antimicrobial discovery involves combining the in-depth knowledge of specific targets in academia
with the drug development expertise and resources of industry. As an exemplar of the strengths
and challenges of navigating such partnerships, here we describe a high-throughput screen
(HTS) performed as a collaboration between the University of Pennsylvania (UPenn) and
GlaxoSmithKline (GSK) against the LexA/RecA axis. The effort built on a novel fluorescence
polarization assay that reports on RecA-induced self-cleavage of LexA. 1.8 million compounds
were screened on GSK’s platform and 144 potential inhibitors were identified and grouped into
distinct chemical families. 32 representative compounds were transferred to UPenn in a blinded
manner for further analysis, resulting in six leads whose structures were then disclosed by GSK
to UPenn. These selected leads show activity in orthogonal assays, including cell-based assays
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reporting on SOS activation in cells, and provide a starting point for dedicated lead optimization.
Our experience describes one pathway for advancement in the anti-infective realm.
4.2 Introduction
The ability of bacteria to rapidly adapt and evolve resistance to our antibiotic agents has
contributed to the ongoing decline in effective treatments against infections. New therapeutic
strategies are therefore required to combat the rise of resistance and lengthen the lifetime of our
antibiotic arsenal. Recently, acquired drug resistance and enhanced bacterial survival during
antibiotic treatment have been linked with the bacterial stress (SOS) response, which is a widely
conserved network of genes involved in DNA damage repair and mutagenesis (Figure 15A)
(Michel, 2005). Two proteins, a DNA-binding ATPase, RecA, and a repressor-protease, LexA,
regulate the SOS response. Under conditions of genotoxic stress, which can be induced by many
antibiotics, RecA polymerizes along single-stranded DNA and stimulates the self-cleavage
(autoproteolysis) of LexA, thereby inducing SOS-associated genes. Genetic inactivation of these
two regulator proteins has been shown to reduce the level of resistance and increase bacterial
drug susceptibility, while also compromising horizontal gene transfer, persistence, and the
expression of resistance genes (Figure 15A) (Cirz et al., 2005; Da Re et al., 2009; Dorr et al.,
2009; Lu and Collins, 2009). Studies have further revealed that genetically modulating the activity
of LexA can tune the level of mutagenesis and resistance across a host of antimicrobial stressors
(Mo et al. 2016). Therefore, targeting the RecA/LexA axis with small molecules in combination
with conventional antibiotics has been proposed to attenuate the SOS response and reduce the
rise of resistance (Cirz et al., 2005; Thi et al., 2011).
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Figure 15. Targeting LexA and RecA to inhibit the bacterial SOS response
(A) Exposure to antibiotic stress triggers RecA polymerization along exposed single-stranded
DNA, forming RecA* (red ovals). Formation of RecA* catalyzes the autoproteolysis of the LexA
repressor-protease (blue rectangles), leading to the induction of the SOS response. Targeting
LexA autoproteolysis has been proposed as a therapeutic strategy to attenuate the expression of
downstream SOS genes, thus increasing antibiotic susceptibility and reducing acquired
resistance. (B) Design of the FlAsH-LexA HTS assay. The N-terminal DNA binding domain of
LexA was replaced with the short hexapeptide motif CCPGCC, which specifically binds to FLAsHEDT2. (C) Incubation 50 nM FlAsH-LexAEc with RecA* induces self-cleavage of FlAsH-LexA,
resulting in a reduction in fluorescence anisotropy.
The RecA/LexA axis represents a less conventional and potentially challenging target, as
it involves two biochemical steps – RecA polymerization and LexA autoproteolysis. To date,
forays into discovering SOS inhibitors have largely focused on perturbing RecA activity. Notably,
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inhibitors discovered by Singleton and colleagues prevent the formation of ssDNA/RecA filaments
or the protein’s ATP-dependent activities, while more recently, Alam et al. reported inhibitors in
the form of phthalocyanine tetrasulfonic acid molecules that disrupted binding between RecA and
DNA (Alam et al., 2016; Lee et al., 2007; Peterson et al., 2012; Sexton et al., 2010; Wigle et al.,
2006; Wigle et al., 2009). Despite these promising results, the specificity of any putative RecA
inhibitor must contend with ubiquitous homologs of RecA, which exist across eukaryotes; indeed,
a 2011 screen for Rad51 inhibitors by Huang et al. reported the discovery of molecules active
against both Rad51 and RecA (Huang et al., 2011). By contrast, LexA does not possess close
eukaryotic homologs and could therefore mitigate the risk of off-target effects of any potential
agents. However, the autocatalytic nature of LexA’s cleavage reaction is likely to pose a barrier
for competitive inhibition of the LexA’s protease active site, making the discovery of LexA-specific
inhibitors particularly challenging, and to our knowledge, no LexA inhibitors have been discovered
(Mo et al., 2014; Roland and Little, 1990). The challenges associated with targeting LexA and
RecA would ordinarily exclude them from conventional drug discovery efforts, but filling the need
for new antibiotics might require alternative approaches to accommodate such “higher risk”
targets.
Academic-industry partnerships have emerged as an attractive model for developing
novel antimicrobials. Academic institutions can provide in-depth knowledge in a given area of
investigation and offer fresh paradigms for potential discovery, while reciprocally, industry offers
the infrastructure and expertise needed for large-scale discovery and translational efforts, which
are typically not accessible to academic laboratories. Although in recent decades academic
research has identified a host of unconventional targets, including the SOS response, that have
the potential to address the problem of resistance, new antibiotic drug discovery efforts in industry
have largely focused on conventional, essential targets (Brown and Wright, 2016). Thus,
partnership models that offer a platform to test unconventional targets in an industry setting could
greatly accelerate the discovery process of novel antimicrobial therapies, while also yielding tool
compounds that may benefit the fundamental academic research of these biological targets
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themselves.
Recognizing compatible objectives and complementary strengths, the University of
Pennsylvania (UPenn) and GlaxoSmithKline (GSK) engaged in a collaboration to screen for
inhibitors of the bacterial stress (SOS) response as part of GSK’s Discovery Partnerships with
Academia (DPAc) program. Here, we report our discovery of SOS inhibitors from high-throughput
screening and describe the collaborative process as an illustrative example of both the scientific
and administrative aspects of our academic-industry partnership. Before the start of collaboration,
UPenn designed and validated a robust, high-throughput screen based on fluorescence
polarization that recapitulates the key reaction involving RecA and LexA that marks the start of
the SOS response. Building on this assay, 1.8 million compounds from GSK’s discovery library
were screened, during which the academic side remained blinded to the chemical structures of
the compounds until the final disclosure. Confirmatory testing and dose-response analysis
narrowed the focus to 144 compounds grouped into chemotypes. Representatives spanning the
chemotypes were then sent to UPenn for further testing in orthogonal biochemical assays and
screens that report on SOS activity in cells. Based the results from the secondary screening and
the physical chemical properties of the compounds, UPenn selected 6 lead compounds, whose
structures were released to us. These compounds, which highlight the value of our partnership,
display chemical diversity, show activities across multiple assays, and provide a foundation for
dedicated medicinal chemistry efforts aimed at optimization and therapeutic translation.
4.3 Experimental procedures
4.3.1 Construction of FlAsH-LexA
The N-terminal fragment (Residues 1-74) was removed from the LexA of E. coli and
replaced with a FlAsH peptide (CCPGCC) via cassette mutagenesis to form the FlAsH-LexA(75202) construct of E. coli (hereafter referred to has FlAsH-LexAEc). Analogous methods were used
to generate the FlAsH-LexA of P. aeruginosa (FlAsH-LexAPa(81-204); hereafter referred to as
FlAsH-LexAPa). To improve protein stability and expression levels, a maltose-binding protein was
appended to the N-terminus of both FlAsH-LexA constructs and bridged by a TEV protease
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cleavage site to allow for the eventual removal of the MBP tag. A poly-His tag was attached to the
C-terminus if the FlAsH-LexA protein to allow further purification. This fusion constructs were
cloned into the pET41 expression vector.

4.3.2 Expression and gravity purification of MBP-FlAsH-LexA-His
pET41 expression vectors harboring either the fusion constructs of either FlAsH-LexAEc
or FlAsH-LexAPa were transformed in BL21 E. coli expression strains using standard
transformation techniques. Overnight cultures of BL21 cells were diluted 100-fold into fresh LB
media supplemented with selective levels of kanamycin and grown until an OD595 of ~0.5 at 37 °C
and with shaking (220 rpm). The cultures were then induced with 1 mM IPTG and grown at 30 °C
for 4 hours, after which they were centrifuged at 4000 rpm and resuspended in wash buffer (50
mM Tris-HCl, 150 mM NaCl, 0.1 mM TCEP, pH 7). Resuspended cultures were then lysed via
sonication. The lysate was then spun down at 13000 rpm in order to separate supernatant from
the insoluble detritus. Supernatant was then incubated with amylose resin (Thermo Pierce) for 2
hours at 4 °C to allow for batch binding. Following incubation, the supernatant/resin mix as
poured into a gravity column, and the resin was subsequently washed with wash buffer. Following
the washes, bound protein was eluted by adding one column volume of elution buffer (50 mM
Tris-HCl, 150 mM NaCl, 10 mM maltose, 0.1 mM TCEP, pH 7). Purified protein was then digested
with TEV overnight at 4 °C, following established guidelines before labeling (described below).

4.3.3 Labeling of FlAsH-LexA-His
Digested protein was then labeled overnight at 4 °C with 2-fold molar excess FlAsH-EDT2
(Santa Cruz BioTechnologies), following established guidelines. Following labeling, the protein
was passed over a second His-Cobalt column to separate the labeled FlAsH-LexA-His protein
from the free MBP. The column was washed with wash buffer (50 mM Tris-HCl, 150 mM NaCl, 25
mM imidazole, pH 7), and the bound protein was eluted with elution buffer (50 mM Tris-HCl, 150
mM NaCl, 250 mM imidazole, pH 7). As final step of purification, protein samples were passed
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over a size-exclusion column to remove unbound FlAsH-EDTs and any undigested MBP-FlAsHLexA-His. Purified proteins were eluted and stored in 50 mM Tris-HCl, 150 mM NaCl, 0.1 mM
CEP, 10% glycerol, pH 7.

4.3.4 Expression and purification of RecA
RecA gene was purchased from IDTDNA and cloned with an N-terminal His tag into the
pET41 vector and expressed in BL21 cells. Overnight cultures of transformed BL21 cells were
diluted 100-fold into fresh LB media supplemented with kanamycin and grown at 37 °C with
shaking until an OD595 of ~0.5. Cultures were then induced with 1 mM IPTG and left to grow for 4
hours at 30 °C. Following growth, cell cultures were centrifuged at 4000 rpm and resuspended in
wash buffer (50 mM Tris-HCl, 150 mM NaCl, 25 mM imidazole, pH 7). Analogous to the
purification methods for MBP-FlAsH-LexA-His, the cells were lysed via sonication, centrifuged to
separate the supernatant from cellular detritus, and incubated with His-Cobalt resin for batch
binding of the RecA. Resin-bound RecA was washed and eluted with the same set of buffers
described above for the His-Cobalt purification of labeled FlAsH-LexA-DN-His. Eluted RecA
proteins were then dialyzed into 50 mM Tris-HCl, 150 mM NaCl, 10% glycerol, pH 7 for the
storage.	
  	
  

	
  
4.3.5 LexA cleavage assay conditions and plate setup
HTS reagents were transferred to GSK for further assay optimization and miniaturization.
LexA cleavage conditions were optimized to volumes suited for 1536-well plates. Conditions
included 50 nM FlAsH LexA, 133 nM RecA, 5 uM ssDNA (SKBT25, ordered from IDTDNA), 5 uM
ATPγS in 100 mM Tris-HCl, pH 6.5, 150 mM NaCl, 5 mM MgCl2, 0.01% (w/v) BSA, 0.1 mM
TCEP, and 0.01% (w/v) Pluoronic-F127. The low control, utilized to the Z’ and S/B calculation
was located in the columns 35 and 36 of the 1536-well plate and included all components of the
assay listed above except for the RecA. Reaction components were added into the 1536-well
plate as 2 µL additions of ATPγS, ssDNA, and +/- RecA, and 2 µL of FlAsH-LexA using a Combi

	
   68	
  
	
  

liquid handler (Thermo-Fisher). Reactions were centrifuged for 1 minutes at 500 rpm and
incubated for 30 minutes at room temperature and then quenched with a 2 µL addition of 45 mM
EDTA, pH 8, in deionized water. The 1536-well plates were optimized to read on the ViewLux
imagers (PerkinElmer) in order to increase throughput. The final assay conditions resulted in 100120 mP difference between the uncleaved and cleaved control wells, representing an
approximately 60 percent cleavage of the FlAsH-LexA-CTD. For each plate, the Z’-score was
calculated from the cleaved and uncleaved control wells according to standard procedures.

4.3.6 HTS validation at GSK
To assess the robustness of the FlAsH-LexA assay, a pre-defined representative set of
9854 compounds, which will be referred to as the Validation Set, was tested in triplicate at 10 µM.
This allowed for performance statistics to be calculated for predicting likely outcomes of the HTS.
These metrics the Z’ score, the standard deviation of the sample population, false
positive/negative rates, and statistical active rate and determined by a potency cut-off defined as
the robust 3 standard deviation plus the mean. Prior to initiation of the HTS run, one bulk run of
80 plates was performed to gauge the overall performance over a full HTS production run. Robust
hit marking statistics and assay quality control metrics were measured across the run to ensure
no loss in quality was endured.

4.3.7 Post-HTS analysis
Compounds in the HTS screening campaign that displayed a percent inhibition of greater
than or equal to 16% were selected for retesting in duplicate. Retested compounds that displayed
autofluorescent properties were eliminated. The remaining compounds were then tested in
duplicate for dose-response in 2-fold serial dilutions with a top concentration of 200 µM and a
total of 11 dose response points. Compounds that displayed dose-dependent changes in
fluorescence were also eliminated. The remaining compounds were then grouped by chemical
family.
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4.3.8 Orthogonal

32

P-LexA cleavage assay

In order to validate the compounds in an assay that is independent of fluorescent
readout, a radioactive LexA cleavage assay was designed. Full-length LexA was engineered with
a PKA tag (RRXS) on the N-terminal domain and labeled with

32

P following as described in

Chapter 3 (See supplemental material for Chapter 3 in the Appendix). Labeled LexA was
subjected to a 2-fold dilution series of compound, with the highest concentration being 200 µM.
Cleavage assays were performed under the following conditions: 100 nM LexA, 200 nM of RecA*,
10 µM of ATPγS, 5 mM MgCl2, 70 mM Tris-HCl, pH 7.0. Reactions were incubation for 15 minutes
at 25 °C, stopped with the addition of 2X Laemmli Buffer, and run out on 15% SDS-PAGE gels.
Protein bands were visualized by phosphorimaging on a Typhoon Imager and the level of
cleavage was quantified.
For the LexA-only cleavage assay,

32

P-LexA was subjected to the identical compound

concentrations and buffer conditions as above, except without RecA* and ATPγS. Reactions were
run at 37 °C for 4 hours and reaction aliquots were taken at 2 hours and 4 hours. Protein bands
were visualized with phosphorimaging.

4.3.9 Cell-based SOS reporter assay
To assess activity inside cells, a cell-based SOS reporter assay was employed. MG1655
E. coli strains without the tolC transporter (ΔtolC) (Baba et al., 2006) were transformed with a
reporter plasmid where gfp expression is under the control of the recA promoter (pMS201 pRecA
GFP) (Zaslaver et al., 2006). Overnight cultures of the reporter strain were diluted 100-fold in M9
minimal media and grown at 37 ºC with agitation to an OD595 of ~0.6. 100 µL of culture were then
added to a dilution series of compound in 96-well deep-well plates. To induce the SOS response,
100 µL of M9 media with 256 ng/mL of ciprofloxacin was added to the wells. In each well, the final
concentration of ciprofloxacin is 128 µg/mL and the starting OD595 of the bacteria is ~0.3. Cultures
were then incubated at 37 ºC with agitation for 4 hours, after which the cells were fixed by adding
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200 µL of phosphate buffer saline and 4% paraformaldehyde to the wells. Fixed cells were
analyzed using flow cytometry (BD FACSCalibur, Ex/Em: 488 nm/530 nm) and the mean
fluorescence of 20000 cells in each condition was recorded. Population histograms were
analyzed with the FlowJo software.

4.3.10 RecA polymerization assay
Compounds from the HTS assay were tested for their ability to inhibit RecA
polymerization, using an assay adapted from Singleton and colleagues (Lee et al., 2007). In brief,
4 mM of RecA, 2 mM ATPγS, and 0.5 µM FAM-ssDNA were prepared in buffer containing 100
mM Tris-HCl, pH 7.0, 10 mM MgCl2, 10 mM DTT, and 0.01% Tween-20. Reaction components
were incubated at room temperature for 15 minutes and then 8 mL of the reaction was dispensed
into wells of a 384-well black LV Greiner plate (Cat. No, 784076) containing compound using a
Combi liquid handler. The plates were centrifuged for 1 minute at 500 rpm, incubated for another
15 minutes at room temperature, and then fluorescence polarization (480 nm, em: 530 nm) was
measured on an Analyst GT (Molecular Devices).

4.4 Results and Discussion
4.4.1 Design of HTS FlAsH assay
Both LexA and RecA have been proposed as targets for adjuvant therapies designed to
reduce resistance and re-sensitize bacteria to current antimicrobials. Given their roles in initiating
the SOS response, we (the UPenn group) designed a biochemical assay to report on RecA*induced LexA self-cleavage. LexA autoproteolysis within the CTD occurs between Ala84 and
Gly85 in LexA of E. coli (LexAEc) (Luo et al., 2001; Zhang et al., 2010). Early work on LexAEc
suggested that tryptic removal of much of LexA’s DNA-binding N-terminal domain prior to Leu68
does not have a significant impact on the self-cleavage ability of the protease domain (Little,
1984). Building on this observation, we further truncated the NTD and appended a CCPGCC
peptide sequence ahead of Gly75. The CCPCCC motif can be specifically labeled using FlAsH-
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EDT2 (Figure 15B) (Adams et al., 2002). When fluorescently-tagged protein construct is
stimulated to self-cleave with RecA*, release of the short, FlAsH-labeled peptide results in a
significant drop in fluorescence anisotropy compared to FlAsH protein samples where RecA* was
omitted, allowing for either continuous monitoring of LexA self-cleavage or endpoint
measurement after quenching with EDTA (Figure 15C). As expected, the change in anisotropy is
also prevented by mutation of the catalytic Ser119 to Ala. Endpoint assays performed on a 384well plate displayed reproducibility, with a Z’-score of ~0.7 when using a fixed 30-min endpoint
(Figure 16).

Figure 16. FlAsH-LexA endpoint assays on 384-well plates
WT and the inactive mutant of FlAsH-LexA (FlAsH-LexAEc-S119A) show comparable anisotropies
prior to stimulation with RecA* (top panel). Following a 30 minute incubation RecA*, the WT
protein displays a drop in anisotropy, compared to the inactive mutant, with a Z’ score of 0.71.
The FlAsH-LexA:RecA* assay possesses several distinguishing features when compared
with previous screening assays for SOS inhibitors. Notably, to our knowledge it is the first assay
to focus on LexA inhibition specifically as the endpoint. This design enables the discovery of
molecules with different mechanisms of inhibition, including inhibitors specific to either LexA or
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RecA, and interfacial inhibitors that target the interface of the protein-protein interaction between
the two proteins. Further, LexA and its self-cleavage reaction is widely conserved across bacterial
species (Chapter 2), which enables our approach to be extended to the LexA proteins of other
pathogens, including LexA of Pseudomonas aeruginosa (LexAPa) (Figure S14).

4.4.2 Validation of the HTS FlAsH assay with LexA of P. aeruginosa
To validate the FlAsH-LexA assay, we (the UPenn group) first performed a small-scale
screen of the Microsource Spectrum library (2560 compounds), using the FlAsH-LexA of P.
aeruginosa (FlAsH-LexAPa) under conditions described in the supplemental material for Chapter 4
in the Appendix. Compounds were screened at a fixed concentration of 16 µM in a single
endpoint assay on two separate days. For Day 1 the average Z-score of all measurements across
the plates was 0.77, while on Day 2 the average score was 0.65 (Figure S15). The anisotropy
values of each individual well of the two independent replicates showed strong linear correlation
2

(y = 0.73*x+42.78; R = 0.93). Overall, both the Z-scores and the correlation analysis indicated
that the assay was robust and reproducible, and therefore suitable for larger, more diverse
compound libraries. Notably, one of the active compounds identified in this assay was the
promiscuous agent suramin, which had been identified in prior RecA-focused screening efforts
(Nautiyal et al., 2014; Wigle and Singleton, 2007).

4.4.3 Engagement of collaboration
Given the results obtained from pilot screening, in order to gain access to a large, curated
compound library and leverage pharmaceutical drug discovery expertise, we (the UPenn team)
entered in the GSK DPAc Fast Track Competition, which enables academic laboratories to
submit proposals of therapeutic targets as potential candidates for drug discovery efforts in
partnership with GSK. The selection process proceeded in two stages. During the initial stage, we
presented our therapeutic hypothesis of targeting LexA and the SOS response, highlighting the
scientific knowledge of the system and the novelty of the target; this phase did not require the
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disclosure of confidential intellectual material. Out of 140 applications, the UPenn group was
selected as one of 20 finalists to give a detailed presentation of the target background, availability
of primary and secondary assays, and potential clinical applications. This finalist phase
proceeded under a confidentiality disclosure agreement, which included a “non-use” clause
prohibiting the unauthorized use of the disclosed material without consent of the academic
institution. At the end of the selection, UPenn’s LexA project was among 8 chosen winners of the
competition. Four of the eight groups selected involved anti-infective targets, highlighting the
potential strengths of partnership approaches in this therapeutic area.
At the inception of the joint effort, investigators worked as an integrated team to establish
project plans and objectives. The UPenn team was expected to provide assay design and
reagents, secondary screens and target expertise, while GSK provided screening resources and
expertise, which included the additional assay optimization, encoded library technology, discovery
library, HTS platform and initial lead characterization. Given the pharmaceutical priority for
protection of chemical matter, UPenn would remain blinded to the structures of compounds being
investigated during the screening process. At the same time, the end objective of lead
identification for UPenn would be satisfied by the disclosure of three compound structures by
GSK, including associated composition of matter rights, at the conclusion of the screening
campaign. At that point, both groups would have the right to decide whether to continue to
advance the project. If one group wished to proceed without the second, the groups agreed to
revenue sharing in the event that leads eventually advanced to therapeutics.

4.4.4 Assay transfer and validation screen with FlAsH HTS assay
The screening campaign was designed to leverage the resources and expertise of both
sides (Figure 17). As an initial step, we decided to move the FLAsH assay from a P. aeruginosa
background to an E. coli background. Although P. aeruginosa is considered a more clinically
relevant pathogen, genetic tools already established by UPenn in E. coli could accelerate
downstream validation steps in cells. Further, since both LexAPa and LexAEc share a high level of
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sequence identity (Mo et al., 2014), we hypothesized that hit compounds would potentially be
active in both biochemical systems.
UPenn contributions

GSK contributions

Reagent generation
and scale-up

GSK discovery library
1.8 million compounds
Primary
HTS assay
(n=1)

Assay miniaturization
and validation

5544 statistical actives
Retesting
of actives
(n=3)

High-throughput screen

396 confirmed actives
Dose
response
(n=2)

List of 144
active compounds

144 compounds

32 select compounds

Validation & secondary
assays

32

P-LexA assay

Cell-based assay
RecA* polymerization

6 lead compounds

Figure 17. Partnership between the University of Pennsylvania (UPenn) and GSK to screen
LexA inhibitors
Contributions of UPenn and GSK are colored with cyan and pink, respectively. The panels on the
left summarize the major milestones in the partnership, while the right panels provide details on
the HTS screen and the secondary screens.
Assay reagents were transferred to GSK under a Material Transfer Agreement (MTA) and GSK
independently validated the assay approach on their platform by performing a preliminary screen
on 9722 compounds in triplicate, termed the validation set. This validation screen predicted a hit
rate of 0.14% and a 3SD cutoff ~15% (Table 3).

4.4.5 HTS screening and compound triage
Following validation, screening proceeded to the full GSK discovery library of
approximately 1.8 million compounds in a 1536-well format. The screening statistics (Table 3)
were of high quality with an average Z’ score of 0.72 and the average robust 3SD cutoff being
~16% inhibition. The screening campaign yielded 5,544 compounds selected for confirmation,
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corresponding to a hit rate of 0.31%. Re-testing of the initial hits in duplicate identified 396
statistical actives after removal of 111 auto-fluorescent compounds, yielding a confirmation re-test
rate of 7.1%. Compounds were subjected to a two-fold serial dilution to generate an 11-point
dose response, with the highest compound concentration at 200 µM. Performed in duplicate, the
dose response analysis yielded a preliminary list of 245 compounds of interest with curve fits with
asymptotes >50% inhibition. Re-examination of the dose response curves by overlaying the total
fluorescence intensity values of each dose versus normalized percent response data identified an
additional 101 compounds with confounding fluorescent interference. Overall, the HTS earmarked
a total of 144 compounds for further biochemical studies, which were grouped into 20 chemical
families. The GSK team assessed these clusters for potential reactive functionality and physical
chemical properties, which triaged the series down to seven chemotypes. Notably, while UPenn
remained blinded to the specific structures of the compounds according to the pre-established
agreement, plate statistics and IC50 curves were shared throughout to foster joint decisions about
the screening and triage process.
Table 3. Screening statistics

a

Total HTS compounds screened
1,814,611
a
Predicted hit rate, %
0.14
a
Predicted 3SD cutoff, %
15.10
No. primary 1536 assay plates
1376
Average Z' (SD)
0.72 (0.03)
Average robust 3SD cutoff, %
15.95
Average hit rate, %
0.31
Number primary robust actives
5544
Statistical actives
396
Potency bins (pIC50) earmarked compounds
<5
125
5-6
17
6-7
2
>7
0

Based on triplicate data of the validation set

4.4.6 Secondary screening of candidates
Since the HTS assay contained both the LexA and RecA proteins, the compound could in
principle inhibit the activities of either protein and thus perturb the SOS response. Compounds
could also potentially interfere with the fluorescence polarization of the assay. To help
differentiate the mechanism of action and further narrow the list of candidate compounds to a
smaller group of disclosable leads, we subjected the compounds to validation assays that the
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UPenn team had optimized prior to the inception of the collaboration: a

32

P-LexA cleavage assay,

a cell-based SOS reporter assay, and a RecA polymerization assay. 32 exemplars of the
compounds were sent to UPenn under an MTA for further secondary screening. In addition,
aggregation propensity, solubility and chromatographic logD were measured for the exemplars in
each series. Within this group, select members of the seven chemotypes along with 12 singleton
compounds were selected to advance for further profiling.

4.4.7

32

P-LexA cleavage assay
We first subjected the 32 candidate compounds to an orthogonal confirmatory LexA

cleavage assay (Mo et al., 2014). In this assay, full-length LexA protein was N-terminally labeled
with radioactive

32

P and subjected to RecA*-mediated cleavage under an 8-point compound

gradient with 2-fold dilution, the highest concentration being 200 µM. The extent of self-cleavage
was then by visualized by phosphorimaging, allowing us to quantify the dose-response activity of
the compounds (Figure 18).

NTD

RecA*
+ Select
compounds

50
10
0
20
0

A3 (µM)

1.
6
3.
1
6.
3
13
25

+ -

CTD

-FL

+ -

C1 (µM)

1.
6
3.
1
6.
3
13
25
50
10
0
20
0

32
PLexA

-NTD
D1 (µM)

S5 (µM)

S8 (µM)

50
10
0
20
0

1.
6
3.
1
6.
3
13
25
50
10
0
20
0

+ -

1.
6
3.
1
6.
3
13
25

+ -

J2 (µM)

1.
6
3.
1
6.
3
13
25
50
10
0
20
0

+ -

1.
6
3.
1
6.
3
13
25
50
10
0
20
0

+ -

32

Figure 18. P-LexA cleavage assay
32
Representative gels showing P-LexA cleavage with 6 select compounds (A3, C1, D1, J2, S5,
32
S8) from the 32 transferred actives. DMSO was used as a negative control (-), while P-LexA
that did not get stimulated by RecA* acted as the positive control (+). Most compounds show
IC50’s in the mid-micromolar range, while some, such as S8, display no activity. The doseresponse curves of all 32 actives, including the six compounds shown here, are provided in
Figure S16 in the Appendix.
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We defined “active” compounds as candidates that displayed a maximal inhibition of
>80% and a calculated IC50 of <200 µM. Of the 32 compounds, 28 compounds were marked as
active. We observed varying IC50 values ranging between 3 µM (C2) and 67 µM (A1) in most
compounds. Compounds within the chemotypes displayed varying potencies. Notably, in
chemotype A, for example, IC50 values ranged from 7 µM (A5) to 67 µM (A1), while in chemotype
C, potencies were more clustered, spanning between 3 µM (C2) and 10 µM (C1) (Figure S16 in
the Appendix). These results within the chemotypes suggest structure-activity relationships (SAR)
within each chemical family.

4.4.8 Cell-based assay for SOS induction
To screen for the activity of compounds in cells, we employed a well-established cellbased SOS reporter assay. In this assay, a MG1655 E. coli strain with a deletion of the tolC efflux
gene (ΔtolC) was transformed with a SOS induction reporter plasmid, which harbors GFP under
the control of the recA promoter. Under exposure of ciprofloxacin stress (128 ng/mL), a 100-fold
increase in GFP induction can be observed at a 4 hour time point relative to un-induced strains,
which can be quantified by flow cytometry (Figure 19A). Compounds that displayed activity inside
cells would therefore result in a reduction in fluorescence.
We assayed the 32 compounds in dose response, with 2-fold dilutions of compound and
a top concentration of 200 µM. For each condition, the level of GFP induction was determined by
quantifying the mean fluorescence of the cell population, and the IC50 of each compound was
calculated (see Experimental Procedures). Compounds that displayed a maximal inhibition of
>80% and a calculated IC50 of <200 µM were earmarked as being potentially active in cells. With
these criteria, we observed three trends. The four compounds that did not show activity in the

32

P-

LexA assay also did not exhibit activity in the SOS reporter assays. Of the 28 biochemically active
compounds, 25 did not show notable activity in the cell-based assay, while the remaining 3 (C1,
J2, S5) were active in both assays (Figure 19B, see Figure S17 in the Appendix for all dose
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responses). Both C1 and S5 displayed an increase in IC50 values when transitioning from the
biochemical to the cell-based assay: C1’s potency dropped from 10 µM to 31 µM, while S5’s
decreased from 4 µM to 46 µM; J2’s IC50 values underwent minor, non-significant changes,
dropping from 25 µM to 19 µM.
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Figure 19. Cell-based SOS reporter assay
(A) E. coli MG1655 strains lacking the tolC efflux pump were transformed with a SOS reporter
plasmid where GFP expression is under the control of the recA promoter. Exposure of this strain
to fluoroquinolone stress induces the SOS response and GFP expression. Inhibitors that block
SOS induction would cause a reduction in GFP fluorescence. (B) Dose response curves of 3
active compounds in the SOS reporter assay. The percent inhibition was calculated relative to
fluorescence of cells not exposed to ciprofloxacin. Each data point represents the mean of two
independent measurements and the error bars represent the range of values. Dose responses of
all 32 transferred actives are shown in Figure S17 in the Appendix. (C) Compounds show distinct
cell population phenotypes with increasing concentration. The left panel is representative of a
bimodal population, while the right panel represents a unimodal population.
Our dose response assay revealed two distinct cell population types (Figure 19C).
Chemotypes such as C and S5 displayed a bimodal distribution of fluorescence, with “high”
fluorescence and “low” fluorescence population peaks. With increasing level of compound, the
“high” fluorescence peak diminishes, while the “low” fluorescence peak rises. By contrast,
chemotype J displayed a gradated reduction in fluorescence: with increasing compound
concentration, the entire population shifts from high fluorescence to low fluorescence in a
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unimodal fashion. The two types of population profiles suggest the possibility that these
compounds are inhibiting the cells through different classes of mechanisms, although the nature
of these mechanisms remains unknown and is an area of further study.

4.4.9 RecA polymerization assay
Finally, we subjected the 32 candidate compounds to a RecA polymerization counterscreen, as described by Singleton and colleagues, to see if any candidate could prevent the
formation of RecA* filaments (Lee et al., 2007). RecA filaments were pre-formed on fluorescently
labeled single-stranded DNA and then added to a gradient of compound and tested for a drop in
fluorescence polarization, which signified the dissolution of the ssDNA/RecA polymer. Of the 32
compounds, one compound, Singleton 8, inhibited RecA polymerization, with a potency that
matched its potency displayed in the full HTS assay (pIC50 = 3.98 +/- 0.08).

4.4.10 Decisions to advance leads
Having achieved the stated goal of identifying potential lead inhibitors for SOS inhibition,
each party independently decided about whether further advancement of the leads was desirable
for their goals. For GSK, several considerations were at play. First, the ability to evaluate
compounds that delay the acquisition of resistance raised concerns, as, to date, no clinical model
for examining acquired resistance during antibiotic treatment has been developed, thus obscuring
the clear benchmarks for successful therapies. Therefore, improving MICs or kill curves might be
a more tractable endpoint. However, such synergetic approaches would likely need to
demonstrate superiority when compared to the standard of care; monotherapy antibiotic trials
generally only need to demonstrate non-inferiority. Secondly, the low potencies of the compounds
were deemed prohibitive for drug development, since ideal lead compounds typically possess
IC50 values in the single-digit micromolar to high nanomolar range at this stage. Due to these
projected challenges associated with pursuing the LexA/RecA inhibitors, GSK decided not to
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proceed with the partnership and agreed to disclose compound structures for the UPenn group to
pursue independently.
Despite the end of the partnership, the UPenn group accepted these parting conditions.
Given the unconventional nature of the target, the repertoire of agents that selectively target the
SOS pathway is limited, and lead compounds offer strong starting points for revealing new
biology. Medicinal chemistry may feasibly optimize the compounds to elicit drug-like potency and
properties and is now being pursued by the UPenn group (see Chapter 5). Further the study of
how these compounds affect SOS induction, bacterial fitness, and mutagenesis are being
advanced in order to assess their value as experimental tools.

4.4.11 Disclosure of structures of selected leads
The biochemical and cell-based data on the candidate compounds provided the major
means to triage compounds for disclosure, with the criteria based on the IC50 values obtained for
each compound and family in both the FlAsH and

32

P-LexA assay, as well as the in vivo SOS

reporter assay. As one of the main goals of the UPenn group was to further elucidate the
consequences of inhibiting the RecA/LexA system, it was key to eliminate false positives,
especially given the low potency of the hits. In order to ensure that the hit structures were
responsible for the activity, GSK re-purified and confirmed the activity of all structures that were
revealed to the UPenn group. To further gauge the specificity of the compounds, the GSK team
analyzed cytotoxicity of the six compounds using a standard mouse lymphoma assay (L5178Y
TK +/-) (Table 3). For compounds D1, S5, and S8, TC50 values were ≥ 100 µM, while A3 and C1
had TC50 values of 50 µM and 25 µM, respectively. J2 was not tested for cytotoxicity because
there was not enough compound for the evaluation. Finally, GSK provided a list of physical
chemical properties and advice on the chemical tractability of the compounds. Considering the
aforementioned variables and aiming to incorporate a wide range of chemical structural diversity,
GSK released the structures of six compounds: A3, C1, D1, J2, S5, and S8 (Figure 20). It needs
to be emphasized that the number of released compounds greatly exceeded the number – three
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compounds – stated in the initial agreement, indicative of the flexibility and generosity between
the two parties of the partnership.
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Figure 20. Structures of the six released compounds

	
  
In making these selections, the dominant selection criterion was activity in the cell-based
assay, given that cell-based activity is often a major bottleneck in moving forward from a
biochemical screen. Additionally, we selected A3 as it was the most active of the A chemotypes,
given that this chemotype was highly represented in the HTS hits. While S8 showed low potency,
its activity in the RecA polymerization assay offered the possibility of developing a specific tool
compound. Finally, we picked D1 as a member of the chemotype D to further expand the
chemical diversity of the selected compounds. The properties of these six compounds are
summarized in Table 4. With the structures released to us, we sought to further assess the
specificity of the compounds. Compounds A3, C1, D1, and J2 were repurchased from commercial
vendors, while compounds S5 and S8 were unavailable from external sources. Therefore followup studies conducted by the UPenn group are currently focused on A3, C1, D1, and J2.
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Table 4. Properties of the six released compounds
Compound

IC50 (µM)
32

L5178Y TK
+/Cytotoxicity
TC50 (µM)

MW
(g/mol)

PFI

LogD, pH
7.4

IFI**

FlAsHLexAEc

PLexA

RecA

Cellbased
assay

A3

0.5*

14

No
activity

No
activity

50

468.51

Not
tested

Not tested

3/196,
2%

C1

32

10

No
activity

31

25

408.45

8.28

5.28

1/97, 1%

D1

20

9

No
activity

No
activity

>100

379.44

Not
tested

Not
measureable

0/179,
0%

J2

2

25

No
activity

19

Not tested

321.40

9.37

5.37

9/134,
7%

S5

40

4

No
activity

46

>100

607.58

8.03

5.03

5/153,
3%

105

102

105

No
activity

100

475.58

Not
tested

Not tested

S8

29/230,
13%

* Total inhibition asymptotes at 30%
** Inhibition Frequency Index; how often >50% inhibition is observed out of the GSK
screens conducted with the compound.
4.4.12 Specificity of compounds
Since LexA’s active site contains a serine-lysine catalytic dyad, we wanted to examine
whether the hit compounds displayed promiscuous inhibition against other classes of proteases.
We therefore sent the four repurchased compounds to BPS Biosciences to be tested for dosedependent inhibition against two other serine proteases (HCV1a protease and DPP4), an aspartyl
protease (renin) and a cysteine protease (caspase 3). Whereas A3, C1, D1, and J2 had all
displayed activity in the µM range in the FlAsH and

32

P-LexA assays, none of them exhibited

significant activity against these other representative proteases (Table 5). These results suggest
that the inhibition of the LexA/RecA system is not caused by non-specific protease inhibition, and
are qualitatively in agreement with the inhibition frequency index (IFI) of each compound shown in
Table 4.
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Table 5. Inhibitory effects of the four GSK compounds on protease activities
IC50’s or Percentage Inhibition
Enzymes
DPP4
Caspase3
HCV1
Renin

A3

C1

D1

J2

>100 µM, 36.5% at
100 µM
>100 µM, NI at
100 µM
>100 µM, NI at
100 µM
>100 µM, 22% at
100 µM

>100 µM, 31% at
100 µM
>100 µM, 26% at
100 µM
>100 µM, NI at
100 µM
>100 µM, NI at
100 µM

>100 µM, NI* at
100 µM
>100 µM, NI at
100 µM
>100 µM, NI at
100 µM
>100 µM, NI at
100 µM

>100 µM, 34% at
100 µM
>100 µM, NI at
100 µM
>100 µM, NI at
100 µM
>100 µM, 21% at
100 µM

IC50 (nM) of reference
inhibitor
4.7 (Sitagliptin)
1.6 (Caspase 3/7
Inhibitor II)
14 (Danoprevir)
11 (Aliskiren)

* NI: no inhibition
More recently, we have tested three of the four repurchased compounds (A3, C1, and
D1) in a LexA-only autoproteolysis assay that can report on whether a given compound is active
on the LexA protein alone. As discussed in Chapter 2, LexA is able to undergo self-cleavage
under exposure to high, non-physiological pH. However, since it is unclear how the compounds
behave under basic conditions, we repurposed our radioactive assay to report on LexA
autoproteolysis under more physiological pH. In this approach,

32

P-LexA is incubated at 37 ºC in

pH 7 buffer for 4 hours in the presence or absence of compound and the basal level of selfcleavage can be quantified with standard phosphorimaging methods (Figure 21).

32

Figure 21. P-LexA-only autoproteolysis assay on A3, C1, and D1
32
P-LexA (100 nM) was incubated with compound at the amounts indicated and incubated at 37
ºC, pH 7 for 4 hours. Aliquots of the reaction were taken at 0, 2, and 4 hours.
Performing this experiment on A3, C1, and D1, we observed two trends: neither A3 nor
C1 displayed detectable activity across the concentrations tested, while D1 exhibited inhibition at
concentrations >12.5 µM, which is comparable to its activity in the FlAsH-LexA and standard

32

P-

LexA/RecA assays (Figure 21, see Table 4 for comparison). These preliminary results suggest
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that D1 might be targeting the LexA protein itself, while A3, and C1, which show activity in both
FlAsH-LexA and

32

P-LexA/RecA assays, could potentially be LexA/RecA interfacial inhibitors. The

identification of D1, which targets LexA alone in the µM range is significant, as prior attempts to
inhibit LexA autoproteolysis required mM levels of the inhibitor diisoproyl fluorophosphonate
(Roland and Little, 1990). Further validation work (discussed in Chapter 5) needs to be performed
to assess the specificities and mechanisms of these compounds.

4.4.13 Discovery in the anti-infective realm via academic-industry partnerships
The problem of antimicrobial resistance requires novel approaches and models. Both
scientific challenges and economic disincentives, spanning discovery and marketing processes,
are barriers to antibiotic discovery in industry. Further complexities that arise in industry include
competition and lack of open communication, as well as a so-called “herd-mentality” in industry
that focuses attention on well-trodden targets (Schachter, 2012). On the academic side, studies in
the past decades on quorum sensing, stress responses, bacterial virulence, and host-pathogen
immunity have identified novel targets that could help stem the tide of resistance. However, to
date, none of these insights have led to the development of clinical treatments, in part because of
more limited practical experience with the requirements for drug development, but also due to the
regulatory challenges to advancing agents that do not kill the bacteria directly. Models that
encourage the pursuit of novel, less validated targets and the exchange of ideas and expertise
can help stimulate the antimicrobial discovery field.
Our specific experience offers examples of the strengths and challenges associated with
academic-industry partnerships. From the industry perspective, the DPAc competition process
helps to mitigate the risks and costs associated with identifying novel targets, such the
RecA*/LexA axis. Furthermore, academic partnership can often exploit established systems for
biological validation, in our case exemplified by strains with specific perturbations to the SOS
pathway. Although the cost of HTS on the scale performed is significant, the volume of screening
distributes these costs, and larger numbers of therapeutic hypotheses can be examined before
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incurring the more significant costs, which occur in downstream optimization and clinical
development of leads.
From the academic perspective, partnering with industry offers a unique perspective on
the drug discovery process. Most academic laboratories typically lack the resources to efficiently
screen large compound libraries and process hits. Furthermore, unlike commonly used
commercial drug libraries, libraries maintained by industry have been highly curated to remove
compounds with high false positive rates, thus increasing the chance hit compounds will be viable
Once leads are identified, academic groups do not have a clear picture of the regulatory
benchmarks that need to be met for a drug to eventually make it into the market, an area where
industry researchers can provide valuable feedback. Partnerships between industry and
academia therefore could provide a synergistic collaboration: academic labs can gather
experience in drug discovery processes, while industry labs can benefit from gaining exposure to
novel ideas.
Critical to this synergic partnership is a clear description of the agreements and tolerance
of the cultures of the two different institutions. In our case, enthusiasm on both sides fostered
trust between the two parties, and this helped in finding compatible solutions to questions of
intellectual property and material transfers. The academic objective was achieved, as we were
able to probe a large library for compounds that effectively inhibit our challenging target, opening
up avenues for both basic research and potential drug development. Challenges remain in
advancing the lead compounds, especially in addressing regulatory guidelines and benchmarks
for clinical success that might be applied to unconventional targets, such as those that alter
acquired resistance or pathogenicity. Continued innovation in the many different phases of
discovery of anti-infectives -- including target identification, assay development, translating leads
into therapeutically viable compounds, and developing pathways for evaluating alternative
strategies in clinical settings – all are highly justified given the pressing clinical needs.
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CHAPTER 5: Future directions and concluding remarks
The studies presented here have sought to clarify the mechanism of the LexA repressorprotease and examine the impact of the LexA autoproteolysis reaction on broader bacterial
physiology, with the encompassing goal of exploiting these insights for developing therapeutics to
target the SOS response. Biochemically, we aimed to understand how the architecture of LexA’s
active site mediates both substrate recognition and conformational change, and helping to inform
rational inhibitor discovery efforts. Extensive mutagenesis of LexA enabled us to elucidate the
substrate specificity determinants (Chapter 2). These experiments suggest that several residues
within the cleavage loop make essential recognition contacts, while other specificity determinants
are likely involved in facilitating LexA’s conformational change. Interestingly, stabilization of the βturn within the cleavage loop accelerates self-cleavage, suggesting that small cyclic peptides may
be tractable rational inhibitor starting points. Our study also gave us access to LexA variants
displaying a wide range of cleavage rates, which provided molecular tools for us to probe the
effect of LexA cleavage rates inside a live bacterial cell (Chapter 3). Finally, our results might
provide insights into how other members of the LexA superfamily achieve self-cleavage.
On a cellular level, LexA lies at the heart of the bacterial SOS response and has been
shown to regulate a multitude of processes involved in bacterial adaptation and evolution.
However, a majority of these studies focus on mutations that eliminate lexA or abrogate its
activity, thereby masking the dynamic nature of LexA’s biochemical activity exhibited in Chapter
2. Exploiting our biochemical insights on LexA cleavage rates, we generated E. coli strains that
endogenously expressed LexA variants with a wide range of cleavage rates, ranging from noncleavable to hypercleavable (Chapter 3). These strains, along with select recA mutant strains,
enabled us to probe the effects of LexA cleavage on bacterial antibiotic susceptibility and stressinduced mutagenesis. We showed that deviations of LexA’s cleavage activity from the wild type
rate resulted in a drop in the minimal inhibitory concentration in E. coli of a number of DNAdamaging antibiotics, while perturbations to the LexA cleavage rate can tune the level of the
mutagenesis in bacteria exposed to a wide range of antibiotics. From these insights, we provide
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the first comprehensive assessment of how to target the SOS response in order to increase
bacterial susceptibility and reduce mutagenesis under antibiotic treatment. Our work also raises
questions about the selection pressures on LexA’s self-cleavage mechanism and the role of
LexA’s autoproteolytic rate in regulating the SOS response.
Finally, from a therapeutic angle, LexA’s unique conserved function across bacterial
species makes it an attractive target for drug discovery efforts. We therefore designed an assay
based on fluorescence polarization that could test for LexA cleavage in a high throughput screen
(Chapter 4). Unlike previous studies, which focused on RecA inhibitors, our work bore the distinct
advantage of being able to detect both LexA and RecA inhibitors. We first validated the assay in
collaboration with the Wistar Institute’s screening facility, showing that the screen displayed
robust plate statistics and reproducibly. We then partnered with GlaxoSmithKline (GSK) as part of
their Discovery Partnership with Academia (DPAc) Program to screen for small molecule
inhibitors of LexA/RecA axis and discovered six compounds that displayed inhibitory effects in
both biochemical and cell-based assays. These compounds provide the foundation for future
medicinal chemistry efforts to develop and optimize leads for further drug discovery efforts.
Although historically, the SOS pathway has been a well-studied stress response system,
our work summarized in this thesis provides the foundation to examine the pathway from novel
and more advanced angles. The following sections will introduce and discuss future directions of
the three areas described in the Chapters 2-4, which are currently being pursued by other
members of the Kohli laboratory.

5.1 Examination of the autoproteolysis rates of LexA from different species
Although the LexA protein is widely conserved, it is not clear how the activity of LexA
varies across bacterial species. In Chapters 2 and 3, we examine the kinetics of autoproteolysis
of the LexA of P. aeruginosa and E. coli, respectively, noting that the two proteins possessed
comparable cleavage rates under alkali conditions. Interestingly, in unpublished data we have
observed that the LexA proteins from more distantly related species, such as Staphylococcus
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aureus (Gram-positive) or M. tuberculosis (Mycobacteria), exhibited alkali cleavage rates that are
qualitatively slower than those of LexAPa or LexAEc (Amanda Samuels, personal communication).
At a molecular level, the sequence conservation between the LexA of different species could
allow for a systematic analysis of which molecular mechanisms determine the differences in LexA
cleavage rate observed between the species (Figure 5C, Figure S1 in the Appendix). For
example, the P3 position in LexA of M. tuberculosis (LexAMtb) is an isoleucine, which according to
our analysis in Chapter 2, reduces the alkali-mediated cleavage rate by 5-fold. Similarly, the LexA
of S. aureus (LexASa) has a threonine at the P2 position, which inhibited self-cleavage by 30-fold.
Thus, it is possible that both LexAMtb and LexASa possess non-ideal internal substrates to curb
their activity. To test this hypothesis, we propose swapping the non-ideal residues in LexAMtb and
LexASa with better-tolerated ones and measuring if these mutations can yield cleavage rates
similar to LexAEc.
The observation that the LexA of different bacterial species possess varying activity
levels raises the possibility that the cleavage rate of LexA could have distinct regulatory roles in
different bacterial species, analogous to the cleavage rates of other LexA superfamily members,
such as UmuD or the λ CI repressor, discussed in Chapter 2. It will be important to examine how
different LexA autoproteolysis rates affect the physiologies of different bacterial species in order
to gain further understanding of how the SOS response is regulated across species.

5.2 Investigating the dynamics of LexA self-cleavage
As described in Chapter 2, one of the central components of the LexA self-cleavage
reaction is the large conformational change of the internal cleavage loop. As Luo et al. have
shown in the detailed crystallographic studies, LexA’s internal cleavage region can occupy two
distinct conformational states: a so-called open conformation, where the cleavage region
assumes an unstructured loop which positions the scissile bond approximately 20 Å removed
from the serine-lysine dyad of the LexA protease domain; and a closed conformation, where the
cleavage region has inserted itself into the active site, forming close contacts with active site
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pocket and bringing the scissile bond in close proximity to the active site (Luo et al., 2001).
However, these structural studies provide only snapshots of the conformational loop and do not
capture the dynamics of the inter-conversion between active and inactive states. Further, current
biochemical assays that probe LexA activity, such as the base- and RecA*-mediated cleavage
assays, cannot distinguish proteolysis from the conformational change. Although studies using
electron paramagnetic resonance spectroscopy have examined the dynamics of LexA’s DNAbinding domain during operator binding, to our knowledge, no studies to date have examined the
conformational dynamics of the LexA cleavage loop itself (Butala et al., 2011).
Our biochemical studies on the LexA cleavage region offer the possibility for in-depth
studies into the conformational changes. The cleavage region possesses tolerant residues (P4
and P2’ positions) that can be mutated to all possible amino acids, making them amenable for the
installation of smaller non-pertubing molecular probes, such as unnatural amino acids (UAAs).
Installation of such probes could in turn provide a way to measure the conformational dynamics of
the cleavage region. Shown in Figure 22 is an initial proof-of-principle experiment, where a
fluorescent UAA acridon-2-ylalanine (Acd) was stably incorporated into the P2’ (E86) position of
LexAEc, using a tRNA/aminoacyl tRNA synthetase system developed by Petersson and
colleagues (Figure 15A, work by Zach Hostetler) (Speight et al., 2013). When the labeled protein
is subjected to base-mediated cleavage conditions, it is able to readily undergo autoproteolysis,
displaying an approximate half-life of 15 minutes, suggesting that the Acd does not perturb LexA
activity (Figure 15B). Thus, by carefully positioning UAAs with their corresponding fluorescence
partners and employing cleavage deficient mutants could allow us to separate the conformational
changes from protein proteolysis, and thus identify of rate-determining step of LexA’s selfcleavage. Furthermore, from a drug discovery perspective, such a labeled LexA construct could
enable us to elucidate the mechanism of potential inhibitors.
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Figure 22. Incorporation of acridon-2-ylalanine into the P2’ position of LexAEc
(A) The amino acid tolerance of the P2’ position the LexA cleavage region (E86 in LexAEc)
permits the incorporation of the unnatural amino acid acridon-2-ylalanine (Acd, δ). (B) Acd-labeled
LexAEc is able to undergo base-mediated self-cleavage. Acridone fluorescence was visualized
using long wave UV illumination.
5.3 Examination of the effects of LexA cleavage rates on bacterial physiology
As we have demonstrated in Chapter 3, altering the rate of LexA autoproteolysis can
impact both bacterial susceptibility to antibiotics and stress-induced mutagenesis, depending on
the type and level of stressor applied. Under the exposure of DNA-damaging antibiotics and
agents the wild type LexA cleavage rate conferred, on average, the highest level of tolerance,
while mutations in LexA that altered the activity of the protein reduced the fitness of bacteria. This
trend suggests that LexA’s activity is subjected to stabilizing selection, where the intermediate
phenotype is preferred over extreme phenotypes. We speculate that LexA’s regulatory role in the
SOS pathway is responsible for this selection. Inactivation or hypo-activation of the pathway likely
prevents proper activation of the DNA damage repair mechanism, thus resulting in reduced
fitness and survival. Conversely, constitutive or hyper-activation of the pathway could potentially
perturb the repair mechanism, disturb the cellular metabolism, or result in genomic instability due
to over-activation of the error-prone polymerases. Due to this dual nature of the SOS response,
LexA’s activity might have evolved to balance repair and mutagenesis.
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Although the evidence for stabilizing selection is compelling, several questions remain
unanswered about SOS regulation. Notably, our studies in Chapter 3 were performed under in
vitro culture- and plate-based conditions, which do not accurately reflect the environmental
conditions experienced by bacteria. Further, the fitness defects seen in the LexA mutants are less
obvious when the mutants are grown in the absence of stress or with antibiotics that do not
directly cause DNA damage. Combined with the fact that, to our knowledge, no LexA cleavage
mutants have been isolated from natural bacterial strains, it remains unclear what selection
pressures the LexA protein is subjected to when the bacteria is inhabiting its natural environment,
or how different levels of the SOS response contributes to the ability of bacteria to survive and
adapt in a host organism. In an effort to further investigate these questions, work led by Amanda
Samuels is in the process of transforming the five LexA cleavage mutants discussed in Chapter 3
into an E. coli strain that is able to stably colonize the intestinal tract of mice (MP1 strain) (Lasaro
et al., 2014). These five strains with varying SOS activities would then enable us to examine, for
the first time, how different levels of LexA activity impact bacterial fitness and mutagenesis in a
mouse gut colonization model. This approach will also provide the opportunity to test putative
SOS inhibitors in an animal model.

5.4 Synthetic biology of the SOS system
A further open question in the field of the SOS response is how the different components
of the pathway individually contribute to bacterial survival and mutagenesis. For example, not
only are genotoxic stressors, such as fluoroquinolones or UV radiation, strong inducers of the
SOS response, but can also be inherently mutagenic themselves, increasing the mutation rate in
the absence of SOS induction. Furthermore, these external stressors can trigger other classes of
stress responses, such as the stringent response or the general stress response, which have the
potential to increase mutagenesis as well. At a regulatory level, RecA, which acts as the
molecular sensor and trigger of the SOS response, is known to participate in a multitude of other
DNA repair events, notably homologous recombination (Chen et al., 2008). Activated RecA also
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serves as a co-protease to UmuD, another member of the LexA superfamily and a component of
the SOS error-prone polymerase PolV, and has also been shown to interact with the UmuD’2C
mutasome (Godoy et al., 2007; Nohmi et al., 1988). Finally, self-cleavage of LexA has been
shown to induce the SOS genes in a chronological order, with processes involved in high-fidelity
DNA repair preceding mutagenic repair, yet the dynamics of this transition remains poorly
understood. Thus, efforts to answer these questions would greatly benefit from tools that can
specifically perturb the regulatory components of the SOS pathway.
As a future direction, efforts led by Jeffrey Kubiak have adopted a synthetic biology
approach to analyze the contributions of the individual components to SOS-mediated DNA repair
and mutagenesis. As discussed in the Introduction and Chapter 2, the N-terminal and C-terminal
domains of LexA are connected by a flexible, solvent-exposed protein linker that can range
between 6 and 12 amino acids in length, depending on the bacterial species. The low
conservation and variable length across species led us to hypothesize that this region is
amenable to extensive mutagenesis with minimal perturbation to DNA binding and LexA
dimerization. We therefore introduced a TEV protease cleavage site into LexA’s linker region,
which enables in trans cleavage by the TEV protease. This mutant LexA construct was then
inserted into the native lexA locus with gene recombineering techniques described in Chapter 3.
By transforming these strains with a plasmid with an inducible TEV protein under the control of
the tet promoter, the SOS response can be activated by the addition of an orthogonal inducer
molecule, anhydrotetracycline. Current work in the laboratory is focused on examining how this
synthetic SOS response system influences bacterial survival and mutagenesis in the presence or
absence of genotoxic stress. Further, it can serve as an orthogonal method to activate the SOS
response to assess the specificity of inhibitor compounds in cells.
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5.5 Optimization of inhibitor leads
5.5.1 Medicinal chemistry
In Chapter 4, we performed a high throughput screen and discovered six lead
compounds that show a range of inhibitory effects on the in vitro RecA/LexA system, with three of
the six leads, C1, J2, and S5, displaying further activity inside reporter cells. These results
encouraged us to initiate lead optimization efforts to improve potency and reduce cytotoxicity of
these compounds. Partnering with the Fox Chase Chemical Diversity Center (FCCDC), we
selected the C1 compound for medicinal chemistry efforts. This choice was based several key
characteristics of the compound. First, the compound backbone is highly modular, with a central
triazole ring linked to two flanking phenyl rings by two amide bonds, thus permitting the facile
synthesis of analogue compounds with click chemistry. Second, face-to-face discussions with
GSK revealed that C1 (and other members of chemotype C whose structures we were blinded to)
displayed clear structure-activity relationships on the two phenyl rings (Katherine Widdowson,
personal communication). Finally, the central 1,4-connected 1,2,3-triazole ring of the molecule
has been reported to provide a geometry that is similar to that of the β-turn (Li et al., 2013). Since
LexA’s cleavage loop adopts a β-turn in the protein’s active conformation (Chapter 2), this
structural feature of C1 might play a role in the molecule’s inhibition of LexA (Mo et al., 2014).
With this knowledge in hand, we recently began a systematic examination of how
altering the substituents on the two flanking phenyl rings or the compound backbone might affect
inhibition potency. Of the analogues tested to date, select compounds display enhanced potency:
one analogue, which has the two methyl groups removed from the right phenyl ring, shows the
largest increase in IC50 potency (~40 µM to 9 µM). These initial results therefore offer the promise
that further medicinal chemistry on the chemotype C will be able to improve the potency of the
compounds. Current work is focused on further iteratively improving the potency of C analogues
and also potentially expanding medicinal chemistry to another chemotypes, such as the D and J
families. Further, with the availability of the FlAsH-LexAPa construct, it will be possible to test the
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potency of these compounds across species. We hope to generate molecules with IC50’s < 1 µM
to help facilitate further downstream in-cell and mechanistic studies.

5.5.2 Compound binding to LexA and RecA
In Chapter 4, we discussed biochemical assays that report on whether compounds are
active on LexA or RecA. Of the six compounds that were transferred to us, S8 shows inhibition of
RecA filamentation, while D1, in preliminary studies, appears to inhibit the LexA protein alone.
Further, we hypothesize that C1 is an interfacial inhibitor, since it is inactive in both LexA- and
RecA-specific assays, but active in our assays involving both LexA and RecA. To complement
these assays, we have adopted a temperature-based assay to probe for interactions between
compounds and the LexA/RecA axis (Lavinder et al., 2009). In this method, a small volume of
protein is mixed with SYPRO Orange dye, which, upon binding to hydrophobic patches of
denatured proteins or molten globules, fluoresces with excitation and emission wavelengths of
470 nm and 570 nm, respectively. Increasing the temperature of the reaction causes the protein
to unfold and results in a rise in fluorescence, which can be monitored and used to calculate the
protein melting temperature (Tm). Addition of small molecules that bind to the protein can increase
or reduce the thermostability of the protein, resulting in a shift in the Tm relative to the untreated
protein.
As an initial step, we have measured the Tm’s of RecA and LexA variants in isolation and
in complex (Figure 23A). With RecA, we observed a melting temperature of ~40 °C, while adding
ssDNA and ATPγS to form activated RecA (RecA*) increased the melting temperature of the
system to 50 °C. It should be noted that ATPγS is responsible for this thermal shift, since ssDNA
alone does not result in a change in Tm. Examining the LexA variants, we observed that both the
WT protein and the catalytically inactive mutant S119A showed Tm’s of 60 °C (Figure 23B). When
we introduced mutations that, according to the crystal structures by Luo et al, locked the cleavage
region into the active conformation (L89P, Q92W, E152A, K156A) we observed that this protein
(QM/S119A) displayed a significantly elevated Tm of 75 °C. A mutation hypothesized to lock the
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cleavage loop in an inactive, open conformation (G85D/S119A) caused a reduction in melting
temperature, from 60 °C to 50 °C. These results suggest that the conformation of LexA’s
cleavage loop can influence the stability of the protein.

1.0

C

S119A
G85D/S119A
QM/S119A

30

40

50 60
Temp(*C)

70

80

90

0.0
20

1.5

1.0

0.5

0.5
0.0

1.5

Normalized signal

1.0

B

RecA
RecA/ssDNA
RecA/ssDNA/ATPγS

Normalized signal

1.5

Normalized signal

A

RecA* + Buffer
RecA* + LexA WT
RecA* + LexA S119A

0.5

30

40

50 60
Temp(*C)

70

80

90

0.0
20

30

40

50 60
Temp(*C)

70

80

90

Figure 23. SYPRO Orange thermostability analysis of of LexA and RecA
Plotted are the normalized fluorescent signals of the SYPRO Dye with increasing temperature.
The increase in signal corresponds with the melting of the protein and the Tm each protein is
defined to be the inflection point of the slope. (A) Melting curves of RecA, RecA/ssDNA, and
RecA/ssDNA/ATPγS (RecA*). (B) Melting curves of non-cleavable LexA mutants with variations
in the cleavage loop. The S119A variant possesses the WT loop; the G85D variant has a
mutation that purportedly keeps the loop in an open conformation; the QM variant has four
mutations that constrain the loop in a closed conformation. (C) Melting curves of RecA* coincubated with equimolar amounts of LexA variant (both at 1 µM).
Since our biochemical HTS screen contains both LexA and RecA, it is possible that
compounds could perturb the interaction between the two protein partners. Therefore we were
interested to see how mixing LexA with RecA* affected the melting temperatures of the proteins.
Interestingly, when we co-incubated non-cleavable LexA (S119A) with RecA* at equimolar levels
(1 µM each), we observed that the melting temperature of the RecA* filament increased even
further, rising from 50 °C to 57 °C; the melting curve of the LexA is not measureable at this
concentration (Figure 23C). When we performed a similar co-incubation with cleavable WT LexA,
this stabilization effect disappeared, suggesting that full-length LexA protein interacts with RecA*
and stabilizes the filament. This thermal characteristic of the LexA/RecA axis potentially enables
us examine whether a small molecule can disrupt the interaction between the two proteins. We
envision that the thermal melting assay will be employed in the future to assess the binding of
promising lead compounds. For example, inhibitors that act on LexA alone, such as D1, might be
able to stabilize the LexA protein, while compounds hypothesized to act at the interface between
LexA and RecA, such as C1, could destabilize the LexA(S119A)/RecA* interaction.
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5.5.3 Cell-based assays
With the development of compound analogues with enhanced potency, it will be
important to examine the activity of the compounds in cells. To this end, we have designed cellbased assays, not discussed in Chapter 4, that can provide further insight into the activity of the
compounds in vivo. First, we have transformed the pRecA-GFP reporter plasmid into wild type
MG1655 strain with intact tolC, thus enabling us to examine the performance of the compounds
the presence of functioning cellular efflux. Secondly, as discussed in Section 5.4, work by Jeffrey
Kubiak in the laboratory has developed E. coli strains with an SOS system that can be induced
through the addition of anhydrotetracycline, rather than DNA damaging agents. These strains
would enable us to identify off-target effects of our compounds. Finally, we have developed a
LexA antibody assay that is able to detect the presence of full-length LexA in cells. Exposure of
cells to DNA stressors causes the level of LexA to become depleted. An active LexA inhibitor
would reduce this drop of the protein level, which can be detected with Western blotting. Thus,
with these cell-based assays, we are well positioned to test the activity of LexA compounds inside
cells. Once in-cell activity as been confirmed, MIC assays and fluctuation analyses, as described
in Chapter 3, can be used to further assess the activity of compounds on bacterial susceptibility
and mutagenesis.

5.6 Concluding remarks
We have provided an overview of our efforts to understand and target the SOS response
in order to curb the evolution and spread of antibiotic resistance. Studying the SOS response and
related pathways could not only provide insight into how bacteria evolve and adapt but also
expose weaknesses that we are hopeful can be exploited in the form of new, “anti-evolutionary”
therapeutics. Pursuit of such therapies will pose a unique set of challenges and open up new
areas of inquiry. As one notable challenge, purely anti-evolutionary drugs will not reverse
preexisting genetic resistance in either nature or patients. Indeed, this problem is ancient and
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embedded in natural history, as the analyses of bacteria present before the rise of civilization
have shown that antibiotic resistance genes far predate our use of antibiotics (D'Costa et al.,
2011). However, rather than focusing on the existing pool of resistance, we posit that antievolutionary agents could prevent, or at least delay, the de novo generation and acquisition of
resistance in pathogens, thus increasing the lifespans of our agent. Indeed, our collaboration with
GSK was driven in part by the fact that several of their promising antibacterial inhibitors had to be
shelved due to the rapid emergence of resistance mutations (Katherine Widdowson, personal
communication). Clinical cases in which pathogens are repeatedly exposed to antimicrobial
therapy, as in the case of cystic fibrosis, severely immunosuppressed patients, complicated
medical device infections, or mycobacterial infections, are the main areas in which such novel
therapies might be employed. Further, as stress responses are linked to bacterial persistence,
biofilm formation, and the expression of virulence factors, targeting evolutionary processes may
decrease pathogenicity (Clatworthy et al., 2007; Conlon et al., 2013).
This thesis also highlights the gaps in basic science knowledge regarding how to assess
the clinical viability of targeting evolution. With genomic advances, we are learning more about
the relative frequencies of clinically relevant resistance determinants. Many studies are also
beginning to look at transmission events between patients within hospital settings, and even the
molecular relationship between resistance genes found in human pathogens and the environment
(Forsberg et al., 2012; Perry and Wright, 2013; Snitkin et al., 2012). However, insight into the
relative rates, timing, and location of each of these events remains lacking. Does antibiotic stress
enhance the mutation rate to a degree that has biological consequences within an individual
patient? A similar set of questions applies to understanding the clinical relevance of non-genetic
mechanisms for antibiotic tolerance, such as bacterial persistence and biofilm formation. This
type of knowledge, broken down by relevant ecosystem and pathogen, and coupled to the
kinetics of the biochemical steps, would offer enormous insight into which mechanisms to target,
as it would tell us what the “rate-limiting” steps are in evolution and adaptation to antibiotics. We
are hopeful that this body of work here, with its emphasis on understanding the biochemistry of
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the SOS response, and further advances in DNA sequencing and microbiome research will lead
to answers to these questions. On the surface, the problem of antibiotic resistance appears
insurmountable, but bridging the gaps in our knowledge holds the promise of unmasking great
opportunities to intervene. The scale of the clinical problem suggests the need for innovative new
approaches to antibacterials. It is our hope that these efforts will take many forms: from
augmenting natural product discovery by accessing the uncharted molecular diversity present
within “unculturable” organisms to counteracting non-genetic mechanisms that mediate antibiotic
tolerance and, finally, targeting the very mechanisms that underpin the evolution of genetic
resistance (Conlon et al., 2013; Ling et al., 2015; Thaker et al., 2013). 	
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Appendix
Supplemental material for Chapter 2

Figure S1. Alignment of LexAPa with LexA of E. coli and other bacterial species
Amino acids sequences of LexA of different species were obtained from Uniprot and aligned in
BLAST. (A) The full alignment between LexAPa and LexAEc is shown (sequence identity: 64%).
The residues surrounding LexA’s scissile bond show a strong degree of conservation across
species. (B) Alignment of the cleavage region of LexAPa and LexAEc to the cleavage regions of
other LexA superfamily members. Amino acid sequences of the different proteins were obtained
from Uniprot and aligned in BLAST.
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Figure S2. Structural homology model of the LexAPa CTD
The model was generated with Modeller 2.0, using the active form of the E. coli LexA CTD as a
template (PDB 1JHE). The internal peptide containing the cleavage region is shown as pink
sticks, with the scissile bond between A90 and G91 colored green. The catalytic serine (S125)
and basic lysine (K162) are shown are red and blue surfaces, respectively. The rest of the protein
is shown as blue surface. The same model is used in Figure 10.

Figure S3. In vitro self-cleavage of purified LexAPa
Purified wild type (WT) LexA from P. aeruginosa of the active site mutant S125A were incubated
overnight at (A) various pH ranging from 7.2 to 11.6 or (B) in the presence of absence of RecA*.
The top band (~25.7 kDa) after autoproteolysis. Loss of the catalytic serine (S125A mutation)
prevents autoproteolysis under both alkali-mediated and RecA* stimulation.
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Figure S4. Schematic of cassette mutagenesis
(A) To facilitate cassette mutagenesis, mutation encoding for AgeI and EagI were introduced into
positions flanking the LexAPa cleavage region (red mutations). An additional internal BamHI site
and a stop codon were introduced (green mutations) to facilitate high-efficiency cassette
mutagenesis and to prevent the expression of the full-length LexA cloning vector gene product.
(B) For cassette mutagenesis, the parent vector was digested with AgeI, BamHI, and EagI.
Duplexed oligonucleotide cassettes (shown in blue) containing either generate NNS codons for
saturation mutagenesis or point mutations for positional scanning mutagenesis are
phosphorylated and ligated into the digested vector. Note that, in addition to introducing the
desired mutations, the cassette oligonucleotides revert position 95 back to a wild type leucine
codon, with associated less of the EagI site. The ligated vector was transformed into the cloning
strain and the sequence confirmed. The plasmid and plasmid library (for saturation experiments)
were transformed into BL21(DE3)-pLysS cells for expression and subsequent purification.

	
  102	
  
	
  

Figure S5. RecA*-mediated cleavage of LexAPa variants from saturation mutagenesis
As with base-mediated cleavage, each variant, containing a single diversified position, was
purified as a cohort in parallel with the wild type enzyme and subjected to overnighted selfcleavage with (+) or without (-) RecA*. The fraction of cleavage product detected under each
condition is shown (no RecA*, gray columns; with RecA*, black columns). Reactions were
performed in duplicate and error bars reflect the range of error.
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Figure S6. Alkali-mediated and RecA-mediated cleavage screen of positional scanning
mutants of LexA’s cleavage region
Proteins were purified in parallel at each position and subjected to two cleavage conditions.
Shown are representative cleavage experiments with mutants from (A) position 86, (B) position
87, (C) position 88, (D) position 89, (E) position 90, (F) position 91 and (G) position 92. Alkalimediated cleavage (left panels) and RecA* stimulation (right panels) produced similar cleavage
profiles for all positions, with the notable exception is G86, where select mutants display basal
cleavage under alkali stimulation, but not under RecA* stimulation. The alkali-mediated cleavage
results for R87 and A90 are identifical to those shown in Figure 4 and are included again to
facilitate comparison across positions. The wild type enzymes in each batch is denoted as WT.

	
  107	
  
	
  

Figure S7. First-order kinetic plots of cleavable LexAPa point mutants from position 86 to
92
For each plot, the bolded dashed line represents the wild type enzyme. Plots for positions 87 and
90 are identical to those in Figure 2. Mutants are grouped by the property of their side chains at
physiological pH (orange: hydrophobic; purple: aromatic; yellow: hydrophilic; green: positive
charge; blue: negative charge). The rates of cleavage determined by each fit are given in Table 1.
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Figure S8. Mass spectrometry analysis of LexAPa A89C/I94C double mutant reveals the
presence of disulfides between positions 89 and 94
In the non-reduced formed, residues C89 and C94 show a mass decrease of 1.01 amu, indicative
of the loss of the proton of the thiol. When reducing agent is added, both residues become
alkylated by the iodoacetamide. Both samples display strong -10log(P) values and the two
conditions together confirm the presence of the disulfide bond.
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Supplemental material for Chapter 3
Generation, expression, and purification of LexA cleavage mutants
A synthetic gene encoding E. coli LexA was obtained from Integrated DNA Technologies
and cloned it into a pET41 expression vector with a N-terminal poly-His tag and a PKA
phosphorylation site. Unique restriction enzyme cut sites were positioned throughout the gene,
allowing for facile cassette-based mutagenesis, as previously described in Chapter 2 (Mo et al.,
2014). Using cassette mutagenesis, four LexA variants representing a spectrum of LexA
cleavage rates were made: the catalytic mutant (S119A), a slow cleaver (G80A), the wild type
enzyme (WT), and a fast cleaver (E86P). Following cloning, the S119A, G80A, and WT proteins
were expressed and purified as previously described in Chapter 2 (Mo et al., 2014). The proteins
were then further purified using size-exclusion chromatography into storage buffer (50 mM TrisHCl, pH 7.0, 150 mM NaCl, 10% glycerol). Due to its hypercleavable nature, the E86P variant
was expressed at 16 ºC overnight, rather than at 30 ºC for 4 hours, and all subsequent
purification steps were carried out at 4 ºC, rather than room temperature.

Radioactive labeling of purified LexA
LexA labeling was performed on the S119A, G80A, and WT proteins for 1 hour at 30 ºC.
Reactions contained 50 mM Tris-Cl, pH 7.5, 70 mM NaCl, 10 mM MgCl2 and 1 µM ATP (3000 Ci
32

[γ- P] ATP/mmol ATP) with 40000 units of PKA kinase. Unincorporated label was removed using
a Microspin G50 spin column pre-equilibrated with a PIPES buffer (50 mM PIPES pH 6.5, 150
mM NaCl). Due to its hyperactive nature, we had difficulty obtaining adequate amounts of

32

P-

labeled, full-length E86P protein. A large portion of the protein underwent self-cleavage during the
labeling and subsequent purification processes. Therefore, for the subsequent cleavage assays
below, unlabeled E86P protein was used at a higher concentration.

	
  110	
  
	
  

Base-mediated kinetic evaluation of LexA cleavage mutants
Purified LexA has been shown to undergo self-cleavage under elevated pH (Little, 1984).
We therefore examined the activities of the four LexA variants under base-mediated cleavage.
0.3 µM of

32

P-labeled S119A, G80A, and WT LexA, or 2.5 µM of unlabeled E86P were exposed

to alkaline cleavage buffer (100 µM of Tris-Glycine-CAPS, 150 µM NaCl, pH 10.6) and incubated
at 37 ºC. Samples were taken in intervals, quenched with Laemmli buffer, and separated on 15%
SDS polyacrylamide gels. The

32

P-labeled proteins were imaged via phosphor screen on a

Typhoon imager, while the E86P was stained with Coomassie and imaged on a BioRad GelDoc.
Protein bands were quantified with densitometric analysis and the fraction of full-length relative to
total protein was calculated and fit to determine a first-order exponential decay rate using
GraphPad Prism. The results are shown are in Figure S9.

RecA-mediated cleavage of LexA cleavage mutants
To examine LexA self-cleavage under more physiological conditions, RecA-mediated
LexA cleavage was characterized. Activated RecA (RecA*) was formed as previously described
in Chapter 2 (Mo et al., 2014). For the RecA* titration, 0.3 µM of

32

P-labeled S119A, G80A, and

WT LexA, or 2.5 µM of unlabeled E86P was incubated with variable amounts of RecA* for 30 min
at room temperature. Reactions were quenched with Laemmli buffer and separated as above. For
each reaction, pre-existing cleavage products, as determined from samples run without RecA*,
were subtracted, and the cleavage product was calculated. For time course, the RecA*
concentration was kept constant at 2.5 µM, quenched in intervals, and analyzed as above. The
results are shown are in Figure S9.

Evaluation of SOS induction levels in the lexA mutants
Strains were transformed with a GFP reporter plasmid containing gfp under the control of
the recA promoter (pMS pRecA-GFP) (Zaslaver et al., 2006). To assess SOS induction, strains
with the reporter were grown in standard M9 minimal media supplemented with casamino acids
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overnight at 37 ºC in the presence of kanamycin selection (30 µg/mL). The next day, the strains
were diluted 1:100 fold into fresh M9 media and allowed to grow at 37 ºC until an OD595 of 0.3. In
a 96-well plate, 75 µL of the cultures were then mixed with 75 µL of media with or without the
indicated antibiotic stressor (150 µL total culture volume; initial OD595 0.15). To prevent
evaporation, 50 µL of mineral oil (Sigma) was added to each well. The cultures were then grown
at 37 ºC in a plate reader under agitation and the culture density (OD595) and GFP fluorescence
(Ex/Em: 485 nm/535 nm) were monitored continuously for 3 hours. The level of SOS induction
was determined by taking the ratio of the fluorescence intensity and the optical density (FI/OD).
To quantify the level of SOS induction in cultures growth for longer time periods, we grew strains
6

overnight LB media with kanamycin (30 µg/mL) at 37 ºC. Overnight cultures were diluted 10 -fold
into 200 µL of fresh LB/Kan in the presence of given levels of stressor antibiotics in a 96-well
deep-well plate. The cultures were incubated at 37 ºC with agitation. After 16 hours, the cells
were spun down and fixed in 200 µL of phosphate buffer saline and 4% paraformaldehyde. Fixed
cells were analyzed using flow cytometry (BD FACSCalibur, Ex/Em: 488 nm/530 nm) and the
mean fluorescence of 20000 cells in each condition was recorded. The results for SOS reporter
expression at early and late time frames are shown in Figure S11.

Design of a constitutively active and repressed GFP plasmid reporter
For the co-culture competition experiments, we generated two plasmid constructs to
distinguish and quantify cultures: a reporter plasmid with constitutive GFP expression and a
plasmid with constitutively repressed GFP expression. For the constitutive plasmid, we took a
reporter plasmid containing GFP under the control of the lexA promoter and reversed the
sequence of the lexA-binding box in order to prevent LexA repression, thus forming pMS pRevGFP. For the constitutively repressed plasmid, we obtained the plasmid pMS pAra-GFP from the
available promoter collection, which has GFP expression tightly repressed by the arabinose
promoter (Zaslaver et al., 2006). These plasmids were then transformed into and used to
distinguish the strains, as described in the Experimental Procedues section in Chapter 3.

	
  112	
  
	
  

Table S1. MICs for drug - E. coli strains combinations
Strains

Antibiotic
(µg/mL)

S119A
+
(sulA )

G80A
+
(sulA )

MG1655

E86P
+
(sulA )

Δ recA

S119A

G80A

WT

E86P

Delta

recA730

Mitomycin C
Ciprofloxacin
Levofloxacin
Nitrofurantoin
Novobiocin
Trimethoprim
Ampicillin
Ceftazidime
Streptomycin
Spectinomycin
Tetracycline
Erythromycin

0.88
0.012
0.004
3
128
0.256
6
192
8
16
2
64

4
0.028
0.016
8
128
0.256
6
224
7
16
2
64

4
0.028
0.008
8
64
0.128
8
160
5
16
2
64

3
0.024
0.012
10
160
0.256
6
224
4
16
2
64

0.25
0.004
0.0018
0.375
64
0.128
8
384
4
16
1
20

0.75
0.004
0.006
5.5
128
0.128
7
288
8
24
2
24

4
0.016
0.028
8
128
0.128
6
288
8
16
2
32

4
0.016
0.028
12
128
0.128
6
256
6
32
2
32

3
0.016
0.016
12
128
0.128
6
256
6
28
2
32

2
0.008
0.007
8
128
0.128
4
160
7
16
2
20

2
0.012
0.014
8
64
0.128
7
384
10
32
ND
32
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Table S2. Mutation rate for drug - E. coli strains combinations
Strain

Ampicillin

Nitrofurantoin

Mitomycin C

Ciprofloxacin

No stress

+

S119A (sulA )
+
G80A (sulA )
MG1655
+
E86P (sulA )
ΔrecA
S119A
G80A
WT
E86P
Delta
recA730
recA730/
lexAS119A
+
S119A (sulA )
+
G80A (sulA )
MG1655
+
E86P (sulA )
ΔrecA
S119A
G80A
WT
E86P
Delta
recA730
+
S119A (sulA )
+
G80A (sulA )
MG1655
+
E86P (sulA )
ΔrecA
S119A
G80A
WT
E86P
Delta
recA730
+
S119A (sulA )
+
G80A (sulA )
MG1655
+
E86P (sulA )
ΔrecA
S119A
G80A
WT
E86P
Delta
recA730
+
S119A (sulA )
+
G80A (sulA )
MG1655
+
E86P (sulA )
ΔrecA
S119A
G80A
WT
E86P
Delta
recA730

Drug
(sublethal
concentration, µg/mL)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Mutation rate

95% Confidence Interval

2e-09
2e-09
4e-09
3e-09
5e-09
3e-09
4e-09
3e-09
3e-09
2e-08
6e-08

8e-10 – 3e-09
7e-10 – 4e-09
5e-09 – 7e-09
1e-09 – 5e-09
3e-09 – 7e-09
2e-09 – 6e-09
2e-09 – 7e-09
1e-09 – 5e-09
2e-09 – 4e-09
2e-09 – 3e-08
4e-08 – 7e-08

N/A

4e-09

3e-09 – 5e-09

0.0025
0.01
0.01
0.01
0.001
0.0025
0.01
0.01
0.01
0.005
0.001
0.125
0.25
0.5
0.5
0.0625
0.125
0.25
0.5
0.5
0.5
0.5
0.25
2
2
2
0.1
0.5
4
4
4
2
2
2
2
2
2
2
2
2
2
2
2
2

6e-09
1e-08
3e-08
3e-09
5e-09
4e-09
5e-09
2e-08
4e-08
6e-08
7e-08
N/A
2e-08
2e-08
5e-08
N/A
N/A
2e-09
8e-09
3e-08
4e-07
4e-07
4e-09
9e-09
1e-08
2e-08
N/A
2e-09
2.0e-08
3.0e-08
4.0e-08
1.2e-07
1.6e-07
6e-09
7e-09
8e-09
2e-08
2e-09
4e-09
7e-09
7e-09
9e-09
1.7e-08
7e-08

3e-09 – 1e-08
7e-09 – 2e-08
2e-09 – 4e-08
2e-08 – 4e-08
3e-09 – 9e-09
2e-09 – 5e-09
3e-09 – 8e-09
2e-08 – 4e-08
3e-08 – 6e-08
5e-08 – 8e-08
4e-08 – 1e-07
N/A
8e-09 – 4e-08
1e-08 – 4e-08
3e-08 – 8e-08
N/A
N/A
6e-10 – 5e-09
5e-09 – 1e-08
2e-08 – 4e-08
4e-07 – 5e-07
3e-07 – 5e-07
2e-09 – 8e-09
7e-09 – 1e-08
9e-09 – 2e-08
1e-08 – 2e-08
N/A
1e-09 – 4e-09
1.6e-08 – 2.5e-08
2.0e-08 – 3.1e-08
3.5e-08 – 5.3e-08
1.0e-07 – 1.5e-07
1.3e-07 – 1.9e-07
4e-09 – 8e-09
5e-09 – 1e-08
5e-09 – 1e-08
1e-08 – 3e-08
1e-09 – 4e-09
3e-09 – 6e-09
4e-09 – 1e-08
4e-09 – 1e-08
6e-09 –1e-08
1.3e-08 – 2.2e-08
6e-08 – 9e-08
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Supplemental Table 2; continued from above
Strain

Novobiocin

Trimethoprim

Streptomycin

+

S119A (sulA )
+
G80A (sulA )
MG1655
+
E86P (sulA )
ΔrecA
S119A
G80A
WT
E86P
Delta
recA730
+
S119A (sulA )
+
G80A (sulA )
MG1655
+
E86P (sulA )
ΔrecA
S119A
G80A
WT
E86P
Delta
recA730
+
S119A (sulA )
+
G80A (sulA )
MG1655
+
E86P (sulA )
ΔrecA
S119A
G80A
WT
E86P
Delta
recA730

Drug
(sublethal
concentration, µg/mL)
2
2
2
2
2
2
2
2
2
2
2
0.032
0.032
0.032
0.032
0.032
0.032
0.032
0.032
0.032
0.032
0.032
16
16
16
16
16
16
16
16
16
16
16
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Mutation rate

95% Confidence Interval

2e-09
1e-09
2e-09
2e-09
3e-09
9e-10
2e-09
4e-09
4e-09
9e-09
6e-09
4e-09
7e-09
1e-08
1e-08
6e-09
1.0e-08
8e-09
1e-08
3e-08
1.0e-07
1.6e-07
3e-09
3e-09
3e-09
3e-09
6e-09
5e-09
8e-09
5e-09
2e-08
4e-08
5e-08

1e-09 – 5e-09
7e-10 – 3e-09
9e-10 – 5e-09
1e-09 – 3e-09
2e-09 – 5e-09
4e-10 – 2e-09
9e-10 – 4e-09
2e-09 – 7e-09
3e-09 – 7e-09
6e-09 – 1e-08
3e-09 – 1e-08
3e-09 – 6e-09
5e-09 – 1e-08
9e-09 – 2e-08
9e-09 – 2e-08
4e-09 – 9e-09
7e-09 – 1.4e-08
5e-09 – 1e-08
9e-09 – 2e-08
2e-08 – 4e-08
9e-08 – 1.4e-07
1.3e-07 – 2.0e-07
1e-09 – 7e-09
2e-09 – 5e-09
1e-09 – 5e-09
2e-09 – 6e-09
4e-09 – 1.0e-08
3e-09 – 7e-09
6e-09 – 1.0e-08
3e-09 – 7e-09
1.4e-08 – 2.2e-08
3e-08 – 5e-08
4e-08 – 6e-08

S119A

1.0

Fraction uncleaved

Mutant

0.0

0

1.0

20

40
60
80
Time (minutes)

E86P
2.0

~ 0.2x

S119A

Not detectable

0

1

2 .5 µ M R e c A * tim e c o u r s e
S119A
G80A

0.5

WT

1.0
1.5
RecA (µM)

5.2 ± 0.4

1.0

G80A

0.5

G80A

120

S119A

0.5

0.0
0.0

100

R e c A * titr a tio n

Fraction uncleaved

B

WT

E86P

220 ± 30
22 ± 3

~ 10x

WT

E86P

G80A

0.5

k (10-3 min-1 ) Rel. to WT

Fraction uncleaved

A

2.5

0.0

WT
E86P
0

250

500
750
Time (seconds)

1000

Figure S9. LexA mutants display a spectrum of cleavage activities
(A) Base-mediated cleavage activity of S119A (red), G80A (gray), WT (blue), and E86P (purple)
LexA. The fraction of full-length protein remaining over time was fit to a first-order exponential
decay and the rate constant, k, was calculated. (B) RecA*-induced LexA cleavage. The left panel
32
shows a RecA* titration cleavage assay of the mutants (0.3 µM of P-labeled S119A, G80A, and
WT LexA, and 2.5 µM of unlabeled E86P). The right panel shows a reaction time course of the
four mutants under 2.5 µM RecA* stimulation. The formation of free NTD (product) was monitored
over time. The data symbol indicates the mean of 2 replicates and the error bars denote the
range of the observations.
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M

4

1

0.028
1

0.016

2
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1
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1
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1
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2
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1
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1
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A
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4
1
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80

G
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19
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-
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ΔsulA

E8
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19
A
G
80
A
W
T

x MIC of WT
1/2 1/4 1/8 1/16

G
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E8 55
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1
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6
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1
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1
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5
1

1

1

16
1

1

1

1

2
1

1

1

1

64
1

1

1.4

256
6

+

32
2
32

Figure S10. MIC values for sulA and sulA strains
+
The left panel is a heat map of the sulA strains’ MICs relative to MG1655. The MIC values of the
MG1655 strain are shown as white numbers in µg/mL. The right panel shows presents analogous
data in the ΔsulA background, and is a subset of Figure 12 in the Chapter 3.
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No stress
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FI/OD

FI/OD

1.5 105
1.0 105

1.0 105
5.0 104

5.0 104
0.0

5 ng/mL ciprofloxacin

2.0 105

0

20

40

60

0.0

80 100 120 140 160 180

0

20

40
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0
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0.0

0
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Mean Fluorescence (A.U.)

400
300
200

S119A
G80A

WT
E86P

60

80 100 120 140 160 180

Time (min)

Time (min)

B

80 100 120 140 160 180

2 μg/mL nitrofurantoin

2.0 105

1.5 105

0.0

60

Time (min)

Time (min)

Delta

* Above MIC

100
80
60
40
20
0

No stress

0.125 μg/mL
mitomycin C

*

5 ng/mL
ciprofloxacin

*

2 μg/mL
nitrofurantoin

Figure S11. Bacterial SOS induction directly correlates with in vitro LexA cleavage rates
(A) The GFP fluorescence normalized by optimal density of the lexA strains during a 180-minute
exposure to no stress or sub-lethal doses of ciprofloxacin, mitomycin C, and nitrofurantoin. The
data is represented as the mean of 3 independent measurements and the error bars reflect the
standard error of the 3 replicates. (B) Mean GFP induction under mitomycin C, nitrofurantoin, and
streptomycin stress after 16 hours evaluated by flow cytometry. The data bar represents as the
average of two independent measurements and error bars denote the range of observed values.
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No stress
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Time (hours)

14

Figure S12. Growth curves of variant E. coli stains under mitomycin C and nitrofurantoin
stress
The top panel is the same no-stress growth curve shown in Figure 13. The data is represented as
the mean of 3 independent measurements and the error bars reflect the standard error of the 3
replicates.
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Figure S13. Mutation rates of the lexA mutants and recA mutants under different types of
antibiotic stress
In each plot, the stressed strains (color) are shown in comparison to the non-stressed control
(black), which is the same across all conditions. Ciprofloxacin data are replicated from Figure 14A
to allow for ease of comparison. The symbol denotes the mean mutation rate, while the error bars
span the 95% confidence interval derived from 6 independent measurements. Strains that did not
show resistant colonies under a particular antibiotic stress are marked with a star (*) in the color
of that antibiotic. The attributed value of the (*) denotes mutation rate detection limit under those
conditions.
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Supplemental material for Chapter 4
Validation screen with FlAsH-LexAPa
To validate the FlAsH-LexA assay, we performed a screen on the Microsource Spectrum
library (2560 compounds) at the Wistar Molecular Screening Facility. Proteins and components of
the assay were prepared as described in Experimental Procedures section in Chapter 4. Stocks
of FlAsH-LexAPa and RecA stocks were diluted into 100 mM Tris-HCl, pH 7, 5 mM MgCl2, 0.1
mM TCEP, 0.01% Tween. To form RecA*, 10 µM of ATPgS and 10 µM if ssDNA were added to
the RecA. 15 µL of 100 nM FlAsH-LexAPa was dispensed into 384-well plates (Optiplate-Black,
Perkin Elmer) using a Biotek Microflo. 0.05 µL of compound from the 10 mM Spectrum library
stock were transferred with a Perkin Elmer Janus 96/384 Modular Dispensing Tool (MDT). To
stimulate the reaction, 15 µL of 100 nM RecA* (or plain buffer) was added with the Biotek
Microflo. Plates were then sealed and incubated at room temperature for 30 minutes. Following
incubation, the reactions were quenched with 25 mM of EDTA. Fluorescence polarization reads
were performed on the plates with a PerkinElmer EnVision Xcite Multilabel plate reader. This
experiment was performed on two separate days and the polarization values of each compound
in the two independent trials were plotted in Figure S15.

200

Anisotopy

FlAsH-LexAPa

100

FlAsH-LexAPa-S125A

0

10

20

30

40

Time (min)

Figure S14. Cleavage kinetics of FlAsH-LexA of P. aeruginosa (FlAsH-LexAPa)
RecA-mediated cleavage of FlAsH-LexAPa results in a drop in fluorescence polarization over time.
The cleavage reaction is abolished by mutation of of the catalytic serine in LexAPa.
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Figure S15. FlAsH-LexAPa screen of the Spectrum library on two independent days
For each well, the anisotropy values on Day 1 and Day 2 are plotted. Points were fit using a
standard linear regression.
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Figure S16. Dose-response curves of the P-LexA cleavage assay performed on the 32
transferred actives
32
The P-LexA cleavage assay was performed as described in Chapter 4. Compounds were
grouped by their chemotype, and the percent inhibition was calculated relative to the positive, no
RecA* control. Plots reflect the mean of two independent measurements and the error bars
represent the range of values observed.
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Figure S17. Dose-response curves of the cell-based SOS reporter assay
Compounds were grouped by their chemotype, and the percent inhibition was calculated relative
to the no ciprofloxacin control. Plots reflect the mean of two independent measurements and the
error bars represent the range of values observed.
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